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Abstract
The aim of our work was to produce bispecific antibodies using biological and 
chemical methods. Bispecific antibodies recognise two antigens simultaneuosly. The 
bispecific antibodies produced were used in the development of novel ELISA and 
immunocytochemical techniques for the detection of antigens present on the peripheral 
blood cells of patients with Chronic Lymphocytic Leukemia, (CLL). Cytokine 
production in these patients was also determined.
Biological production involved the production of triomas which were formed by the 
fusion of hybridoma cells with immunized splenocytes. This method required back- 
selecting the hybridoma cells for HAT-sensitivity, a procedure which was performed 
firstly by growing the cells in increasing concentrations of 8-azaguanine and, secondly, 
by treatment of the hybridoma cells with the mutagenic reagent, ethyl 
methanesulfonate. The cells were then fused with horseradish peroxidase-immunized 
mouse and rabbit splenocytes.
The chemical method chosen involved the activation of thiol groups on Fab" fragments 
of one antibody. These Fab" fragments were reacted with the second reduced Fab" 
fragment to form the heterogeneous F(ab'y)2 bispecific antibody.
Studies were also performed on the cytokine, interleukin-6 (IL-6). These included 
measurement of the concentration of IL-6 in the plasma and in conditioned medium 
(CM), prepared from the peripheral blood lymphocytes of patients with CLL. The IL-6 
levels were measured by an ELISA and by a bioassay using an IL-6-dependent cell 
line. The levels of circulating IgG present in the plasma of these patients were also 
determined by ELISA, but did not correlate. The effects of feeder cell layers and 
various medium supplements, including both IL-6-CM and CLL plasma, on the growth 
of hybridoma cells were also studied.
The growth of hybridoma cells which are of B-cell origin under such conditions may 
give indications of how the various growth factors present in CLL plasma affect B-cell 
growth in these patients.
Chapter 1
Introduction
1.1. An introduction to Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL), was first clinically described by Turk in 1902. 
CLL is a disease involving the progressive accumulation of immunologically non­
functional lymphocytes (Dameshek, 1967). 95% of all CLL cases are of B-cell origin 
(Dighiero et al., 1991). In western countries CLL is the most frequent chronic 
leukemia in middle and elderly life; there is a higher incidence of the disease in males 
than in females with a ratio of 1.5:1 (Finch and Linet, 1992).
Some links between CLL and occupations have been reported although CLL is the 
only leukemia not associated with an occupational exposure to radiation (Dighiero et 
al., 1991). These occupations include soybean production, cattle raising and dairy 
production in the farming sector and exposure to herbicides. Rubber manufacturing 
workers and asbestos workers also have increased incidences of the disease. In a 
cooperative chromosomal study on CLL, 51/433 patients examined had a structural 
abberation affecting the 13ql4 band (Dighiero et al., 1991). This is the region where 
the retinoblastoma tumor suppressor gene has been mapped. Rearrangements in the 
14q32 band of 41 patients and less frequent alterations of chromosomes 11, 6, 18, 3, 
17, 7 and 8 were also detected. Persons with first degree relatives suffering from the 
disease have between 2-7 times greater expectancy of developing the disease than have 
persons without such relatives.
Although therapy can improve the quality of life among CLL patients, no cure has yet 
been found and the median survival period of 96 months has not been altered by 
therapy (Finch and Linet, 1992). The clinical course of CLL is variable. Patients 
presenting with elevated lymphocytes, asymptomatic lymphadenopathy or 
splenomegaly do not benefit from treatment as they will not die from their leukemia. 
Patients presenting with lymphoma-like symptoms or features of bone marrow failure 
(severe anemia and thrombocytopenia), have a less than 2 year median survival. The 
majority of patients are in an intermediate group who only require treatment several 
years after the initial diagnosis.
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1.1.2. Clinical staging of Chronic Lymphocytic Leukemia
Rai et al. (1975) have described a clinical staging systems of patients with CLL which 
involves 5 stages, Stage 0 - Stage IV. Binet et al. (1981) have also described a clinical 
staging system which involves three patient groups: Stages A, B and C. Both staging 
systems take into account the clinical presentation of patients. In the case of Rai et al. 
(1975) these clinical presenting features include lymphocytosis, enlarged lymph nodes, 
hepatomegaly, splenomegaly, anemia and thrombocytopenia. The staging system of 
Binet et al. (1981) takes into account the numbers of sites affected by the disease. 
These sites are the cervical, axillary or inguinal lymph nodes, spleen and liver. Both 
staging systems are summarised in Table 1.1.2.
Staging Clinical symptoms
Rai et al. (1975) 
Stage 0 
Stage I 
Stage II 
Stage in  
Stage IV
Lymphocytotosis in blood and lymph nodes 
Lymphocytosis and enlarged lymph nodes 
Lymphocytosis and/or splenomegaly 
Lymphocytosis and anemia 
Lymphocytosis and thrombocytopenia
Binet et al. (1981) 
Stage A
Stage B
Stage C
Less than three areas involved*, Hb > lOg/L and 
platelets > 100xl09/L
At least three areas involved*, Hb > lOg/L and 
platelets > 100xl09/L
Hb > lOg/L and platelets > 100x109/L independent of 
the number of areas involved*
Table 1.1.2. The staging systems used for the diagnosis of patients with CLL.
* The 5 areas used in the staging system of Binet et al. (1981) are the cervical, 
axillary and inguinal lymph nodes, spleen and liver.
Hb Haemoglobin.
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Other prognostic factors include rapid lymphocyte count doubling times and diffuse 
patterns of infiltration, both of which carry poor prognosis. Patients with a normal 
karyotype fare better than those with an abnormal one (Dighiero et al., 1991).
1.1.3. Phenotypic characterization of Chronic Lymphocytic Leukemia
The phenotypic characteristics of B-CLL have been well established (Dighiero et al.,
1991). CLL cells express surface membrane Ig, C3dr complement receptors and 
receptors for the Fc portion of Ig. Monoclonal antibodies against CD 19, CD20, CD24, 
CD37, and CD21 are reactive with CLL cells. About 60% of B-CLL are positive for 
CD23. CLL B-lymphocytes are usually CD5-positive. Phenotypic alterations may 
occur over time (Patrick et al., 1987). This could be an important feature of the 
biology of the disease. If clinical course and phenotypic profile can be correlated then 
treatment may be suitably tailored (Patrick et al., 1987). These workers have detected 
phenotypic changes in the expression of CD20 and CD21.
1.1.4. Therapy in Chronic Lymphocytic Leukemia
Therapy in CLL has been reviewed extensively (Robertson and Keating, 1991). 
Chemotherapy involves treatment with an alkylating agent such as chloroambucil, 
alone or combined with a corticosteroid. The French cooperative group on CLL 
(1986), studied the efficacy of several drug regimens for the treatment of CLL. The 
patients were treated according to their clinical staging. Stage A patients (good 
prognosis), received either no treatment or chlorambucil. Stage B patients 
(intermediate prognosis), received either chlorambucil or COP (cyclophosphamide, 
vincristine and prednisone). Stage C patients (poor prognosis) received either COP or 
CHOP (COP plus doxorubicin). The survival rates were similar in stage A and B 
patients. In the final group, stage C, the 2 year survival rate was 44% for COP-treated 
patients and 77% for CHOP-treated patients. The effectivness of the CHOP regimen 
in stage B patients is now being determined. The potential of a-interferon as a 
biological agent for use in CLL has been studied (Foon, 1989), and was shown to be 
of no benefit to CLL patients with advanced CLL but maybe of greater use in 
untreated patients at an early stage of disease.
One of the clinical symptoms associated with CLL is hypogammaglobulinemia
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(Cooperative group on CLL, 1988). Given the association of hypogammaglobulinemia 
with CLL intravenous IgG treatment has been used in the treatment of patients with 
CLL. As the disease progresses the most common cause of mortality and morbidity 
is due to infection and this may be a consequence of the decrease in normal IgG 
levels.
Splenectomy is often a chosen form of therapy when symptoms such as autoimmune 
haemolytic anemia or thrombocytopenia and massive painful splenomegaly exist. 
Ferrant et al. (1986) reported that splenectomized CLL patients did not have increased 
survival periods.
1.1.5. Chronic Lymphocytic Leukemia in relation to the work described in this 
thesis
This work is divided into three areas. Firstly, bispecific antibodies were produced for 
use in the development of ELISAs and immunocytochemical techniques for the 
detection of antigenic determinants present on the peripheral blood cells of patients 
with CLL. Secondly, production of the cytokine, interleukin-6, was examined in these 
patients. This was correlated with levels of IgG present in the circulating plasma as 
determined by ELISA. Thirdly, and finally, given that patients with CLL have been 
reported to produce various cytokines (Schena et al., 1991), the plasma of these 
patients was examined for its ability to promote hybridoma cell growth at the clonal 
stage.
These research areas have been more fully discussed in Sections 1.2, 1.3 and 1.4.
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1.2. An introduction to bispecific antibodies
Bispecific antibodies (bsabs) have dual specificity for two distinct antigens. This 
enables them to be used in a variety of ways. For example, cancer cells can be 
targeted for lysis (Fanger and Guyre, 1991), drugs and toxins can be localised to cells 
(Flavell et al., 1991) and enzyme immunoassays with one arm directed against an 
enzyme and the second arm against a tumour cell can be developed (Gorog et 
al., 1989; Nolan and O’Kennedy, 1990; Takahashi et al., 1991).
Synthesis of bsabs can be divided into three main categories: biological, chemical, and 
genetic (Nolan and O’Kennedy, 1990; O’Kennedy and Roben, 1991; Kostenly et al.,
1992). Biological production involves manipulation of standard somatic cell 
hybridization techniques to produce quadromas and triomas. Chemical production 
involves modifying two distinct antibodies. Finally, a method using "leucine zippers" 
has been developed to generate genetically engineered bispecific antibodies (Kostenly 
et al., 1991). Leucine zippers are stretches of amino acids containing leucine residues 
at every seventh position.
1.2.1. Production of bispecific antibodies
1.2.1.1. Biological production
The general structure of an antibody is outlined in Figure 1.2.1.1.(a). This is a bivalent 
monospecific molecule which binds to a single antigen via its two antigen binding 
regions. An antibody consists of two light (L) and heavy (H) chains which are joined 
together by disulphide bonds [Figure 1.2.2.1.(a)]. The binding site of the antibody is 
situated at the amino terminal end, termed the variable (V) region of the L and H 
chains. The constant (C) region of the antibody is relatively conserved within a given 
species and may have a number of effector functions such as complement fixation 
and Fc receptor binding. In the germ line cells an antibody sequence is encoded in 
multiple gene segments scattered along a chromosome. When a lymphocyte is formed, 
recombination of these gene segments takes place to form a complete gene. Mutations 
also occur ensuring a high variability of amino acids at the amino terminal region 
(Tonegawa, 1983).
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Figure 1.2.1.1.(a).
An antibody consists of four polypeptide chains. These consist of two identical light 
(L) chains and two identical heavy (H) chains. These chains are held together by a 
combination of noncovalent interactions and covalent disulphide bonds. The L chain 
consists of a single variable (VL) and a single constant (Q) region. The H chain 
consists of a single VH and three distinct C (CHW) regions. The L and H chain V 
regions consist of a highly conserved framework structure linked by three 
hypervariable loops known as the complementary-determining regions (CDR 1,2 and 
3). The V region binds antigen whereas the C region controls effector functions such 
as complement activation. Proteolytic digestion of the antibody with the enzyme 
pepsin yields Fab and F(aby')2 antibody fragments.
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Biological production of bsabs involves manipulation of the somatic cell hybridization 
techniques first developed by Cotton and Milstein (1973) and Kohler and Milstein 
(1975). Reading et al. (1981) reported on the fusion of hybridomas to form quadromas 
which secrete bsabs [Figure 1.2.1.1.(b)]. Hybridomas may also be fused directly to 
antibody-producing splenocytes to form triomas [Figure 1.2.1. l.(b)]. One of the 
obstacles encountered during biological production of bsabs is selecting out hybridoma 
cells for use in cell fusions. Monoclonal antibody (mAb) production involves selecting 
for fused cells that grow in medium containing hypoxanthine, aminopterin and 
thymidine (HAT). The principle behind this approach is that the parent myeloma cell 
line is HAT-sensitive (HAT-s) and the parent lymphocytes are HAT-resistant (HAT-r). 
Cells that are HAT-s lack enzymes such as hypoxanthine guanine 
phosphoribosyltransferase (HGPRT) and thymidine kinase (TK), and, therefore, cannot 
chemically synthesise DNA and RNA when exposed to aminopterin. The parent 
lymphocytes contain these enzymes and are, thus, HAT-r. However, they cannot live 
long in culture.
To allow for selection of quadromas and triomas in HAT-containing medium 
hybridomas must be back-selected for HAT-sensitivity prior to cell fusion. This can 
be carried out in a number of ways. The cells may be grown in medium containing 
drugs such as 8-aza, 6-thioguanine and 5-bromodeoxyuridine, but, these methods can 
be long and tedious. Orikasa et al. (1985) have described a method for obtaining 8- 
aza-resistant leukemic and myeloid cell lines. The cells were cultured in RPMI 
medium containing 8-aza and 15% FCS and large amounts of amino acids and 
vitamins. The large amounts of amino acids and vitamins increase by about 15 times 
the chances of obtaining mutant cell lines. The correlation of amino acid levels with 
increased mutation levels is not known. One possibility is that the 8-aza results in the 
enhancement of the de novo purine synthesis by suppressing the salvage pathway 
resulting in a gradual loss of HGPRT activity. Kontsekova et al. (1991) have described 
a method which speeds up considerably the induction of HAT-resistance using 8-aza. 
This involves growing the cells in soft agar supplemented with 20pg/ml of 8-aza.
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HAT-s/Ouabaìn-r
Hybridoma
HAT-r immunized 
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Trioma
A A A
Parental antibodies Bispecific antibody
Figure 1.2.1.1.(b).
Biological production of bispecific antibodies can be achieved by the fusion of two 
hybridomas to form quadromas or by the fusion of one hybridoma directly to 
immunized splenocytes to form triomas. It is necessary that the hybridomas carry 
appropriate selection markers. In the examples given above for production of bsabs 
with quadromas one hybridoma is HAT-s/Ouabain-r and the second is HAT-r/Ouabain- 
s. In the second example of bsab production by triomas, HAT-r immunized 
splenocytes are fused with HAT-s hybridoma cells.
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HAT-sensitivity can also be induced using mutagenic reagents such as ethyl 
methanesulphonate (EMS) or X-irradiation. Other properties such as resistance or 
sensitivity to drugs, for example, ouabain (Staerz and Bevan, 1986), emetine, 
actinomycin-D (Suresh et al., 1986) and neomycin (De Lau et al., 1989) may be used 
in selection procedures. The development of cells resistant to neomycin is performed 
by transfecting the cells with the bacterial neomycin resistance gene (Moran et al., 
1990).
Karawajew et al. (1987) have developed a method to aid selection of hybrid- 
hybridomas. Prior to fusion the hybridomas were labeled with the fluorescent markers 
fluorescein isothiocyanate (FITC) and tetramethyl rhodamine isothiocyanate (TRITC). 
This enabled hybrid-hybridomas which were heterofluorescent to be detected and 
selected by FACS. Shi et al. (1991) labeled two hybridomas internally with two 
fluorescent dyes, rhodamine 123 and hydroethidine, and the hybrid-hybridomas, 
showing dual fluorescence were separated by cell sorting. Viability assays on labelled 
cells indicated little kill due to the dye treatment. Recently a variation on these 
methods has been devised (Jantscheff et al., 1993). This involves staining a HAT-s 
anti-CEA hybridoma with the TRITC. These cells are then fused with a second HAT-r 
anti-HRP hybridoma. Fluorescing cells were separated by FACS. These would include 
HAT-s parent anti-CEA cells and the desired hybrid-hybridomas. Selection of these 
cells in HAT-containing medium results in the outgrowth of only HAT-r hybrid- 
hybridomas.
Hudson et al. (1987) have studied immunoglobulin chain recombinations formed after 
fusion of anti-digoxin hybridomas. A cell line was formed which contained H chains 
derived from the first antibody (ab-1) and L chains derived from the second antibody 
(ab-2). The recombined antibody (bsab) expressed altered antigenic specificity 
dominated by the H chain donor and retaining the idiotype of ab-1. De Lau et al. 
(1991) reports on an absence of preferential homologous H/L chain recombination in 
fusions involving hybrid hybridomas. Milstein and Cuello (1984) have shown, using 
in vitro studies, that under conditions of competitive reassociation, the homologous L- 
H chain prevail in 80% of cases. Smith et al. (1992) have examined the light and 
heavy chain recombinations of a hybrid hybridoma called 28.19.8 developed by fusing 
an anti-CEA hybridoma and anti-vinca alkaloid (anti-VDS) splenocytes [Figure
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1.2.1.1.(c)]. This hybrid-hybridoma has been shown to secrete monoclonal anti-CEA 
and anti-vinca alkaloids antibodies as well as the bsab. Purified ascitic fluid contained 
four antibody populations three of which are immunoreactive. The four fractions were 
monoclonal anti-CEA and anti-vinca alkaloids antibodies, the bsab and finally an 
immunoglobulin fraction with no antigen specificity. Of the ten possible combinations 
of heavy and light chains seven exist as immunoreactive forms, suggesting that the 
other three combinations exist as the inactive form [Figure 1.2.1.1.(c)]. The bsab was 
shown by FPLC to be monomeric. SDS-PAGE analysis revealed the presence of one 
H chain band and two L chain bands. Isotyping revealed that IgGl and IgG2a heavy 
chains from the anti-CEA and anti-vinca alkaloid were present. The anti-CEA and 
anti-VDS fractions both showed negligble cross reactivity for the other. It was 
expected that the anti-CEA fraction would consist soley of IgGl and the anti-vinca 
alkaloid of IgG2a. Isotype analysis, however, revealed that the anti-CEA had some 
anti-vinca alkaloid lymphocyte IgG2a heavy and light chains. These Trans H and L 
chains in the anti-CEA population cannot be linked as they would then exhibit anti­
vinca alkaloid activity. Analysis reveals that the anti-CEA fraction consists of IgG 
with no free heavy or light chains. Therefore, anti-vinca alkaloid H chains and anti- 
CEA L chains must be linked through disulphide bonds as must the anti-vinca alkaloid 
light chain and the anti-CEA heavy chain. Thus, three possible assemblies of chains 
exist. The reverse situation would represent the anti-vinca alkaloid fraction. Recent 
reports suggest that H chains alone can result in antigenic binding capabilities (Collet 
et al., 1992). Referring back to the work of Smith et al. (1992) this would suggest that 
all recombined antibodies with H chains of both species and, therefore, 4 and not just 
1 of their recombined antibodies could be bsabs [Figure 1.2.1.1.(c)]. The antibody 
products formed when a murine hybridoma secreting IgM antibody to calf alkaline 
phosphatase and a hybridoma secreting IgA antibody to human chorionic 
gonadoprotein were fused have been reported (Behrsing et al., 1992). The results 
indicate that the bsab are IgM-like polymers or monospecific IgG-like antibodies. Only 
the IgM-like species had bsab activity.
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Figure 1.2.1.1.(c).
The possible heavy and light chain species obtained by Smith et al., (1992). Four 
antibody populations were obtained; these were the bispecific antibody, anti-CEA 
antibodies, anti-VDS antibodies and mixed chain species. It has now been shown that 
the H chain alone can bind antigen (Sastry et al., 1989; Collet et al., 1992). This 
infers that recombined antibodies containing the H chain of both parental antibodies 
(boxed species) may have bispecific antibody activity.
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The feasibility of producing large amounts of bsab by growing a quadroma in a 
hollow fibre bioreactor has been examined (Gorter et al., 1993). The relative 
production of bsab was greater using this method than either of ascitic fluid or cell 
culture supernatant obtained using conventional flasks.
L2.1.2. Chemical production of bispecific antibodies
As early as 1962 Nisonoff and Mandy demonstrated that random re-oxidation of the 
hinge region -SH group of two separate Fab'y yielded both heterodimer and 
homodimer F(ab'y)2. Some workers have modified the method of protein thiolation 
developed by Carlsson et al. (1978) to chemically crosslink whole antibody molecules 
forming heteroconjugates. Briefly, parental IgG is thiolated with the heterobifunctional 
reagent SPDP resulting in pyridyl disulfide (PD) antibodies. One of the IgG-PD 
species thus formed is reduced with dithiothreitol (DTT). The IgG-PD and IgG-DTT 
are then mixed to form heteroconjugates. These heteroconjugates can be formed 
relatively quickly and separated from unreacted components by size exclusion. This 
method of crosslinking whole antibody molecules has been used successfully by a 
number of workers who developed heteroconjugates which lyse tumour cells such as 
ovarian cancer cells (Mezzanzanica et al., 1988), murine and human tumour cell lines 
(Perez et al., 1985; Perez e ta l. ,  1986; Titus eta l.,  1987a), B-cell lymphoma cells (Liu 
et al., 1985) and virally (HIV-1) infected cells (Zarling et al., 1988). Alternatively, the 
antibodies may be chopped up and recombined to form bsabs (Brennan et al., 1985; 
Glennie et al., 1987). Brennan et al. (1985) reported a method which involves 
treatment of parental antibodies with pepsin, yielding F(ab'y)2 fragments. Reduction 
of the F(ab'y)2 fragments to Fab fragments is carried out using 2-mercaptoethylamine. 
Further reaction of the Fab fragments with Ellman’s reagent yields Fab-TNB 
derivatives. One of the Fab-TNB is then reconverted to the Fab-thiol by further 
reduction with 2-mercaptoethylamine. Equal amounts of Fab-thiol and Fab-TNB are 
reacted to form the bsab. In the approach of Glennie et al. (1987) F(ab'y)2 fragments 
formed by peptic digests were reduced to FabSH with 2-mercaptoethanol. One FabSH 
species was alkylated with o-phenylenedimaleimide to yield FabMAI which has free 
maleimide groups. The F ab ^  and FabSH were then reacted together to form bsab 
(Figure 1.2.1.2.) Both of these methods prevent any parental antibody recombinations.
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Figure I.2.I.2.
The structure of the F(ab'y)2 bispecific antibody described by Glennie et al. (1987). 
The bispecific antibody is formed via thioether-linked Fab' fragments. The protocol 
can be divided into three steps. F(ab'y)2 were first prepared using pepsin and reduced 
to Fab'ySH. Secondly, all the SH groups on one species were maleimidated with the 
bifunctional cross-linking agent o-phenylenedimaleimide yielding Fab'yMAL, and 
thirdly, Fab'ySH and Fab'yMAL were reacted under conditions favouring reactions 
between-SH and maleimide groups. These conditions are low pH and the inclusion of 
EDTA.
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The method of Glennie et al. (1987) has been used successfully by a number of 
researchers, for delivery of an immunotoxin (saporin) to tumour cells (Flavell et al., 
1991; Flavell et al., 1992; French et al., 1992) and for targeting T-lymphocytes to 
tumour cells (Mezzanzanica et al., 1991). Tutt et al. (1991) reported on a method for 
the formation of trispecific antibodies used to redirect resting cytotoxic T- cells to 
lymphoblastoid B-cell lines.
I.2.I.3. Genetic production of bsabs
A genetic method for the production of bsab fragments has recently been described 
(Kostelny et al., 1992). This involves producing F(ab'y)2 antibody fragments directly 
by gene expression and using leucine zippers to generate the bispecific antibody 
fragments. A leucine zipper is a stretch of 35 amino acids containing leucine residues 
at every seventh position (Abel and Maniatis, 1989). These sequences are found in a 
number of DNA binding proteins. The regions used for bsab formation are obtained 
from the Fos and Jun protein products. These zipper regions are genetically fused to 
each of the Fab genes and, when expressed, result in Fab fragments complete with a 
zipper region. The two antibody species required in the bsab can then be simply 
mixed in vitro to result in heterodimer formation. The bsabs can also be obtained by 
co-expressing the Fab-Jun and Fab-Fos proteins in one cell line. The in vitro method 
is preferred due to the greater purity of the final product. Chimeric derivatives have 
also been made. Anderson et al. (1992) have used the method of Fc addition to form 
chimeric derivatives. Here the Fc portion of normal human Ig is linked by thioether 
bonds to proteins with suitable sulfhydryl groups. The Fc portion is linked via its 
hinge region and is therefore able to recruit effector molecules. These workers have 
made chimeric derivatives consisting of Fab derived from murine IgG and the Fc 
portion of normal human IgG.
O’Kennedy and Roben (1991) also report on the possibilties of using genetic 
engineering in the development of bsabs. These bsabs would be made up 
predominantly of the heavy chain variable regions of the antigen binding regions of 
both parental antibodies.
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1.2.2. Applications of bispecific antibodies
1.2.2.1 Drug targeting
Corvalan and co-workers have shown that a bsab, targeting vinca alkaloids to the 
carcinoembryonic antigen (CEA) present on established MAW 1 human colorectal 
xenografts in nude mice, was capable of reducing both tumour growth and volume 
(Corvalan et al., 1987a; Corvalan et al 1987b; Corvalan et al., 1988; Corvalan and 
Smith 1987 & Apelgren et al., 1988). Histological studies revealed that the remaining 
cells had altered morphology and cell organisation (Corvalan et al., 1987a). One of 
the advantages of using bsabs to target tumour cells with toxins is that they eliminate 
the need for chemical conjugation of toxin to antibody, a process which may cause 
inactivation of the toxin (Tazzari et al., 1993). A variety of toxins have been targeted 
to cells using bsabs (Figure 1.2.2.1.). These include ricin, pokeweed antiviral protein, 
cytostatic YDS (vinblastine and vindesine), anthracycline (Nolan and O’Kennedy,
1990) and saporin (Glennie et al., 1988). Raso and Griffin (1981) have targeted Ig- 
expressing cells with a chemically made bsab consisting of anti-ricin and anti-human 
IgG binding regions. Protein synthesis in these cells was inhibited. Toxicity in non-Ig 
bearing cells was not augmented. Circulating Ig was capable of blocking the bsab 
effect.
Glennie et al. (1988) investigated the toxic effect of a bsab with specificty for L2C 
leukemic guinea pig cells and saporin. Concentrations of saporin which had previously 
failed to elicit a cytotoxic effect were now found to be cytotoxic. Flavell et al. (1991) 
demonstrated the cytotoxic effect of bsab used to redirect saporin to an acute T cell 
leukemic CD7-positive cell line HSB-2. Combinations of bsab have also been used to 
deliver saporin to T-ALL tumour cell lines (Flavell et al., 1992). The principle behind 
this concept is that within any tumour cell population not all cells will be positive for 
a specific antigen and may thus escape potential therapeutic bsabs. Anti-saporin 
crossed with anti-CD7 and anti-CD38 were used singly and in combination and the 
relative cytotoxicities were assesed. It was shown, firstly, that combination therapy 
exhibited increased cytotoxicity and that this was more than just an additive effect 
and, secondly, that the rate of protein inactivation in targeted cells was enhanced.
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Figure I.2.2.I.
Bispecific antibodies have been used to (a) direct immunotoxins to target cells and (b) 
target cells using a redirected effector cell. This cell could be a cytotoxic T cell, a 
natural killer cell or any cell capable of inducing cell death. It is vital that the 
bispecific antibody activates a molecule on the effector cell which can induce cell 
death. An example is the CD3 antigen on cytotoxic T cells. Another use for bispecific 
antibodies is in immunoassays (c) with one arm recognising a tumor cell and the 
second recognising an enzyme whose activity can be detected visually or 
spectrophometrically using a suitable substrate that is converted into a coloured 
product.
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The CD25 antigen, which is present on activated lymphoid cells and leukemic and 
lymphoma cells with an activated membrane phenotype, has been used as a target 
molecule by Tazzari et al., (1993). These have made a bsab using biological methods 
which can bind CD25 positive cells and saporin. This antibody has been shown to 
enhance the toxicity of free saporin against these CD25-positive cells. Embelton et 
al. (1991) used a combination of anti-ricin A chain, anti-CEA bsab and evaluated the 
cytotoxic effect of this bsab on a gastric tumour cell line, MKN45, which expresses 
large amounts of CEA. The cytotoxic effect of ricin A was observed at concentrations 
which would not normally be cytoxic. The inclusion of the ricin toxin B chain 
potentiated the cytotoxic effect of the ricin A chain.
I.2.2.2. Cell lysis
Fc receptors, FcyR, are present on a variety of cells. These act as cytotoxic trigger 
molecules when activated [Figure 1.2.2.1.]. CD3 complexed with ocf} and y5 receptors 
is present on cytotoxic T cells. FcyR I (CD64) is present on monocytes, macrophage 
and INF-y-activated PMN cells. FcyR 11 (CD32) is present on monocytes, macrophage, 
PMN and eosinophils and, finally, FcyRIII (CD 16) is present on macrophages, NK 
cells and large granular lymphocytes as a transmembrane molecule and acts as a 
cytotoxic trigger molecule. On PMN’s, however, FcyRIII is linked via 
phosphatidylinositol glycan and does not mediate cytotoxicity. Bsabs have been made 
with one arm against these receptors or effector cells and a second arm against a 
target cell such as a tumour cell. Normal functioning of lymphocytes and monocytes 
requires accessory molecules which are involved in migration, phagocytosis and 
extracellular cytotoxicity. These may be important in bsab-mediated cytotoxicity. 
Examples are the leucocyte function antigen (LFA-1) and CD56 (neural cell adhesion 
molecule N-CAM) which are accessory molecules in bsab-mediated cytotoxicity by 
myeloid cells and large granular lymphocytes, respectively. The purpose of these 
accessory molecules could be as a protection to the triggering of cytotoxicity unless 
the the target cell is bound. In addition, to trigger molecules (CD3 and FcyR) and 
accessory molecules, the cytokines may be involved in the activation of effector cells. 
For example IL-2, IL-4 and IL-7 are involved in T cell activation (Fanger and Guyre,
1991).
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Heteroconjugates have been used to redirect cytotoxic T cells to lymphoma cells (Lui 
et al., 1985). These consisted of anti-CD3 crossed with an anti-B-cell lymphoma 
idiotype. Heteroconjugates have been used to successfully mediate lysis of xenogenic 
tumour cells and chicken erythrocytes (Perez et al., 1985). These workers have also 
mediated lysis in a variety of human tumour cell lines including lymphoblastoid cells, 
a Reed-Stemberg cell line, small cell lung cancer cell lines, lung and colon 
adenocarcinoma cell lines and a lung carcinoma cell line (Perez et al., 1986) using 
redirected cytotoxic T cells. Heteroconjugates capable of targeting tumour cells with 
natural killer cells (anti-CD 16) have proven successful in the lysis of fresh human 
melanoma cells and are capable of preventing tumour growth in vivo (Titus et al., 
1987a). Titus et al. (1987b) have demonstrated that heteroconjugates targeting a 
human subcutaneous colon adenocarcinoma tumour in nude mice with cytotoxic T 
cells via the CD3 T cell receptor can prevent tumour growth. Zarling et al. (1988) 
reported that heteroconjugates consisting of anti-CD3 crossed with anti-HIV and anti- 
C D ^  crossed with anti-HIV were used to target cytotoxic T cells and large granular 
lymphocytes to HIV-infected cells to induce cell lysis. Lysis was found to be 
augmented by pre-treatment of peripheral blood lymphocytes with anti-CD3 or IL-2. 
Mezzanzanica et al. (1988) also used heteroconjugates successfully to target human 
ovarian carcinoma cell lines for lysis by cytotoxic T cells. Nitta et al. (1990) have 
reported a clinical trial in which patients were treated with heteroconjugates 
consisiting of crosslinked anti-CD3 and anti-glioma mAB which redirected 
lymphokine-activated killer cells to the tumour site. Treatment of patients with LAK 
cells alone proved to be as effective as conventional treatment (i.e. surgery, 
radiotherapy, chemotherapy). However, treatment with the heteroconjugates was even 
more successful than any of the conventional methods already listed.
F(ab'y)2 molecules have also been used to redirect effector cells. Athymic mice 
bearing human ovarian carcinoma cells had prolonged survival time when treated with 
anti-CD3 cross-linked with anti-tumour cell F(ab'y)2 (Mezzanzanica et al., 1991). 
Greenman et al. (1991) have created F(ab'y)2 bsabs with one arm recognising chick 
red blood cells (CRBC) and the second recognising the FcyRII (CDw32) present on 
monocytes. These bsabs were as efficient as monoclonal and polyclonal anti-CRBC 
in inducing lysis in CRBC’s. Addition of the Fc portion of human antibody in vitro
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at a concentration equivalent to that found in serum was capable of inhibiting the 
activity of the monoclonal and polyclonal anti-CRBC. This is due to the competition 
between the added Fc with the Fc present on the CRBC for the antibody. This 
inhibition of lytic ability was not evident in the bsab system. This would be a 
beneficial property if the bsab was to be used in vivo. This also highlights how subtle 
changes in the bsab binding capabilities can have beneficial effects not present in the 
parental mAbs. There now exist trispecific antibodies, F(ab'y)3 which are capable of 
activating T cells with two arms and retargeting them with a third (Tutt et al., 1991).
Bonardi et al. (1993) have created a panel of F(ab'y)2 with specificities for saporin 
and various B-cell antigens present on Raji and Daudi Burkitt’s lymphoma cell lines. 
The antigens chosen were CD 19, CD22, CD37 and p-chain or K-chain. When the 
tumour cells were targeted using these bsabs only the anti-saporin-anti-CD22 caused 
a significant cell kill, with a 1000 fold decrease in the amount of saporin required to 
achieve an IC50. Bsab recognising either p or k  chain and saporin resulted in about a 
10 fold increase in saporin toxicity. The final two bsabs which recognised saporin and 
either CD 19 or CD37 both failed to enhance toxicity significantly. These results are 
not due to the lack of bsab binding to the cells as work with 125I-saporin indicates that 
the most toxic bsab is not the one which binds most abundantly to the cell surface. 
For example, the most abundant of the antigens present on the cells here is CD37 and, 
as expected, the bsab recognising CD37 and saporin is the one which binds most 
saporin to the cell surface. However, what seems to be most important is the ability 
of the bsab, when bound, to be internalized by processes such as endocytosis and/or 
intracellular routing of the bsab-complexes. In the example described above bsab 
recognising CD22 was the most efficient at accumulating saporin inside the targeted 
cells and was thus found to be the most cytotoxic.
Biologically formed bsabs have also been used in cytolysis. Staerz and Bevan (1986) 
have used a hybrid antibody with one arm recognising an allotypic determinant on the 
T-cell receptor and the second Thy-1.1. Tumour cells expressing the Thy-1.1 antigen 
are lysed by cytotoxic T cells. Lanzavecchia and Scheidegger (1987) used biologically 
made bsabs to target cytotoxic T cells to a variety of target cells. The bsabs formed 
had one arm against the CD3 T cell antigen and a second against any one of the
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following: HLA antigens, human Ig, Toxoplasma gondii and an ovary carcinoma- 
associated antigen. Van Dijk et al. (1989) have demonstrated the lysis of a human 
renal cell carcinoma (RCC) cell line with cloned CD3-positive lymphocytes using a 
biologically formed bsab with specificities for the CD3 T cell antigen and G250 RCC- 
associated antigen. Bsab reacting with tumour cells and a non-activating T cell 
receptor failed to induce tumour cell lysis. Weiner and Hillstrom (1991) have also 
made bsabs biologically. These bsabs with specificities for CD3 and a tumour- 
associated antigen were superior in their lytic ability than were monospecific anti­
idiotype antibodies. This work was performed on a murine B-cell lymphoma animal 
system. Hseih-Ma et al. (1992) have formed a bsab with specificities for the human 
C-erbB-2 protooncogene product and the FcyRIII (CD 16). This biologically formed 
bsab and a chemically formed bsab with the same specificities were capable of lysing 
C-erbB-2 positive cells using CD16 positive mononuclear cells. Neither of the parental 
antibodies had this capability.
The method of "Fc addition" has been used to form chimeric derivatives which can 
be used to recruit effector molecules, such as complement and Fc receptor-bearing 
cells (Anderson et al., 1992). Murine IgG Fab' fragments which are capable of 
recognising antigens present on neoplastic lymphoid cells were combined to the Fc 
portion of human IgG to form FabFc2 and FabFc (murine Fab and human Fc). FabFc2 
was the most successful in its ability to induce complement lysis and ADCC of guinea 
pig L2C leukemia; this may be due to its dual ability to bind Clq and Fc-receptor 
cells. Treatment and remission of human B-cell lymphoma required a plasma 
concentration of 50pg/ml of chimeric derivatized-antibody.
Shalaby et al. (1992) have used genetic engineering techniques to create bsabs with 
dual specificities for the T cell antigen CD3 and the phosphoglycoprotein 
HER2/pl85HER2. This antigen is overexpressed on breast and ovarian carcinomas as 
their development progresses. Here a bsab F(ab'y)2 with a humanised arm against the 
phosphoglycoprotein and a second against CD3 was formed. The anti-CD3 was 
derived from a hybridoma. The antigen binding region of the anti-CD3 antibody was 
installed in the context of human variable region framework residues. Anti-tumour and 
anti-CD3 Fab fragments were recommbined chemically forming a fully humanised 
F(ab'y)2 bsab. These can be used in vitro to lyse breast tumour cell lines bearing the
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phosophoglycoprotein. The Fabs are chemically coupled after being excreted from E.
coli.
Titus et al. (1987 a & b) have demonstrated the anti-tumour effect of redirected 
peripheral blood T cells, and NK cells, on subcutaneous tumours in nude mice. 
Recently they have reported on the production of a bsab which identified a CD8- 
negative T cell subset and tumour cells. This bsab was incapable of inducing tumour 
cell lysis in vitro but was capable of inhibiting subcutaneous tumour growth in mice 
(Segal et al., 1991). Certain elements in the in vivo system prevent tumour growth and 
are absent from the in vitro system. The reasons for the diverging results in vivo and 
in vitro may be due to two different processes: (1) cytolysis which involves only 
targeted cells (Titus et al., 1987 a & b) and (2) tumour growth inhibition which 
involves bystander cells in lysis (Segal et al., 1991). These bystander cells may be 
absent from the in vitro system.
I.2.2.3. Immunoassays
One of the most powerful antibody-based analytical techniques is ELISA. This 
involves the detection of an antigen using an enzyme-labeled antibody. Bsabs which 
are capable of recognising an enzyme and an appropriate antigen can perform this 
procedure in a single step [Figure 1.2.2.1.]. Given the large potential that bsabs have 
in this research area it is surprising that their study with respect to ELISAs has been 
somewhat overshadowed by their uses therapeutically. Diagnostically ELISAs and 
immunocytochemical techniques can be used to detect proteins (antigens) in diseases 
where bodily fluids and biopsies are available for analysis. Suresh et al. (1986) made 
a biologically-derived bsab which detected peroxidase and substance P. The bsab was 
used in a one step immunoassay and was found to be superior to the peroxidase anti­
peroxidase system in identifying substance P. Karawajew et al. (1988) has also made 
bsabs biologically with specificities for peroxidase and FITC. This bsab system can 
be used as a bridging molecule between various FITC-labeled proteins and peroxidase. 
a-Fetoprotein (AFP) and human chorionicgonadotropin (hCG) have been detected in 
this manner and the levels of detection are equivalent to standard assays used for their 
detection.
Bsabs reacting with CEA and galactosidase have been made and used in the
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development of an homogeneous enzyme immunoassay (Gorog et al., 1989). This 
approach utilizes the ability of the anti-galactosidase antibody to protect the native 
enzyme from thermal degradation. On addition of bsab and enzyme any non-bound 
enzyme can be denatured at 62°C. Substrate for the enzyme can then be added. Using 
optimal conditions, CEA concentrations up to 75ng/ml can be detected. This represents 
the concentration range of CEA which is of clinical significance. Kenisberg et al. 
(1991) have made bsabs biologically with dual specificity for mouse (3 growth factor 
(NGF) and HRP. The bsab, in combination with parental anti-NGF, can be used in an 
homogeneous sandwich enzyme immunoassay to quantify NGF. Takahashi et al. 
(1991) have developed several bsabs using biological methods for use in urease-based 
enzyme immunoassays. The second arm of the bsab generally recognised hCG. The 
assays developed using the bsabs were capable of detecting 25mIU/ml hCG, a 
concentration equivalent to that detected by conventional monoclonal antibody based 
immunoassays. HPLC purification of the bsabs enhanced detection of hCG by bsab 
to as low as 15mIU/ml. This is probably due to the removal of contaminating 
antibodies which would compete with the bsab for binding of the antigens.
Bsabs have been used to determine the concentrations of cytokines. Tada et al. (1989) 
used a biologically produced bsab capable of measuring human lymphotoxin (TNF-P). 
The bsab recognised human lymphotoxin and HRP. This was used in a one step 
ELISA which could detect between l-100U/ml of human lymphotoxin. This correlated 
well with the concentration as determined using a bioassay. The ELISA using bsab 
could be completed in 2 hours whereas the conventional indirect ELISA was 
completed in 3-4 hours and a bioassay used took 3 days to complete. Stratieva- 
Taneeva et al. (1993) developed a bsab capable of measuring the concentration of 
human interleukin-2 (hIL-2) using a biologically made bsab which recognised both 
HRP and hlL-2. When applied to direct and competitive ELISAs this bsab could 
detect between 1.5 - 4ng/ml of IL-2 (the hIL-2 was prepared in PBS).
I.2.2.4. Miscellaneous uses of bispecific antibodies
Bruynk et al. (1993) have made humanized bsabs with dual specificities for CEA and 
a radiolabeled chelate DPTA-90Y for use in two phase radiotherapy. The bsab had a 
humanized anti-CEA arm and a chimerized anti-DPTA-Y arm. Its production involved
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double transfection of the corresponding genes into BHK cells. Bosslet et al. (1991) 
have studied the potential use of a biologically formed bsab in two phase 
radioimmunotherapy. One arm of the bsab recognises a tumour-associated antigen and 
the second recognises the radiolabelled chelate DPTA-Y. Whether or not the bsab has 
the same affinity as does the parental anti-tumour antibody is still under investigation. 
Snider et al. (1992) have used biologically formed bsabs to immunize mice. No 
adjuvant is required in this immunization protocol. The bsab recognised anti-class II 
MHC molecule with one arm and hen egg lysozyme (HEL) with the other. Several 
bsab were used for immunization each recognising a different epitope on the HEL. 
The antibody response in the mice is, therefore, determined by the epitope specificity 
of the anti-HEL arm, and will be against a new epitope. A subsequent single 
immunization with HEL did not effect the epitope response. However, further 
immunizations with HEL did induce an antibody response against new HEL epitopes. 
The Fc portion was not required in these studies for proper functioning of the bsab. 
F(ab'Y)2 bsab fragments were as effective as whole bsabs in causing the anti-HEL 
response.
Stickney et al. (1991) have studied a bsab system for the delivery of imaging or 
therapeutic agents to tumour cells (metastatic adenocarcinoma of the colon). Initially 
the patients were treated with bsab which detected the tumour cell and a hapten. The 
bsab is localised at the tumour site. After 4 days the patients were treated with a 
hapten tagged with a radioisotype. This is bound to the pre-localized bsab. Twenty 
lesions were imaged and 8 new lesions were identified.
1.2.3. Future prospects for bsabs
Bsabs have thus far been used in immunotherapy, redirecting of effector cells or toxins 
to target sites and in immunoassays (Gorog et al., 1989; Nolan and O’Kennedy, 1990; 
Takahashi et al., 1991). One of the most advantageous features of bsabs is that they 
function in their native state and once made no chemical alterations in their structure 
are required. This is not the case with mABs for use in immunotherapy and 
immunoassays which must be chemically modified prior to use. Bsabs allow for one 
step systems whereby both antigens are linked by the one molecule thus negating the 
use of secondary antibodies labelled with enzymes and immunotoxins. They also allow
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for accumulation of the immunotoxin or enzyme close to the cell surface. Appyling 
bsabs to immunotherapy requires that the antibodies be humanised, otherwise the risk 
of a host antibody response is increased. Use of bsabs in immunoassays, however, is 
not hampered by such restrictions and the potential applications of bsabs in this field 
should increase with further research.
In the work described in this thesis bsabs have been made with specificities for HRP 
and antigens present on Chronic Lymphocytic Leukemic cells. These were used to 
develop novel immunoenzymatic techniques.
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1.3. An introduction to IL-6
The cytokines are a group of regulatory proteins which can be produced by almost all 
nucleated cells in the body. These include lymphocytes monocytes epithelial cells, 
keratinocytes and osteocytes. Hormones differ from cytokines in that they are 
produced by specific organs rather than a multitude of cells (Clemens, 1991a). They 
are present in greater quantities than are cytokines in the circulatory system and have 
a more constant and evident role in haemostasis. Cytokines have pleiotropic effects 
on haematopoietic and non-haematopoietic cells. Cells which respond to cytokines 
must possess the appropriate receptor for the particular cytokine. The cytokines act 
within a network and very often one cytokine may stimulate/inhibit another (Clemens, 
1991b). A complete list of the cytokines is given in Table 1.3. and their mode of 
action is outlined in Figure 1.3.
This section deals with the role of interleukin-6 (IL-6) in the normal physiology and 
the pathophysiology of a number of diseases. IL-6 is a multifunctional cytokine which 
is produced by a wide variety of cells including both lymphoid and non-lymphoid 
cells. IL-6 is involved in regulating the final differentiation of B-cells into antibody- 
producing cells (Kishimoto, 1989), the acute phase response (Gauldie et al., 1987; 
Nijstein et al., 1987) and haematopoeisis (Hirano, 1991a). Murguchi et al. (1981) first 
identified human IL-6 in the supernatants of mitogen or antigen-stimulated peripheral 
mononuclear cells as a factor which induced immunoglobulin production in EBV- 
transformed cell lines or in normal B-cells which had been treated with 
Staphylococcus aureus Cowan 1 (SAC). IL-6 was identified independently by a 
number of groups before the protein’s nucleotide sequence was known and hence it 
was known by a variety of names including interferon-(32 (May et al., 1986), 26kDa 
protein (Haegeman et al., 1986), B-cell stimulatory factor-2 (Hirano et al., 1986), 
hybridoma/plasmacytoma growth factor (Aarden etal., 1985; Nordan and Potter, 1986) 
and hepatocyte stimulating factor (Gauldie et al., 1987). In the following section the 
structure of IL-6 and its role in disease are discussed.
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Class Example
Interferon (IFN) 
Interleukins (IL) 
Colony stimulating 
factors (CSF)
Tumour necrosis 
factors (TNF)
IFN-a, IFN-[3, IFN-y.
IL-1 - IL-12.
Colony stimulating factors (CSF) 
granulocyte colony stimulating factor (G- 
CSF), macrophage colony stimulating 
factor (M-CSF), granulocyte/macrophage 
colony stimulating factor (GM-CSF). 
Tumour necrosis factors (TNF) TNF-a, 
TNF-p.
Table 1.3. Classes of cytokines.
1.3.1. Structure of IL-6
IL-6 is a glycoprotein with a molecular mass of 21-28kDa. Human IL-6 consists of 
212 amino acids including a hydrophobic signal sequence of 28 amino acid residues 
(Hirano, 1991). Murine (Van Snick et al., 1988) and rat (Northemann et al., 1989) 
IL-6 have been cloned and have been shown to consist of 211 amino acid residues 
which includes a signal sequence of 24 amino acid residues.
When compared to the cDNA sequence of other cytokines it has been shown that only 
the sequence of G-CSF bears any homology with that of IL-6 (Hirano et al., 1986). 
It was shown that the positions of the four cysteine residues of IL-6 are similar to 
those of human and mouse G-CSF. This may lead to a similarity in tertiary structure 
and there may also be a functional homology. The role of the cysteine residues in the 
protein are not fully understood. Jamblou et al. (1988) replaced the cysteine residues 
with serines and no effect on the biological action of the protein was observed, 
indicating that the cysteine residues are not essential for protein function.
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Figure 1.3.
The cytokines have three modes of operation. These are autocrine, paracrine and 
endocrine. Autocrine stimulation results when a cell secreting a cytokine has a 
receptor for that cytokine and is therefore self-stimulated. In the case of paracrine 
stimulation a cytokine secreted by cell stimulates a cell which is in close proximity. 
In the final case of endocrine stimulation cytokines may be be released into the 
circulatory system and stimulate cells over relatively large distances.
28
1.3.2. IL-6 and haematopoiesis
The involvement of IL-6 in the differentiation of activated B-cells into antibody- 
producing cells is described in Figure 1.3.2. Ikebuchi et al. (1987) were the first to 
report that the proliferation of murine multipotential haematopoietic progenitors 
requires the synergystic action of IL-3 and IL-6. The combination of IL-3 and EL-6 
causes a decrease in the time that blast cell colony forming cells spend in the G0 phase 
of cell division. Bodine et al. (1989) have reported that IL-3, in conjunction with IL-6, 
has a proliferative effect on primitive bone marrow progenitor cells. Chiu et al. (1988) 
demonstrated that survival and proliferation of a myeloid cell line was supported by 
IL-6. IL-6 production in stromal cells was found to be induced by IL-1 giving rise to 
the possibility that the involvement of IL-1 in haematopoeisis could be due to its 
induction of IL-6. Recently, proliferation of NK cells has been linked with IL-6, 
which has been shown to induce a small proliferative effect on these cells 
(Rabinowich et al., 1993). The role of IL-6 in the maturation of megakaryocytes has 
been studied by Ishibashi et al. (1989) who showed that it acted directly in 
augmenting maturation in these cells. The observed effects include a physical change 
in cell size, an increase in acetylcholinesterase activity and a change in the DNA 
content. IL-6 also acts synergistically with IL-3 in the promotion of growth in 
megakaryocytes (Ishibashi et al., 1989).
IL-6 is capable of inducing differentiation in myeloid leukemic cells (Sachs, 1987). 
Various authors have reported similar findings. For example, Onozaki et al. (1989) 
reported that IL-6 acts synergistically with IL-1 in the induction of differentiation in 
some human and mouse myeloid leukemic cells into macrophage-like cells. Chiu and 
Lee (1989) reported that Ml mouse myeloid leukemic cells when treated with IL-6 
alone are induced to terminally differentiate into macrophages. The observed changes 
include an inhibition of M l cell growth and the induction of phagocytic activity which 
is associated with macrophages.
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Figure 1.3.2.
Differentiation and proliferation of B-cells requires the involvement of various 
cytokines at different stages. Interleukin-4 is required for early activation of resting 
B-cells, interleukin-5, is then involved in the proliferation of these activated B-cells. 
Finally, interleukin-6 causes differentiation of activated B-cells into antibody-secreting 
cells.
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1.3.3. IL-6 and the acute phase response
The acute phase response is a systemic reaction to inflammation or tissue injury. It is 
characterized by leukocytosis, fever, increased vascular permeability and alterations 
in plasma metal and steroid concentrations, together with increased levels of acute 
phase proteins (Hirano, 1991 b). Nijsten et al. (1987) examined IL-6 levels and acute 
phase proteins in serum from patients with severe burns and concluded that IL-6 plays 
a causal role in the acute phase response. Human umbilical vein endothelial cells 
(HUVEC) synthesise IL-6. This synthesis can be stimulated by treatment of the cells 
with the inflammatory mediators IL-1, TNF-a, TNI7-[3 (lymphotoxin) and LPS (Jirik 
et al., 1989). In contrast, transforming growth factor-(3 which regulates endothelial cell 
growth and biosynthetic functions, did not detectably stimulate IL-6. This suggests that 
HUVEC selectively respond to inflammatory mediators to increase synthesis of IL-6 
again indicating that IL-6 contributes significantly to the inflammatory response. 
Hypergammaglobulinemia is also associated with inflammation and this too could be 
mediated by the action of IL-6 in the differentiation of B lymphocytes.
Biologically active IL-6 can be induced in cancer patients treated with rTNF (Jablons 
et al., 1989). IL-6 induction decreased after serial daily doses of rTNF. Serum levels 
of acute phase plasma proteins and corticosteroids rose in response to rTNF 
administration. This could in turn be due to the increase in IL-6. MTntosh et al. 
(1989) have also reported that TNF induces IL-6 production in tumour-bearing mice.
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1.3.4. IL-6 and disease
1.3.4.1. The haematopoietic leukemias
Certain haematopoeitic leukemias have been shown to have altered IL-6 levels (Table
1.3.4.10-
Disease IL-6 activity Observed effect of IL-6 on 
tumour growth or symptoms
B-CLL + Not reported
ALL,
(Biondi et al., 1989)
CLL, ProLL,HCL - Not reported
ALL, lymphoma 
(Freeman et al., 1989)
+
Lymphoma (Yee et ah, 1989) + Possibly an autocrine growth factor 
for tumour cells
Lymphoma (Kurzrock et al., 
1993)
+ May induce B symptoms
ATL (Sawada et al., 1990) + Not autocrine
Multiple myeloma (Kawano et + Possibly an autocrine growth factor
al., 1988) for tumour cells
Table 1.3.4.1. Involvement of IL-6 in haematopoietic diseases.
CLL, Chronic lymphocytic leukemia; ALL, Acute lymphoblastic leukemia; ProLL, 
Prolymphocytic leukemia; HCL, Hairy cell leukemia; ATL, Adult T cell leukemia 
"+" IL-6 detected,
IL-6 not detected.
Biondi et al. (1989) investigated IL-6 production in B-cell chronic lymphocytic 
leukemia (B-CLL). B-CLL cells constitutively express IL-6 mRNA and secrete a 
biologically active protein. Six of the 11 B-CLL tested were positive for mRNA 
expression. Conditioned medium collected from freshly isolated B-CLL cells (B-CLL- 
CM) stimulated the growth of an IL-6-dependent cell line 7TD1. Three out of five B-
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CLL-CM tested showed IL-6 activity. These results correlated with the mRNA work. 
In 10 cases of acute lymphoblastic leukemia (ALL) no increase in EL-6 mRNA was 
found. Schena et al. (1991) examined cytokine production by normal and malignant 
B-cells. Normal B-cells from different stages of activation and proliferation were 
examined. These consisted of germinal centre B-blasts (GC-B) and mantle B-cells 
from tonsils. For comparison of malignant B-lymphocytes with their closest normal 
counterpart they chose normal CD5-positive B-lymphocytes from cord blood and 
malignant CD5-positive lymphocytes from a patient with B-CLL. The cytokines were 
analysed using Northern and Western blotting techniques. Among normal B-cells 
"mantle B-cells" (M-B) are the most active cytokine producers. They were found to 
secrete IL-la, IL-6, TNF-a and TGF-(3. This pattern of cytokine production is the 
same in B-CLL cells. The normal equivalent of B-CLL, CD5-positive B lymphocytes 
from cord blood, only produce TGF-p. GC-B produce IL-2, TNF-a and TGF. TGF-(3 
is the only cytokine produced by all cell types examined and, therefore, its production 
in B-CLL cells may be expected. The relevance of the cytokines produced by B-CLLs 
is as yet unknown but it is suggested that IL-la, TNF-a and IL-6 may be responsible 
for some of the sytemic manifestations of the disease such as fever and wasting 
(Schena et al., 1991). The relationship between cytokine production and the 
progressive failure of polyclonal B-cell and T-cell function in CLL has yet to be 
evaluated. An opposite effect is seen in ADDS where elevated IL-6 levels are thought 
to be associated with polyclonal B-cell activation (Nakajima et al., 1989; Breen el al., 
1990).
Freeman et al. (1988) reported that the IL-6 gene is expressed in anti-Ig-activated and 
neoplastic B-cells. After activation with anti-Ig, normal splenic B-cells expressed 
IL-6 mRNA with levels reaching a peak at 4 hours and declining thereafter. The 
expression of IL-6 mRNA was examined in various B-cell neoplasms. 11/25 patients 
with non-Hodgkins B-cell lymphoma and 4/4 patients with plasma cell leukemias 
expressed IL-6 mRNA in their neoplastic B-cells. Of 19 B-cell leukemias, only one, 
an ALL, was found to express IL-6 mRNA. IL-6 mRNA was not detected in B-CLL, 
prolymphocytic leukemia (ProLL) and hairy cell leukemia (HCL) neoplastic cells. Yee 
et al. (1989) established 14 cell lines from patients with non-Hodgkins lymphoma. IL- 
6 mRNA and the secreted protein were detected in two of the cell lines, OCI-LY3 and
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0CI-LY12. It was found that the addition of anti-rIL-6 antibody had an inhibitory 
effect on their growth indicating a possible autocrine role for IL-6. Kurzrock et al. 
(1993) have also reported that a significant number of patients with lymphomas have 
elevated IL-6 levels. "B-symptoms" which are also known as night sweats, are a 
clinical manifestation of lymphoma disease and are associated with the increase in 
serum IL-6 concentrations. The survival period of patients with relapsed or advanced 
Hodgkin’s disease is decreased if serum IL-6 concentration is greater or equal to 
22pg/ml.
The ability of adult T cell leukemia (ATL) which is causally associated with the 
human T-cell lymphotropic virus (HTLV-1) to secrete EL-6 or proliferate in response 
to it was studied by Sawada et al. (1990). Neither control nor ATL sera had detectable 
IL-6 levels. However, conditioned medium collected from growing the cells in vitro 
was found to have detectable levels of IL-6. Conditioned medium from 4/6 patients 
examined had elevated IL-6 levels. Exogenous addition of IL-6 and anti-IL-6 did not 
effect ATL proliferation indicating that tumour growth is not stimulated by IL-6 acting 
in an autocrine manner.
Myeloma cells freshly isolated from patients produce IL-6 and express its receptor 
(Kawano et al., 1988). On treatment with anti-IL-6 antibodies in vitro the myeloma 
cell growth is inhibited. This is direct evidence that an autocrine loop is operating in 
oncogenesis of human myelomas. The predictive significance of IL-6 and neopterin 
levels in patients suffering from multiple myeloma has been investigated (Reibnegger 
et al., 1991). High concentrations of both these molecules are indicative of a poor 
prognosis, but the predictive strength of neopterin exceeds that of IL-6.
I.3.4.2. Non-haematopoietic malignancies
Non-haematopoeitic tumours have also been reported to secrete altered levels of IL-6 
(Table 1.3.4.2.). Blay et al. (1992) reported that 48% of patients with metastatic renal 
cell carcinoma have detectable levels of IL-6 in their serum, whereas only 11% of the 
normal adults tested had detectable levels. The IL-6 levels of expression correlated 
with increased serum levels of C-reactive protein (CRP). These patients were observed 
to give poor response to EL-2 treatment and had shorter survival rates.
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Disease IL-6 activity Observed effect of IL-6 on 
tumour growth or symptoms
Renal cell carcinoma (Blay et 
al., 1992)
+ M ay induce the acute phase 
response
Ovarian carcinoma (Erroi et al., 
1989)
+ May induce the acute phase 
response
Ovarian cacinoma (Watson et 
a l,  1990)
+ Not an autocrine factor for 
ovarian carcinoma cell lines
Glioblastoma (Van M eir et al., 
1990)
+ May induce the acute phase 
response
Prostrate carcinoma cell lines
(Seigall et al., 1990)
+ Possibly an autocrine growth 
factor for tumour cells
Table 1.3.4.2. Involvement of IL-6 in non-haemopoietic malignancies.
"+" IL-6 detected,
IL-6 not detected.
Mullen et al. (1992) transduced fibrosacroma tumour cells with the IL-6 gene. When 
injected subcutaneously into mice these tumours exhibited reduced tumourigenicity, 
increased immunogenicity and reduced metastatic potential. Suppression of 
subcutaneous tumour growth is not seen when using nude or irradiated mice thus 
implicating T-cell-dependent and radiosensitive host contribution to the observed 
effect.
Erroi et al. (1989) investigated IL-1 and IL-6 production in tumour-associated 
macrophages (TAM) isolated from ascitic fluid and solid human ovarian carcinomas. 
TAM were found to release IL-1 when stimulated with LPS. However, IL-6 
production was detected in vitro without deliberate stimulation. IL-6 has also been 
detected in ovarian carcinoma ascitic fluid. This IL-6 may account for the levels of 
liver-derived acute phase proteins associated with malignancies of these carcinomas. 
Watson et al. (1990) has reported that 3/4 ovarian carcinoma cell lines tested 
constitutively produce IL-6. Immunoperoxidase staining reveal that >98% of the cells 
produce some IL-6. The levels of IL-6 may be modulated by other inflammatory 
cytokines such as TNF-a, IL-1(3 and interferon-y. IL-6 is not an autocrine factor here
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as neither exogenous IL-6 or anti-IL-6 affect the cell growth. IL-6 levels were also 
increased in ascitic fluid of ovarian cancer patients and in the supernatants of primary 
cultures from freshly excised ovarian tumours.
IL-6 release by glioblastoma patients has also been investigated (Van Meir et al.,
1990). IL-6 was analyzed in supernatants from glioblastoma cell lines, in cerebospinal 
fluid, in cyst fluids and in the tumoural tissues of glioblastoma patients. IL-6 levels 
in conditioned medium from cultured cells contained significant amounts of IL-6. IL-6 
mRNA was also detected in glioblastoma cell lines. IL-6 was detected in patient body 
fluids and IL-6 mRNA was detectable in solid frozen tumours. Immunohistochemical 
analysis revealed that IL-6 is produced by GFAP-positive cells in glioblastoma, thus 
ruling out the possibility that IL-6 is being produced solely by T-cells. Monocytes and 
macrophages, fibroblasts, microglial cells, astrocytes and endothelial cells all of which 
are present in glioma tissue, are known IL-6 secreting cells. The clinical consequence 
of an increase in EL-6 in these patients is still not known. It may be responsible for 
the acute phase response and the elevated immune complexes often associated with 
glioblastoma patients.
Siegall et al. (1990) have provided data to indicate that IL-6 and its receptor may play 
an important role in prostate cancer. Three prostate carcinoma cell lines were treated 
with a chimeric toxin composed of IL-6 and Pseudomas endotoxin. Under such 
conditions all three cell lines died. This indicates the presence of the IL-6 receptor on 
the cells. Supernatants from the cell lines also had detectable levels of IL-6. These 
results indicate that an autocrine loop similar to that observed in multiple myeloma 
(Kawano et al., 1988) may be in operation here. Pekarek et al. (1993) analyzed the 
cytokine mRNA profile of a range of human sarcoma cell lines and murine UV- 
induced sarcomas. The results obtained indicate that the cytokine profile can differ in 
tumours of the same type and even in variants of parental tumours.
I.3.4.3. Polyclonal B-cell abnormalities
Polyclonal B-cell abnormalities or autoimmune diseases have also been reported to 
have altered levels of IL-6 associated with their development (Table 1.3.4.3.).
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Disease IL-6 activity Role of IL-6 in disease
Cardiac myxoma (Hirano 
et al., 1987)
+ May be involved in 
autoantibody production
AIDS (Breen et al., 1990) + May be involved in 
polyclonal B-cell 
activation
AIDS Kaposi sarcoma- 
derived cells (Miles et al., 
1990)
+ Possibly an autocrine 
growth factor for these 
cells
Psoriasis (Grossman et al., 
1989)
+ Not reported
Mesangial proliferative 
glomerulonephritis (Horii 
et al., 1989)
+ Possibly an autocrine 
growth factor for these 
cells
Acute bacterial infection 
(Helgfoot et al., 1989)
+ May induce the acute 
phase response
Table I.3.4.3. Involvement of IL-6 in polyclonal B-cell abnormalities, proliferative 
diseases and infection.
"+" IL-6 detected,
:- IL-6 not detected.
Cardiac myxoma is a benign intra-atrial tumour. Hirano et al. (1987) reported that 
these cells constitutively produce IL-6. This may be important in the production of 
autoantibodies which are a feature of the disease. In Castleman’s disease activated B- 
cells in the germinal centre of hyperblastic lymph nodes were also found to 
constitutively produce IL-6 (Yoshizaki et al., 1989).
Exposure of peripheral blood monocyte cells (PBMC) from healthy donors to the 
human immunodeficiency virus (HIV) leads to the production of IL-6 mRNA and the 
secreted protein (Nakajima et al., 1989). Breen et al. (1990) detected IL-6 levels in 
the circulating plasma, and IL-6 mRNA in PBMC obtained from HIV infected donors. 
PBMC from these infected donors cultured without IL-6 activators constitutively 
produced elevated levels of IL-6. Levels of acute phase protein (which is induced by
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IL-6) were also increased in HIV-infected donors. The increase in IL-6 levels in HIV 
infected patients may contribute to the polyclonal B-cell activation as seen in HIV and 
AIDS infection. IL-6 and the IL-6 receptor are produced by Kaposi sarcoma-derived 
cells of AIDS patients and IL-6 is required for the optimal proliferation of these cells 
(Miles et al., 1990). There may be an autocrine loop involving IL-6 in the oncogenesis 
of AIDS-Kaposi sarcoma-derived cells. This is the case in multiple myeloma as 
discussed in section 1.3.4.2. IL-6 may therefore be important in the development of 
Kaposi sarcoma in vivo.
1.3.4.4. Infections
Fong et al. (1989) examined the appearance of circulating IL-6 in the plasma of 
healthy volunteers who received intravenous injections of endotoxin. Intravenous 
administration of endotoxin produced a rise in circulating immunoreactive IL-6 levels. 
An increase in circulating C-reactive protein was associated with this IL-6 rise. IL-6 
is, therefore, likely to be one of the endogenous mediators triggered during bacterial 
infection by of the human host. Hellfgoot et al. (1989) have detected elevated levels 
of biologically active IL-6 in the body fluids of patients with acute bacterial infections. 
The levels of IL-6 are sufficiently high as to elicit enhanced synthesis of acute phase 
plasma proteins by hepatocytes. The proposed involvment of IL-6 during infections 
is outlined in Table 1.3.4.3.
1.3.4.5. P roliferative d iseases
Elevated levels of IL-6 mRNA and protein in epidermal and dermal cells have been 
detected in psoriatic plaques (Grossman et al., 1989). IL-6 levels were also elevated 
in the plasma of these patients, probably due to the enhanced production of IL-6 in 
psoriatic lesions. IL-6 was found to stimulate the proliferation of human keratinocytes 
in culture. This may be an important factor for other cutaneous disorders characterized 
by epidermal hyperplasia. The overproduction of IL-6 may contribute to the 
pathophysiology of the disease.
IL-6 may be an autocrine factor for rat mesangial cells (Horii et al., 1989). rIL-6 was 
found to induce in vitro growth of rat mesangial cells and IL-6 activity was detected 
in supernatants obtained from cultured mesangial cells. IL-6 mRNA was also detected
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in the cultured mesangial cells. 50% of urine samples from patients suffering with 
mesangial proliferative glomerulonephritis (PGN) had significant levels of IL-6 
whereas urine from other primary glomerular diseases or healthy volunteers had no 
detectable IL-6 activity. There was also a relationship between the levels of urine IL-6 
and the progressive stage of PGN. Immunohistochemical staining using an anti-IL-6 
monoclonal antibody showed that mesangial cells in the affected glomeruli of PGN 
patients produced IL-6. This was not the case in normal kidney mesangial cells or 
mesangial cells from patients with membraneous nephropathy or minimal change 
nephrotic syndrome. In summary "deregulated production of IL-6 is involved in PGN 
and measurement of urine IL-6 is helpful for the differential diagnosis of PGN as well 
as for monitoring the progression of the disease" (Horii et al., 1989). The involvment 
of IL-6 in proliferative diseases is summarized in Table 1.3.4.3.
1.3.5. IL -6 and im m unotherapy
As discussed in the previous section IL-6 is associated with many diseased states. 
Whether its presence is pathological or therapeutic is of crucial importance if it is to 
be used in immunotherapy. IL-6 is reported to be an autocrine growth factor for many 
diseases including multiple myeloma (Kawano et al., 1988), non-Hodgkins lymphoma 
(Yee et al., 1989), Kaposi sarcoma (Miles et a l ,  1990), and ovarian carcinoma 
(Watson et al., 1990). MTntosh et al. (1989) reported that an increase in tumour 
burden was associated with an increase in IL-6. Various other investigators have 
reported constitutive expression of IL-6 in B-CLL (Biondi et al., 1989; Schena et al.,
1991). A feature of B-CLL is the failure of polyclonal B-cell activation 
(hypogammaglobulinemia). Breen et al. (1990) have suggested that the stimulation of 
IL-6 production in monocytes by HIV may be associated with the polyclonal B-cell 
activation as observed in AIDS patients (hypergammaglobulinemia). This a clear 
example of elevated IL-6 levels in different diseases leading to different/opposite in 
vivo responses. Mulé et al. (1990) examined the therapeutic efficacy of IL-6 on 
established tumours in mice. Metastases from four tumour types examined were 
significantly reduced when treated with recombinant IL-6 alone. IL-6 treatment did not 
exhibit the usual toxic side effects observed with recombinant IL-2 treatment. Also 
unlike recombinant IL-2 treatment, no vascular leak syndrome was observed. The
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mechanisms by which the anti-tumour effect occurs does not appear to be through the 
direct effect of recombinant IL-6 on the tumour since host immunosuppression 
eliminates successful therapy. Recombinant IL-6 may activate secondary cytokines 
which are directly/indirectly involved in tumour regression. Administration of low 
doses of IL-6 together with subtherapeutic doses of TNF to mice bearing an 
established weakly immunogenic syngenic tumour, at a subcutaneous site, resulted in 
marked tumour regression and higher cure rates. A possible mechanism for this anti­
tumour IL-6 effect has been suggested by Rabinowich et al. (1993). This involves the 
upregulation of ft and p2 integrins and the intracellular adhesion molecule ICAM-1. 
Coupled to this is the ability of IL-6 to allow binding of NK cells to the extracellular 
matrix. IL-6 has been shown to have an inhibitory effect on certain breast carcinoma 
and leukemic/lymphoma cell lines (Chen et al., 1988; Danforth et al., 1993).
Ohe et al. (1993) reported that Lewis lung carcinoma cells transfected with IL-6 
cDNA caused a state similar to cachexia when transplanted into mice. The survival 
of these mice was shorter than that of mice transplanted with Lewis lung carcinoma 
cells alone. No difference in tumour growth and metastasis was observed. However, 
Mullen et al. (1992) has shown that fibrosarcoma cells, when transduced with the IL-6 
gene, exhibited reduced tumourigenicity increased immunogenicity, and reduced 
metastatic ability in mice.
Serve et al. (1991) examined the effects of recombinant human IL-6 (rhEL-6) on the 
growth of 26 different cell lines derived from non-haematopoietic cells (solid 
tumours). The growth of the human malignant cell lines was not affected by the rhTL-
6. The tumours examined here were of an advanced nature and, therefore, may not 
reflect the continual growth and development of the tumour. Lu et al. (1992) 
highlights the importance of the time, during tumour development, at which growth 
factors are measured. They report that IL-6 can act as an inhibitor in the early stages 
of melanoma development (metastatically incompetent) but not on advanced 
progression (metastatically competent). IL-6 may act as a growth regulator of other 
non-haematopoietic human solid tumours depending on the stage to which the disease 
has progressed.
Clearly an important point to keep in mind when assessing the potential of IL-6, or 
any other cytokine, as an immunotherapeutic molecule, is the fact that tumour
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development at different stages of development may respond differently 
(inhibitory/stimulatory) to the same growth factor (Schawarz et al., 1988; Lu et al.,
1992) and given the diverse nature of cytokine production in similar tumours (Pekarek 
et al., 1993) it is important to know and essential to understand the cytokine profile 
of the tumour at a given time. Only when all of this infomation is available should 
cytokine therapy be contemplated.
In the work described in this thesis studies on the production and possible roles of IL- 
6 in CLL were investigated.
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1.4. Introduction to hybridoma cell growth
The steps involved in hybridoma technology are represented schematically in Figure
1.4. The medium conditions are crucial if efficient fusion is to be accomplished. For 
example at post-fusion the cells are often seeded in medium containing various 
cytokines such as IL-6 which is reported to increase the numbers of antibody-positive 
hybrids formed. The following section critically examines the conditions affecting 
hybridoma growth post-fusion.
1.4.1. Feeder cell layers and conditioned medium (CM)
The use of conditioned medium (CM), or feeder layers is important for the successful 
growth of hybridoma cells at certain stages such as post fusion or at the low cell 
densities encountered in cloning procedures. At these stages the fused cells are quite 
vunerable and may therefore require the extra growth properties supplied by these 
factors. These factors would include the cytokines in B-cell growth and differentiation 
such as IL-4, IL-5 and IL-6. To a large extent CM and commercial preparations have 
all but replaced feeder cells. This is mainly due to the fact that the growth 
factors/cytokines secreted by feeder cell layers have been identified and, thus, may be 
replaced by defined growth factors. IL-6 or hybridoma growth factor (HGF), is one 
such factor and has been shown to increase the proportion of antibody-producing 
hybridomas post fusion (Bazin and Lemieux, 1989), indicating that IL-6 is involved 
in differentiation of hybridomas into antibody-producing cells. According to 
Sugasawara (1988) (i) the cloning efficiency of IL-6-dependent hybridomas increases 
with the addition of IL-6 and (ii), the total number of hybridomas (antibody positive 
and negative), post fusion are increased in the presence of IL-6 indicating that IL-6 
is involved in differentiation and proliferation of hybridomas. Harris et al. (1992) have 
reported on an improved myeloma fusion system for the generation of a large number 
of hybridomas against specific antigens. This involves a retroviral infectant of Sp2/0 
cells that constitutively expresses recombinant murine IL-6 (Sp2/mIL-6) as fusion 
partner. The results obtained show that yields of both Ig-secreting hybridomas and 
antigen-specific monoclonal antibodies were increased 3-15 fold and 5-9 fold, 
respectively.
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Figure 1.4.
Monoclonal antibody production involves the fusion of splenocytes from an 
immunized animal with myeloma cells using polyethylene glycol which promotes 
membrane fusion. Fused cells containing genetic material from both the myeloma and 
splenocyte cells are selected and screened for specific antibody production. Newly 
formed hybridoma cells can be quite unstable and at this stage the choice of growth 
factors present in the culture medium may increase the chances of hybridoma survival. 
Our work involved studies on the growth of hybridomas at the clonal stage.
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The hybridomas generated with this system are comparable to those obtained using 
conventional systems as regards growth rates, stability and Ig-production.
IL-6 is not involved in the proliferation of activated B-cells but rather it induces final 
maturation of B-cells into antibody-producing cells (Kishimoto, 1989). IL-6 is, 
however, involved in the proliferation of myeloma cells (Kishimoto, 1989). Since 
hybridomas are of B-cell and myeloma cell origin this may account for the growth 
dependence of freshly fused hybridomas on IL-6/HGF.
Various authors have described a wide range of feeder cells and CM used in 
hybridoma technology (Pintus et al., 1983; Sugasawara et al., 1985; Butcher et al., 
1988; Long et al., 1988; King and Sartorelli 1989; Perrson and Lemer, 1990). Pintus 
et al. (1983) compared endothelial cell growth supplement (ECGS), human endothelial 
culture supernatant (HECS), and murine peritoneal cells for their ability to support 
hybridomas during various growth stages and on mAB production. Both ECGS and 
HECS proved superior to mouse peritoneal cells. A 1.5-4 fold increase was obtained 
when fused cells were cloned in ECGS compared to feeder cells. Westerwouldt et al. 
(1983), examined the growth promoting ability of human umbilical cord serum 
(HUCS), HECS, and other B-cell promoters. The numbers of antibody-producing 
hybrids post fusion and the cloning efficiency were examined. The growth-promoting 
ability of HUCS proved to be the best. The number of antibody producing hybrids 
remained constant with all media examined with the exception of FCS. HECS was 
also a potent hybridoma growth medium though not as effective as HUCS.
The effect of macrophage-conditioned medium (MCM) on hybridoma colony 
formation and cloning efficiency experiments has been examined (Sugasawara et al., 
1985). MCM was found to act as a growth promoter for hybridomas (hybridomas were 
made using the P3X63-AG8.653 myeloma). The MCM used was obtained from 
primary mouse peritoneal macrophages and from 3 continuous macrophage cell lines. 
It is not reported if other cell lines produce MCM, or, whether hybridomas derived 
from different myeloma cell lines respond to MCM. ECGS was found to be ineffective 
as a hybridoma growth stimulator in the work described by these investigators. No 
comparison of MCM versus feeder cells was made for either hybridoma colony 
formation or cloning efficiency, but it is reported that previous experience of using 
feeder cells indicated that they were similar or slightly less effective than MCM, but
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that outgrowth of hybridomas was interfered with by growth of macrophages, and 
exhaustion of medium by feeder cells. The macrophage product(s) responsible for 
stimulating hybridoma growth has not been identified. Ransom et al. (1986) used 
ECGS as a growth supplement for hybridomas. Their findings showed that when 
freshly fused cells were plated out in ECGS-supplemented medium the numbers of 
hybridomas formed exceeded those formed using mouse peritoneal cells. An increase 
in the number of fibroblastic type cells in the culture was associated with this increase 
in hybridoma numbers. This could be due to the growth enhancing properties of ECGS 
on splenic tissue in particular connective tissue and these cells may also aid 
hybridoma growth. ECGS was also found to enhance the cloning efficiency of 
hybridomas. Walker et al. (1986) has reported that CM prepared from the murine 
fibroblast cell line, L-929 (L-CM), acted as a growth promoter for B-cell hybridomas 
and increased the proportion of antibody-producing hybrids. In ten fusions those 
grown in L-CM had a significantly higher number of hybrids formed compared to 
peritoneal exudate cells (PEC). The percentage of antibody-secreting clones was also 
increased. L-CM also enhanced the cloning efficiency of the hybridomas as well as 
increasing the number of antibody-secreting clones. Van Mourik and Zeijemaker 
(1986) have demonstrated that culture medium supplemented with HUCS or normal 
human serum did not support the growth of hybridomas during cell fusions, whereas 
HGF and HECS did. All four supplements, however, were capable of supporting the 
growth of established hybridomas during cloning procedures suggesting that growth 
conditions are less stringent at this stage.
Butcher et al., (1988), compared several growth systems for their efficiency at 
supporting hybridoma growth post fusion, during cloning and after recovery from 
liquid nitrogen. They found that mitomycin C-treated 3T3/A31 cells used as a feeder 
layer were the most effective and reliable system for supporting cell growth at these 
stages. A period of 3-5 days was required before the hybridoma cells were added. 
Macrophage cells could be as effective as the 3T3/A31 cells but were less reliable, a 
lot depending on the donor mouse. ECGS inhibited the growth-promoting capacity of 
both macrophages and 3T3/A31 cells.
Long et al. (1988) have examined eight different cell line feeder layers and two 
conditioned media for their abilty to increase the establishment efficiency of newly
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formed hybridoma cells. The feeder layers consisted of three human fibroblast cell 
lines, IMR-90, MRC-5 and WI-38, NIH-3T3 cells, Vero African green monkey kidney 
cells, a clone of the Hela epitheloid cell line and murine macrophage and spleen cells. 
The human lung diploid fibroblastic cells, Vero African green monkey kidney cells, 
MRC-5-CM and medium containing ECGS, were all found to enhance the 
establishment of newly formed hybridomas. Murine splenocytes and macrophages and 
the Hela cell clone did not exhibit this effect and gave similar results to control 
medium. The irradiated lung fibroblast cells were found to be the most efficient at 
supporting hybridoma proliferation.
King and Sartorelli (1989) have compared macrophage and thymocyte feeder cells and 
soluble growth factors, Ewing sarcoma growth factor (ESGF) and ECGS, for the 
cloning of hybridomas. ESGF was comparable to feeder layers in its ability to support 
cloning of hybridomas. ECGS did not support the clonal growth of hybridomas 
examined. This was in agreement with the work of Butcher et al. (1988) but contrasts 
with the results of Pintus et al. (1983).
Medium supplemented with Sp2/0 ascitic fluid, as an alternative to FCS, added post 
fusion has been shown to enhance the cloning efficiency of hybridomas at least 2-fold 
(Stewart and Fuller, 1989). The number of antigen-specific antibody-secreting 
hybridomas was increased 5-fold in the eight fusions. Some of the advantages in the 
use of Sp2/0 ascites includes the ease in which it can be made and the small variation 
in batches. The growth factor(s) responsible is/are unknown. Supplementing fusion 
medium with 5% normal mouse serum has been reported to increase the number of 
monoclonal antibody-producing murine hybridomas by 7-10 fold (Perrson and Lemer, 
1990). The cause of the beneficial effect is unknown. Raybould et al., (1988) reported 
that production of antibody-secreting rabbit-murine hybridomas requires the use of 
rabbit supplemented serum. Without rabbit serum no antibody-producing hybrids were 
formed. These two sets of results are indicate that serum from the species of the cells 
used in fusions aid hybridoma growth. Gomathi et al. (1991) reported on the use of 
CM from the glioma cell line C6 (C6CM) for the growth of mouse hybridomas. They 
found that C6CM improved both hybridoma growth and cloning efficiency. The 
growth-promoting effect was observed on both the 3B3 hybridoma cells which were 
derived in the presence of C6CM and on the hybridoma, 3B6, which was derived
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without C6CM. C6CM was found to have no effect on the growth of the myeloma cell 
line used. However, the survival time for spleen cells was increased. The factor(s) 
involved is(are) not well described, but it is suggested that the factor(s) is novel in so 
far as they say it is reported here for the first time. Sanjeev (1992) indicates that IL-6 
is the factor and that this should have been further investigated by the initial reporters. 
Sharma (1992) claims that the IL-6 dependent cell line 7TD1 was used to test C6CM 
for IL-6 activity and that they are currently assaying the C6 cells for IL-6 mRNA.
1.4.2. Alternative strategies used in hybridoma growth
Bell et al . (1983) used a hanging drop method for cloning hybridomas. The 
concentration of FCS used also affected the cloning efficiency. 30% FCS in complete 
medium was found to be the most efficient. Civin and Banquerigo (1983) have 
described a method for cloning of hybridoma cells in ultra-low gelation temperature 
agarose. The advantages of this agarose method over the liquid systems given are that 
firstly it reduces incubator space and, secondly, the volumes required in the liquid 
systems are reduced. Unlike semi-solid systems, in which it may be difficult to break 
up cell clusters for transfer to liquid culture systems, the medium used here avoids 
gelation at room temperature for long periods. Davis (1986) has used semi-solid 
medium for the growth of hybridomas. This method has several advantages. Clonal 
competition is eliminated and this ensures that relevant antibody-secreting hybridomas 
are not overgrown by faster growing non-antibody-secreting hybridomas. A large 
number of hybridomas can be isolated from a single fusion and almost every colony 
examined will be a clone. This can be explained statistically in that the probability of 
clones which average 0.75mm in diameter overlapping on a plate 35mm in diameter 
is 4%. Given that each each colony can be regarded as a clone the necessity to clone 
is greatly reduced. The time scale involved in the fusion is reduced due to the 
elimination of cloning and feeding stages. One of the most advantageous properties 
listed is the fact that overgrowth with fibroblast cells is prevented because the petri 
dishes used are non-tissue grade. Nowadays, given the range of growth factor products 
available on the market which have replaced feeder cells, this is no longer a problem. 
Disadvantages include the increased workload due to the large numbers of hybridomas 
to be screened and problems associated with picking hybridomas for further culture.
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1.4.3. Human feeder layer systems
Brodin et al. (1983) have reported on the use of human peripheral blood monocytes 
as a feeder layer for use in the growth of human hybridoma, myeloma and lymphoma 
clones. In liquid cultures human monocytes and mouse thymocytes were superior to 
rat and mouse peritoneal macrophages in their ability to enhance cloning efficiency. 
The macrophage may be exhibiting some sort of phagocytic activity on the cloned 
tumour (hybridoma, myeloma and lymphoma) cells. CM obtained from the monocytes 
or the tumour cells did not enhance the cloning efficiency. In semi-solid medium 
feeder cell layers of monocytes, mouse thymocytes and macrophage all exhibited 
enhanced cloning efficiency. B-CLL lymphocytes have also been used as feeder cells 
to clone human heterohybridoma cell lines (Sanchez et al., 1991). The B-CLL cells 
were examined for the presence of CD5, CD21, CD3 and CD19 by 
immunoflourescence. Peripheral blood cells which were both CD5 and CD21 negative 
were selected for several reasons. Firstly, since CD21 is in fact the EBV receptor and 
the heterohybridomas are derived from EBV-infected cell lines this prevented feeder 
cells from being infected by any EBV occasionally released by the hybrids. Secondly, 
since a majority of CD5-positive lymphocytes are involved in the production of 
polyreactive antibodies in vivo this may interfere with the detection of antibody 
secretion by the heterohybridomas. An added advantage of B-CLL cells as feeder cells 
is that given their limited survival time in vitro they do not require irradiation prior 
to use.
There have been mixed reports as to whether or not IL-6 levels are increased in 
patients with CLL (Freeman et al., 1988; Biondi et al., 1989; Schena et al., 1991; 
Aguilar-Santelises et al., 1992). B-CLL have been shown also to produce BCGF 
(Kawamura et al., 1986), a factor with IL-1 type activity (Uggla et al., 1987) and IL- 
a, TNF-a and TGF-fJ (Schena et al., 1991). Given the wide range of cytokines 
produced by these patients the possibility of using CLL plasma as a growth 
supplement, CLL-DMEM, for murine hybridomas was examined. CLL-DMEM was 
found to increase the cloning efficiency of the hybridomas examined. This discovery 
may allow for a better understanding of how the cytokines are effecting these patients 
in vivo, in particular the effects on B-cells since hybridomas are of B-cell origin.
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Aims
Aims of the project
Various aspects of the disease Chronic Lymphocytic Leukemia (CLL) were examined. 
The potential of biologically and chemically produced bispecific antibodies for the 
detection of CLL cells and CLL related antigens using novel immunocytochemical and 
ELISA systems was assessed. The bispecific antibodies recognised both peroxidase and 
an antigen present on CLL cell. The hybridoma G12 secreting the anti-CLL antibody 
was produced and characterized previously in our laboratory. It was found to recognise 
a determinant on the cells with a MW of 69,200D. The antigen was shown to disappear 
subsequent to chemotherapy suggesting a correlation between disease stage and antigen 
expression. The antibody may therefore have be of value diagnostically if used to 
monitor presence of the antigen. The bsabs developed here allow for rapid detection 
of the antigen in single step system.
Aspects of the role of interleukin-6 (IL-6) in CLL were investigated. Among the 
normal functions of IL-6 is the final differentiation of activated B-cells into antibody- 
producing cells. It has been reported that IL-6 levels are raised in patients with CLL. 
The clinical manifestations of this have yet to be elucidated. One of the clinical 
symptoms of CLL is hypogammaglobulinemia and this may be associated with the 
increased susceptibility of these patients to bacterial infections which are a major cause 
of morbidity and mortality. IL-6 levels in the plasma of patients with CLL and CM 
obtained from growing peripheral blood lymphocytes of these patients in culture were 
determined. IgG levels in these plasma samples were also examined. Both sets of 
results were correlated. If elevated IL-6 is associated with normal IgG levels then these 
patients may have an improved prognosis. IL-6 may then have an immunotherapeutic 
potential.
The growth promoting ability of CLL plasma on hybridoma cells at the clonal stage 
was compared to conventional methods of hybridoma cell cloning such as cell feeder 
layers and to a novel growth medium developed in our laboratory. Cytokines levels 
have been well studied in patients with CLL. The role of these cytokines in the 
progression of the disease is not fully understood. Hybridomas are of B-cell origin and 
the effects of the plasma on the growth of hybridomas may mimic the effect of these 
cytokines in vivo on B-cell development in patients with the disease.
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Chapter 2
Materials and Methods
2.1. Materials
All cell culture media, foetal calf serum, L-glutamine, penicillin-streptomycin solutions 
were obtained from Flow Laboratories, Irvine, Scotland. Cell culture vessels were 
obtained from Costar, Cambridge, MA, 02140, USA. Chemicals were of Analar grade 
and were obtained from the ‘Sigma Chemical Co.’, Poole Dorset, England; Riedel de 
Häen, AG, Seelze, Hannover, Germany and BDH Chemicals Ltd., Poole, Dorset, 
England.
Details of specific kits and antibodies are listed in Tables 2.1.1 and 2.1.2.
Cell lines used in the course of the work are listed in Table 2.1.3.
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Materials Supplier
Human recombinant IL-6, Boehringer Mannheim, Hanover, 
Germany.
Enzyme conjugated antibodies 
Alkaline phosphatase-conjugated goat 
anti-mouse whole antibody 
Alkaline phosphatase-conjugated goat 
anti-mouse whole IgM, 
Alkaline-phosphatase conjugated goat 
anti-rabbit whole IgG,
Peroxidase conjugated goat anti-mouse 
IgG,
Sigma Chemical Co., Poole, Dorset, 
England.
Monoclonal antibodies 
Goat anti-human IL-6 antibody
Rabbit anti-human IL-6 antibody,
British Bio-technology Products Limited, 
4-10 The Quadrant, Barton Lane, 
Abingdon, Oxon, OX143YS.
SeraLab, Crawley Down, Sussex, 
RH104FF, UK.
Dako PAP kit System 40, Dakopatts Limited, 16 Manor Courtyard, 
Hughunden Avenue, High Wycombe, 
Bucks., HP13 5RE.
Mouse monoclonal antibody isotyping
reagents,
Sigma Chemical Co., Poole, Dorset, 
England.
Goat anti-mouse IgG, Sigma Chemical Co., Poole, Dorset, 
England.
Table 2.1.1. Specific antibodies, antibody kits and recombinant proteins used and their
sources.
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Materials Supplier
Hoechst 33258, Calbiochem, Behring 
Diagnostics, La Jolla, CA 
92037, U.S.A.
Polyethylene-glycol 1500, Boehringer Mannheim, 
Hanover, Germany.
Rapi-diff II, Triple stain 
set for histochemical 
staining of cells,
Diagnostic Developments, 
Southport, UK.
PD-10 Sephadex columns 
G-25M,
Ficoll-Paque,
Pharmacia, Uppsala, 
Sweden.
Ultragel AcA44, LBK, IBF-
Pharmindustries, Reactifs, 
France.
Bicinchoninic acid protein 
assay kit,
Pierce Chemical Co., 
Rockford, Illinois, 61105, 
U.S.A.
Table 2.1.2. Miscellaneous reagents used in the course of the work and their sources.
54
Cell
line
Cell type Cat. No. Source
SP2/0 Mouse myeloma Flow Laboratories, 
Irvine, Scotland.
Epl6
14E5
7P41
0KT8
LoVo
K562
NRK
Mouse hybridoma
Mouse hybridoma
Mouse hybridoma
Mouse hybridoma
Human colon adenocarcinoma
Human erythroleukemia
Normal rat kidney
CRL 8014 
CCL 229 
CCL 243 
CRL 6509
American Tissue 
Culture Collection, 
12301 Park Lawn 
Drive, Rockville, 
Maryland, 20861, 
USA.
G12
E5
H9
H12
Mouse hybridoma 
Mouse hybridoma 
Mouse hybridoma 
Mouse hybridoma
Produced by 
Dr. B. Lannon at 
DCU
EJ-138 Human bladder carcinoma 8511412 ECACC, PHLS, 
Porton Down, 
Salisbury, 
Wiltshire, SP4 
OJG, UK.
B9 IL-6-dependent mouse 
hybridoma
Dr. L. Aarden, Red 
Cross, Amsterdam, 
Netherlands.
T24 Human bladder carcinoma Dr. J. Tager, 
University of 
Amsterdam, 1105 
AZ, Netherlands.
GCCM Human glioblastoma ECACC, PHLS, 
Porton Down, 
Salisbury, 
Wiltshire, SP4, 
OJG, UK.
HL60 Human promyelocytic 
leukemia
Dr. T. Cotter, St. 
Patricks College, 
Maynooth.
2.1.3. Cell lines used during the project.
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2.2. Equipment
2.2.1. Centrifugation
A Heraeus Christ Labofuge was used for centrifugation of universal tubes (l-25mls) 
and centrifugation tubes (l-50mls). Smaller volumes were centrifuged on a Heraeus 
Biofuge A using eppendorf containers (l-1.5mls). Cytosmears were prepared on a 
Hereaus Sepetech cytocentrifuge. For centrifugation of large volumes (up to 200mls), 
at higher speeds a Sorvall centrifuge was used.
2.2.2. Cell culture
Asceptic cell culture techniques were undertaken in a Holten Laminar Air flow 
cabinet, HB 2448K. Procedures involving mutagenic agents were performed in a 
Cytogard Laminar Air cabinet, (Gelman Sciences). Cells were incubated in a humid 
5% C02 athmosphere at 37°C in a Jouan EG 115 IR incubator.
Long term storage cells were cryopreserved in a cryocontainer, (Union Carbide LR- 
30A).
Cells were visualised on a Nikon phase contrast ELWD 0.3 microscope.
Single cell suspensions of splenocytes were obtained using a Cell Dissociation 
Sieve/Tissue Grinder kit.
2.2.3. Electrophoresis
Electrophoresis was perfomed on a Biorad vertical electrophoresis system.
2.3. Tissue culture methods
2.3.1. Suspension cultures
Sp2/0, G12, Epl6, 14E5, OKT8, 7p41, B9, K562 and HL60 cells were cultured in 
Dulbecco’s Modification of Eagle’s Medium, (DMEM), containing 5% FCS (v/v), L- 
glutamine (2mM), Hepes (ImM) and sodium pyruvate (2mM). B9 cells which are 
interleukin-6-dependent (IL-6-dependent) are further supplemented with 5% T24 (v/v) 
supernatant. T24 cells produce interleukin-6 (IL-6). All cultures with the exception of 
the B9 cell line were seeded in 25cm3 and 75cm3 culture flasks. B9 cells were cultured 
in 24 and 96 well culture plates. All cell lines were incubated in a humid, 5% COz 
atmosphere at 37°C.
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2.3.2. Adherent cell cultures
T24, LoVo, GCCM and EJ cells were cultured in DMEM containing 5% FCS (v/v), 
L-glutamine (2mM), Hepes (ImM) and sodium pyruvate (2mM). All cultures were 
seeded in 25cm3 and 75cm3 culture flasks. For passaging adherent cell lines it is 
necessary to trypsinise the cells. Firstly, the culture medium is decanted. The culture 
vessel is then flushed out with serum-free DMEM. This has a twofold effect in that 
it ensures all FCS, which could potentially interfere with trypsin activity, is removed 
and secondly, any non-adherent dead cells are removed. 5-10mls of the trypsin:EDTA 
solution, [trypsin 0.25% (w/v) with 0.02% EDTA in sterile PBS], was added to the 
flasks. The culture was then incubated at 37°C for 10 minutes. The cell suspension 
was then added to a universal container containing 5mls of complete culture medium 
and centrifuged at 2000rpm for 10 minutes. Cells were resuspended in the appropriate 
amount of culture medium and seeded into culture vessels. All cell lines were 
incubated in a humid, 5% C 02 atmosphere at 37°C.
T24 cells were used as a source of IL-6. IL-6 is required for the growth of B9 cells.
2.3.3. Cell counts
Cell counts were performed on an improved Neubauer Haemocytometer slide using 
the Trypan blue stain. A 1:1 ratio of the cell suspension and stain was prepared. This 
was examined after 2-5 minutes by light microscopy. Live cells exclude the stain and 
maintain their integrity while dead cells stain blue.
2.3.4. Storage of cell lines
Stocks of cells were maintained in the liquid phase of liquid nitrogen in 
Cryocontainers, (Union Carbide). Washed cells were resuspended dropwise in 1ml ice- 
cold FCS supplemented with 5% (v/v) dimethylsulfoxide and transferred to sterile 
cryotubes. The cryotubes were lowered slowly into the gas phase and eventually into 
the liquid phase of liquid nitrogen.
Cells were recovered from liquid nitrogen by thawing the cells rapidly at 37°C and 
then washing in complete medium. The cells were centrifuged at 2000rpm for ten 
minutes and resuspended in complete medium.
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2.3.5. Mycoplasma detection - Hoechst 33258 fluorescent assay
Mycoplasma was detected using the Hoechst stain. The method used was that first 
described by Chen, (1977) and modified by Carroll et al., (1988). Bisbenzimid, 
(Hoechst 33258) is a DNA interchelator which detects mycoplasma in cellular 
cytoplasm. 5xl03 mycoplasma free-NRK cells were cultured overnight in 1ml of 
complete medium on coverslips. Culture supernatant was removed from the test cell 
line and added to the NRK cells which were incubated for a further 3-4 days. The 
coverslips were then washed 3 times in PBS and fixed for 6 minutes in 
methanol:acetone (1:1) solution at -20°C. The coverslips were then washed 3 times in 
PBS and incubated for 10 minutes with the Hoechst 33258 stain. The coverslips were 
washed again to remove unused stain and mounted on fresh slides. Samples were 
stored in the dark until viewed under UV light on a Nikon fluorescence microscope 
at 100X magnification with oil immersion and a B2 combination filter.
2.3.6. HAT sensitivity testing of myeloma cell lines
Sp2/0 cells were plated in complete medium supplemented with lxlO4 M 8-azaguanine 
(8-aza) for 3 days. HAT-sensitive (HAT-s) cells can grow in this medium but HAT- 
resistant (HAT-r) cells die. If the cells are found to be HAT-s they are grown in 8- 
aza-free medium for 1 week prior to use in cell fusions.
2.3.7. Antibody production by somatic cell fusions
2.3.7.1. Immunization
A 1ml solution of HRP at a concentration of 40jag/ml was prepared in PBS pH 7.2. 
The volume was brought to 2mls with Complete Freund’s Adjuvant and emulsified 
using a Kikawerk Ultra-Turrax homogeniser. Balb/C mice were immunized 
intraperitoneally with 1ml of this emulsion. With the exception of the first 
immunization Incomplete Freund’s was used at all times. Complete Freund’s Adjuvant 
contains mycobacterial artifacts which act as an immune stimulant. Immunizations 
were performed fortnightly until a satisfactory antibody titre was detected in the 
mouse serum. The mice were bled via the tail vein. The blood was allowed to clot at 
4°C for between 10-20 minutes before being centrifuged at 2000rpm for 5 minutes in 
a Biofuge. Serum was screened by ELISA for anti-HRP antibody levels as described
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in Section 2.8.7. The final immunization was given 3-5 days prior to cell fusion.
2.3.7.2 Isolation of immune splenocytes
The spleen was removed aseptically and the splenocytes were dissociated on a sterile 
cell dissociation sieve. The resulting cell suspension was washed 3 times in serum free 
DMEM. Red blood cells were lysed using Gey’s haemolytic solution (Mishell and 
Shiigi, 1981). This involved resuspending the pellet in 5mls of Gey’s haemolytic 
solution and incubating at 37°C for 5-10 minutes. The cell suspension was then 
centrifuged for 10 minutes at 2000rpm. The remaining lymphocytes were washed 3 
times in DMEM before fusion as described in Section 23.1.1.
2.3.7.3. LINO medium for use during in vitro immunizations
When preparing LINO medium it is important that the proteins are added before the 
lipids. A 5% (w/v) solution of BSA was prepared in Iscove’s Modification of Eagle’s 
Medium, (IMEM). To 50mls of the medium was added 2mls each of a 5% (w/v) 
solution of bovine insulin made up in 0.01N HC1, a 0.25% (w/v) solution of human 
transferrin prepared in sterile PBS and 2mls of a 1:1000 dilution of ethanolamine 
prepared in sterile 0.15M PBS, pH 7.2. 0.2mls each of 0.5% (w/v) solutions of linoleic 
acid palmitic acid and oleic acid each prepared in absolute ethanol were then added. 
The medium was filter sterilized and brought to 1 litre with IMEM. 50ml aliquots of 
this medium were stored at -20°C until required for use. Just before use L-glutamine 
(2mM) and 50pM 2-mercaptoethanol were added.
2.3.7.4. Thymocyte conditioned medium, (TCM) for use during in vitro 
immunizations
Five female 3-4 week old Balb/c mice were sacrificed. A thymonectomy was 
performed on each mouse and the pooled thymocytes were dispersed by flushing with 
serum-free DMEM using a 21-G needle. The thymocytes were washed twice more 
using serum-free DMEM and for a final time in LINO. The cells were resuspended 
to give a final cell concentration of 5xl06/ml dispensed in 25ml aliquots into 75cm3 
culture flasks and incubated in a humid, 5% C02 atmosphere at 37°C for 48 hours. 
The supernatant was decanted and centrifuged at 200Qrpm for 10 minutes, filter
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sterilized and stored at -20°C for until required for use.
2.3.7.5. In vitro immunization of rabbit splenocytes
The method used was that described by Ossendorp et al., (1986). This method uses 
a serum-free medium called LINO as described in Section 2.3.7.3. (Yssel et al., 1984) 
in which the splenocytes are cultured. Immunization medium consisted of an equal 
volume of LINO and TCM (LINO/TCM). Splenocytes from a New Zealand white 
male rabbit which had been immunized in vivo were isolated as described in Section
2.3.7.2. and stored in liquid nitrogen. The cells were washed in serum-free DMEM. 
The resulting pellet was washed for a final time in LINO/TCM medium. The cells 
were resuspended at a concentration of 5xl06 cells/ml in immunization medium, 
(LINO/TCM), which contained 5pg/ml of HRP and dispensed in 2ml lots into the 
wells of a 6 well culture tray which was then incubated in a humid, 5% C02 
atmosphere at 37°C for 72 hours. After this time period the cells were harvested for 
cell fusion. The concentration of antigen used depends on its antigenicity and this 
must be optimized for each different antigen.
2.3.7.6. Induction of HAT-sensitivity in hybridoma cell lines to be used in the 
production of triomas
HAT-sensitivity can be induced by continuous growth of hybridoma cells in increasing 
concentrations of toxic guanine analogues such as 8-aza, (0-20pg/ml), or by 
mutagenising the cells and subsequently selecting for new phenotypes using selection 
agents such as 8-aza.
The action of 8-aza is mediated through the enzyme hypoxanthine guanine phospho- 
ribosyl transferase, (HGPRT), whereby preformed purines or purine analogues are 
taken up by the so-called "scavenger pathways". Cells having a defective enzyme or 
no enzyme are resistant because they do not incorporate the toxic analogue into their 
nucleic acid.
The first method chosen to induce HAT-sensitivity was to grow hybridoma cells in 
increasing concentrations of 8-aza. Cells capable of growth in complete medium 
containing 20pg/ml 8-aza are considered HAT-s. Hybridoma cells were seeded at
60
lxlO3 cells/well in 24 well plates in complete medium supplemented with various 
concentrations of 8-aza. The cells were initially seeded in low concentrations of 8-aza, 
(O-lOpg/ml). After 3-6 days the cells growing in the highest concentrations of 8-aza 
were removed and seeded in fresh medium containing increased concentrations of 8- 
aza, (up to 20pg/ml). If at this stage cells were found to be growing in 20pg/ml of 8- 
aza they were examined for HAT-sensitivity HAT-sensitivity as described in Section 
2.3.6., and if HAT-s they were ready to fuse to immunized splenocytes for the 
formation of trioma cells.
HAT-sensitivity was also induced in hybridoma cells using the mutagenic reagent 
ethyl methanosulphate (EMS). Mutagenesis allows new and desirable phenotypes to 
exist. New phenotypes were selected from the mutagenised cells using 8-aza as a 
selective agent. Firstly, a kill curve using EMS was established for the particular cell 
line. This was to determine the concentration of EMS which caused a 50% kill of the 
cells. This concentration is arbitrary and allows for the out-growth of new phenotypes. 
2xl04 cells were seeded into 24 well culture plates in complete medium containing a 
range of concentrations of EMS (0-200pg EMS/ml of complete medium) and 
incubated in a humid, 5% C02 atmosphere at 37°C for between 16-24 hours. The cells 
were washed 3 times using sterile 0.15 M PBS, pH 7.2 and re-seeded in fresh culture 
medium. After between 3-6 days cell counts were performed as described in Section
2.3.3. and the 50% kill concentration was determined. Secondly, a kill curve using the 
selection agent 8-aza, was established. To ensure that HAT-s hybridoma cells are 
formed the concentration of 8-aza resulting in a 100% kill of the wild-type hybridoma 
cells was required. Surviving hybridoma cell are therefore HAT-s. Cells were seeded 
at lxlO3 cells/well in 24 well plates in complete medium supplemented with 8-aza 
ranging in concentration from 0-30pg/ml.
Once the concentrations of EMS resulting in a 50% kill and that of 8-aza resulting in 
a 100% kill of hybridoma cells were established the experiment to induce HAT- 
sensitvity was performed. The cells were mutagenised using the concentration of EMS 
resulting in a 50% cell kill and HAT-s cells are selected using 8-aza at a concentration 
determined to be that which results in a 100% cell kill of wild type hybridoma cells.
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2.3.7.7. Production of triomas by somatic cell fusions
G12 hybridoma cells which were rendered HAT-s and tested for the presence of 
mycoplasma were maintained in the mid-log phase of growth for 7 days prior to 
fusion. These cells were fused to HRP-immunized mouse and rabbit splenocytes. On 
the day of cell fusion the cells were washed 3 times in serum free DMEM. Immunized 
spleen cells were depleted of RBC as described in Section 2.3.7.2. Both cell 
populations were counted and mixed at a ratio of 5 spleen cells to 1 myeloma cell and 
centrifuged at 3000rpm for 10 minutes in a 50ml centrifuge tube. The supernatant was 
decanted. It is important at this stage to aspirate all remaining medium from the 
centrifuge tube. This avoids diluting further the PEG-1500 which is to be added 
subsequently. The cells were fused using PEG-1500 at 37°C. One ml of PEG-1500 
was added with a gentle swirling motion to the pelleted cells over a 1 minute time 
period. This swirling motion was maintained for a further 1 minute. Three mis of 
serum free DMEM at 37°C was added dropwise over the next 3 minutes. This was 
followed directly by a further 8 mis over the next 3 minutes. The cells were pelleted 
at lOOOrpm for 2-3 minutes and resuspended in DMEM.S5 supplemented with 5% T24 
supernatant at a cell concentration of lx l06/ml. The cell suspension was plated into 
96 well culture trays, (200pl/well). On the day after the cell fusion, lOOpl of culture 
medium was removed gendy and replaced with lOOpl of culture medium containing 
2x HAT. The cells are fed in a similar manner during the next couple of weeks with 
the HAT concentration being reduced to lx. At this stage any non-fused myeloma 
cells are dead due to the aminopterin in the medium and non-fused lymphocytes die 
naturally. The cells can therefore be weaned off HAT. Over the next 2 weeks the HAT 
is replaced with HT. After a similar time period the HT can be removed altogether.
G12 HAT-s for use in cell fusions involving rabbit splenocytes were grown in 
complete medium supplemented with 5% normal rabbit serum. This was also added 
to the fusion medium. Monoclonal anti-HRP antibodies were produced in a similar 
manner using immunized mouse splenocytes and Sp2/0 myeloma.
2.3.8. Cloning of hybridomas by limiting dilutions
Hybridoma cells must be cloned out to ensure monoclonality. This method was also
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used in cloning efficiency experiments on hybridomas.
Only hybridoma cell lines in the exponential growth phase were chosen. The cell 
concentration was brought to lx l06/ml in serum free DMEM. A 1:1000 dilution was 
prepared in serum free DMEM. This was accomplished in two steps (a 1:100 dilution 
followed by a 1:10 dilution) to reduce error. This preparation contained 1 cell/pl. 
1 OOpl of this suspension was taken and resuspended in 20mls of complete medium and 
dispensed in 200jjl volumes into the wells of a 96 well culture tray. The culture trays 
were incubated in a humid, 5% C02 athmosphere at 37°C. After 1-2 weeks newly 
formed clones were visible to the naked eye. Wells containing single clones were 
grown to confluency and then transferred to larger culture vessels. After 2-3 months 
hybridomas are recloned to ensure continued monoclonality.
2.3.9. Preparation of spleen feeder cells from Balb/c mice
The spleen were isolated as described in Section 2.3.7.2. The cells were brought to a 
final cell concentration of lx l06/ml in complete medium and dispensed in lOOpl 
volumes into the wells of a 96 well culture tray. The culture trays were incubated in 
a humid, 5% C 02 atmosphere at 37°C for up to 5 days before the hybridoma cells, 
which were being cloned, were added at a concentration of 1 cell/well, bringing the 
final volume of medium/well to 200pl.
2.3.10. Preparation of macrophage feeder cells from Balb/c mice
8-12 week old mice were sacrificed. The abdominal skin was cut exposing the 
peritoneal cavity. 10ml of serum-free DMEM was injected gently into the peritoneal 
cavity. It is vital that the intestine which is a potential source of infection is not 
damaged. The abdominal region was massaged to disperse the DMEM throughout the 
peritoneal cavity. The macrophage cell-suspension was removed by inserting a 21-G 
needle into the peritoneal cavity. The cell suspension was removed and washed twice 
in serum-free DMEM. The cells were then treated similarly to those in Section 2.3.9.
2.3.11. Preparation of thymocyte feeder cells from Balb/c mice
3-4 week old mice were sacrificed. A thymonectomy was performed and the
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thymocytes were dispersed by flushing with serum-free medium using a 21-G needle. 
The thymocytes were washed twice using serum free DMEM. The cells were then 
treated similarly to those in Section 2.3.9.
2.3.12. T24-conditioned medium, (T24-CM)
T24 cells were cultured as described in Section 2.3.1. After the second passage 
supernatant was collected from the cells, centrifuged at 2000rpm for 10 minutes and 
filter sterilized. This was used immediately or stored at -20°C. T24-CM was used to 
supplement DMEM.S5 at a concentration of 5% (v/v).
2.3.13. CLL and normal human plasma
10ml aliquots of blood were collected by venipuncture in heparinised tubes from 
patients with CLL or from normal healthy volunteers. The blood was transferred 
aseptically to sterile centrifuge tubes and centrifuged at 2000rpm for 10 minutes. The 
plasma was removed, filter sterilized and used immediately or stored at -20°C for 
future use.
2.3.14. Isolation of mononuclear cells from the heparinised whole blood
Leucocytes were removed from plasma of patients with B-CLL and healthy volunteers 
by density gradient centrifugation over Ficoll-Paque (Boyum, A., 1968). Heparinized 
whole blood was diluted 1:1 with 0.15M PBS, pH 7.2. Two parts of this mixture was 
then layered over 1 part of Ficoll-Paque in a 50ml centrifuge tube and centrifuged at 
2000rpm for 30 minutes. The red blood cells form a pellet and the white blood cells 
form a buffy layer between the plasma and the lymphoprep. This layer can be 
removed with a pasteur pipette and washed twice in 0.15M PBS, pH 7.2. These cells 
may be used immediately or frozen down in liquid N2.
2.3.15. Preparation of conditioned from normal and Chronic Lymphocytic 
Leukemic, (CLL), peripheral blood cells
Peripheral blood cells were isolated as described in Section 2.3.15. The cells were 
brought to a final concentration of lx l0 6/ml in DMEM.S5 and cultured in 25 cm3 and 
75cm3 culture flasks as described in Section 2.3.1. After 48, hours the culture
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supernatant was collected from the cells, centrifuged at 200Qrpm for 10 minutes and 
filter sterilized. This was used immediately or stored at -20°C for future use.
2.4. Production of polyclonal anti-HRP antibodies in a New Zealand White male 
rabbit
Prior to the immunization protocol, normal rabbit serum was obtained from the rabbit 
by bleeding from the marginal ear vein. This was used as a negative control during 
subsequent ELISA’s and protein assays.
A lmg/ml solution of HRP was prepared in 0.15M PBS, pH 7.2. The volume was 
adjusted to 2mls with Complete Freund’s Adjuvant and emulsified as described in 
Section 2.3.7.1. The rabbit was immunized intradermally along the back with 1ml of 
this emulsion. The animal was boosted on day 14, and subsequently on 5 occasions 
at two weekly intervals. After the second immunization the animal was bled via the 
marginal ear vein prior to further boosts. The serum was processed as described in 
Section 2.3.7.1. and assayed for specific antibody production by ELISA. The rabbit 
was boosted until a sufficient titre, (1:100,000), was obtained.
2.5. Purification of antibodies
Antibodies were separated from whole rabbit serum or ascitic fluid according to the 
method described by Hudson and Hay (1980). Inorganic salts are used to reduce the 
dipole forces that exist between the surface amino acids and the solvent. These forces 
are necessary for solubility of the proteins and when reduced allow for non-denatured
precipitation of the protein.
Saturated ammonium sulphate solution was prepared by the addition of ammonium 
sulphate (max. 800g/l) to warm distilled water with continual stirring until no more 
could be brought into solution. This can be stored for several months at 4°C. IgG is 
precipitated out using a 50% SAS precipitation solution. Serum which had been 
separated from whole blood, as previously described, was placed on an ice bath and 
the pH altered to between 4.4 and 5.1 using 0.0IN HCL. The solution was centrifuged 
at 15,000rpm for 20 minutes at 4°C. All remaining steps were also carried out on an 
ice bath. SAS was added dropwise, with constant stirring, to the serum until a 1:1, 
(v/v), ratio was reached. The sample was stirred for a further 1 hour on the ice bath
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followed by centrifugation at 10,000rpm in a Sorvall centrifuge for 30 minutes at 4°C. 
The pellet was dissolved in the minimum volume of the desired buffer. To increase 
purity the pellet can be dissolved in 0.15M PBS, pH 7.2, and a second 50% 
precipitation can be carried out as before. The protein concentration of the pellet was 
estimated using the Bicinchonininic acid assay, (BCA), as described in Section 2.6. 
The SAS-purified sample can be further purified using affinity chromatography.
2.5.1. Affinity purification of antibodies using Protein A columns
This method utilises the ability of the Fc portion of IgG to bind to protein A. Protein 
A is a bacterial cell wall component produced by several strains of Staphylococcus 
aureus. Protein A affinity chromatography columns can be prepared by coupling 
protein A to a solid support such as agarose. Commercial 1ml protein A, 
(Immunopure, Pierce) columns were used. The column was equilibrated using 5 
column volumes of Immunopure IgG binding buffer (Pierce Chem. Co.). A lmg/ml 
solution of antibody was made up in Immunopure binding buffer and applied to the 
column. The antibody solution was allowed to run completely through the column and 
washed with 10-15 column volumes of Immunopure binding buffer and the fractions 
collected were assayed continuously for unbound protein using the BCA microassay, 
(Section 2.6). The bound protein was eluted with 3-5 column volumes of 0.1M glycine 
buffer, pH 2-3 or 0.1M sodium citrate buffer, pH 3.5. 500pl fractions were collected 
into 1ml eppendorfs containing 50ul of 1M Tris, pH 7.5, which readjusted the pH to 
the proper physiological level of 7.3. The eluted protein was detected by determining 
the absorbance at 280nm on a spectrophotometer. This method was used because the 
presence of Tris buffer at certain concentrations, interferes with the BCA assay 
described in Section 2.6.
2.6. Bicinchoninic acid, (BCA), protein assay
This is a colorimetric assay which makes use of the various oxidation states of Cu 
(Smith et al., 1985). Under alkaline conditions Cu ions react with proteins and are 
converted from the Cu^ to the Cu+ oxidative state, a coloured product is thus formed. 
The reagents supplied for the assay are reagent A which is an alkaline bicarbonate 
buffer and reagent B, a 4% (w/v) copper sulphate solution. The BCA working solution
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was made by mixing 50 parts reagent A with 1 part reagent B. This was stable for up 
to 1 week at room temperature. A range of protein standards were prepared in 0.15M 
PBS, pH 7.2, (0-lmg/ml) from a stock solution of 5mg/ml BSA. lOpl of protein 
standard or unknown protein solution were added, in duplicate, to the wells of a 96 
well microassay plate. This was followed by the addition of 190pl of the BCA 
working solution. The plate was incubated for 30 minutes at 37°C and the absorbance 
was measured at 562nm using a Titertek Multiscan plate reader.
2.7. Chemical production of b¡specific antibodies
Affinity-purified antibodies were used for the production of bispecific antibodies. 
Polyclonal and monoclonal IgG molecules at concentration between 10-15mg/ml in 
0.1M sodium acetate buffer, pH 4.2, were incubated with 0.3mg/ml pepsin. Polyclonal 
antibodies were incubated for 18 hours and monoclonal antibodies for 7 hours yielding 
F(ab'y)2 fragments. The F(ab'y)2 were purified from the digest mixture by gel 
filtration using a 1ml Ultrogel AcA44, (LBK), column equilibrated with 0.2M Tris- 
HC1, pH 8.0, containing lOmM EDTA. Fab'YsH fragments were prepared by reduction 
of the F(ab'Y)2 fragments with 20mM 2-mercaptoethanol for 30 minutes at 30°C. Both 
Fab'YsH were cooled to 4°C and run through a Sephadex G-25 column equilibrated 
with 50mM sodium acetate, pH 5.3, containing 0.5mM EDTA. The temperature was 
maintained at 4°C throughout the remainder of the experiment. The mouse antibody 
was treated with a half volume of 12mM o-phenylenedimaleimide, (o-PDM) dissolved 
in chilled dimethylformamide for 30 minutes. The resulting Fab'YMAi. was separated 
from contaminating molecules on a Sephadex G-25 column equilibrated with 50mM 
sodium acetate, pH 5.3, containing 0.5mM EDTA. Both Fab'y were mixed at a molar 
ratio of Fab'yMA^ Fab'YsH 1:1.3 and incubated for 18 hours at 4°C. The pH was 
adjusted to 8 with 1M Tris-HCL, pH 8.0. Treatment of the mixture with 2-Me at a 
final concentration of 20mM and 25mM iodoacetamide for 30 minutes at 30°C 
removes unwanted products. The bispecific F(ab'y)2 were isolated from unwanted 
reactants by gel filtration using a 1ml Ultrogel AcA44, (LBK), column equilibrated 
with 0.2M Tris-HCL, pH 8.0, containing lOmM EDTA.
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2.8. ELIS As
2.8.1. ELISA for the detection of mouse IgG in cell culture supernatant
Supernatants were tested for antibody production after 2-3 weeks of growth in 
complete medium.
96 well microtitre plates were coated overnight at 4°C or for two hours at room 
temperature (RT) with lOOpl of a lOpg/ml solution of goat anti-mouse IgG in 
carbonate/bicarbonate (0.03M NaHC03, 0.01M Na2C03), buffer, pH 9.6. The plates 
were then washed five times with 0.15M PBS, pH 7.2, containing 0.05% (v/v) Tween 
20, and once in 0.15M PBS, pH 7.2, (the plates were washed after each subsequent 
incubation step in a similar manner). The plates were then blocked for 1 hour at 37°C 
with a 2% (w/v) solution of BSA made up in 0.15M PBS, pH 7.2. In the next step, 
supernatant was removed from wells with clones of hybridomas and transferred to the 
96 well microtitre plate and incubated for two hours at RT. Antibody presence was 
detected using a 1:5000 dilution of alkaline phosphatase-conjugated goat anti-mouse 
antibody made up in 0.15M PBS, pH 7.2, which was incubated on the plate for two 
hours at RT. A colour product was obtained by the addition of lOOpl of substrate 
[lmg/ml solution of 5-bromo-4-chloro-3-indolyl phosphate, (BCIP), in 2-amino-2- 
methyl-1-propanol, (AMP), buffer pH 9.5]. Absorbance was read at 620nm using a 
Titretek Multiscan automatic plate reader.
2.8.2. ELISA for the detection of mouse IgM in cell culture supernatant
96 well microtitre plates were coated overnight at 4°C or for two hours at RT, with 
supernatant from wells containing clones of the hybridoma Epl6. The plates were then 
washed five times with 0.15M PBS, pH 7.2 containing 0.05% (v/v) Tween 20, and 
once in 0.15M PBS, pH 7.2, (the plates were washed after each subsequent incubation 
in a similar manner). The plates were then blocked with a 2% (w/v) solution of BSA 
made up in 0.15M PBS, pH 7.2. Antibody presence was detected using a 1:3000 
dilution of alkaline phosphatase-conjugated goat anti-mouse IgM made up in 0.15M 
PBS pH 7.2, which was incubated for two hours at RT, and detected as described in 
Section 2.8.1.
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2.8.3. ELISA for the detection of IL-6
96 well microtitre plates were coated overnight at 4°C, or at RT for two hours, with 
lOOpl of a lOpg/ml solution of goat anti-human IL-6 in carbonate/bicarbonate (0.03M 
NaHCOj, 0.01Na2C03) buffer, pH 9.6. The plates were then washed five times with 
0.15M PBS, pH 7.2 containing 0.05% (v/v) Tween 20, and once in PBS, pH 7.2, (the 
plates were washed in a similar manner after each incubation step). The plates were 
then blocked with a 2% (w/v) solution of BSA, made up in 0.15M PBS, pH 7.2. 
Samples consisting of neat CLL plasma, neat normal human plasma, T24 supernatant 
diluted 1:2 in 0.15M PBS, pH 7.2 and human recombinant IL-6 ranging in 
concentration from O-lOpg/ml in 0.15M PBS, pH 7.2, were added and incubated for 
two hours at RT. Rabbit anti-IL-6 antibody was then added at a concentration of 
lOpg/ml in 0.15M PBS, pH 7.2, and incubated for a further two hours at room 
temperature. A 1:5000 dilution of alkaline-phosphatase conjugated goat anti-rabbit IgG 
made up in 0.15M PBS, pH 7.2 was then added and incubated for two hours at RT 
and detected as described in Section 2.8.1.
2.8.4. Binding of cells to 96 well microtitre plates. These were used to determine 
the binding specificities of antibodies by ELISA (2.8.5.)
(i) Non-adherent cells
96 well microtitre plates were coated for 1 hour at 37°C with lOOpl of a 0.1% (w/v) 
solution of poly-L-lysine. This solution may be reused up to 10 times and on removal 
is stored at 4°C. The plates were then washed five times with 0.15M PBS, pH 7.2 
containing 0.05% (v/v) Tween 20, and once in PBS, pH 7.2, (all subsequent washings 
were carried out in similar manner). 50ul of a 5xl05 cell/ml suspension was added to 
each well. The plates were then incubated at 4°C for 1 hour. 50pl of 0.05% 
glutaraldehyde, (GA), which had been precooled to 4°C was then added directly 
without washing to each well to give a final concentration of 0.025%. The GA was 
added very gently to avoid disruption of the bound cells. The plates were incubated 
for a further 10 minutes at 4°C and washed as before. Residual GA was blocked by 
incubation of the plates with lOOpl/well of a lOOmM glycine solution made up in PBS 
for 30 minutes at 37°C and washed as before. The plates were then blocked with a 2% 
(w/v) solution of BSA, made up in 0.15M PBS, pH 7.2 containing 0.1% (w/v) sodium
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azide. These plates were used immediately or stored at 4°C for up to 6 months.
(ii) Adherent cells
Adherent cells could be grown directly onto 96 well tissue culture trays and the
method is similar to (i) from the addition of GA onwards.
The ELISA’s used in (i) and (ii) were carried out as outlined in Section 2.8.5.
2.8.5. ELISA used for detection of antigenic determinants on cells bound to 96 
well microtitre plates
96 well microtitre plates were coated with cells as previously described, Section 2.8.4. 
The plates were then washed five times with 0.15M PBS, pH 7.2 containing 0.05% 
(v/v) Tween 20, and once in PBS, pH 7.2, (the plates were washed in a similar 
manner after each incubation step). The plates were then blocked with a 2% (w/v) 
solution of BSA, made up in 0.15M PBS, pH 7.2. Samples consisting of supernatants 
from hybridomas were added to the plate and incubated for two hours at RT. Antibody 
presence was detected using a 1:5000 dilution of alkaline phosphatase-conjugated goat 
anti-mouse antibody made up in 0.15M PBS, pH 7.2, which was incubated on the 
plate for two hours at RT. A colour product was obtained by the addition of lOOpl of 
substrate to each well. The substrate consisted of a lmg/ml solution of 5-bromo-4- 
chloro-3-indolyl phosphate, (BCIP), in 2-amino-2-methyl-l-propanol, (AMP), buffer 
pH 9.5. Absorbance was read at 620nm as described in Section 2.8.1.
2.8.6. Isotype analysis of antibody
Monoclonal antibodies were isotyped using a Sigma ELIS A-based kit (Table 2.1.1).
2.8.7. ELISA for the detection of anti-HRP antibodies
Serum from immunized animals was screened for antibody production by ELISA.
96 well microtitre plates were coated overnight at 4°C, or at RT for two hours, with 
lOOpl of a lOpg/ml solution of HRP in carbonate/bicarbonate (0.03M NaHC03, 0.01M 
Na2C03) buffer, pH 9.6. The plates were then washed five times with 0.15M PBS, pH
7.2 containing 0.05% (v/v) Tween 20, and once in PBS, pH 7.2, (the plates were 
washed in a similar manner after each incubation step). The plates were then blocked 
with a 2% (w/v) solution of BSA, made up in 0.15M PBS, pH 7.2. Samples consisting
70
of dilutions of immunized serum and normal rabbit serum were made up in 0.15M 
PBS pH 7.2, added to the plate and incubated for two hours at RT. A 1:5000 dilution 
of alkaline-phosphatase conjugated goat anti-rabbit IgG made up in 0.15M PBS, pH
7.2, was then added, incubated for two hours at RT and detected as described 
previously in Section 2.8.1.
2.8.8. ELISA for the detection of bispecific antibody activity using cells bound to 
ELISA micotitre plates
96 well microtitre plates were coated with cells as previously described in Section
2.8.4. The plates were then washed five times with 0.15M PBS, pH 7.2 containing 
0.05% (v/v) Tween 20, and once in PBS, pH 7.2, (the plates were washed in a similar 
manner after each incubation step). The plates were then blocked with a 2% (w/v) 
solution of BSA, made up in 0.15M PBS, pH 7.2. Samples consisting of dilutions of 
F(ab'y)2 bispecific antibody or whole G12 and anti-HRP F(ab'y)2 molecules were 
made up in 0.15M PBS pH 7.2 added to the plate and incubated for two hours at RT. 
A lOpg/ml solution of HRP, made up in 0.15M PBS, pH 7.2 was then added and 
incubated for two hours at RT and detected as described previously in Section 2.8.1. 
This ELISA was also used to detect bispecific antibody production in the supernatants 
of triomas.
2.8.9. ELISA for the detection of rabbit and mouse Fab' fragments on the 
bispecific antibody
96 well microtitre plates were coated overnight at 4°C, or at RT for two hours, with 
lOOpl of a lOpg/ml solution of anti-mouse IgG in carbonate/bicarbonate, (0.03M 
NaHC03, 0.01M Na2C 03) buffer, pH 9.6. The plates were then washed five times with 
0.15M PBS, pH 7.2 containing 0.05% (v/v) Tween 20, and once in PBS, pH 7.2, (the 
plates were washed in a similar manner after each incubation step). The plates were 
then blocked with a 2% (w/v) solution of BSA, made up in 0.15M PBS, pH 7.2. 
Samples consisting of dilutions of F(ab'y)2 bispecific antibody or whole G12 antibody 
and anti-HRP F(ab'y)2 molecules were made up to a concentration of lOpg/ml in 
0.15M PBS, pH 7.2, added to the plate and incubated for two hours at RT. A 1:5000 
dilution of alkaline phosphatase-conjugated goat anti-rabbit IgG, made up in 0.15M
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PBS, pH 7.2, was then added, incubated for two hours at RT and detected as described 
previously (Section 2.8.1.).
This ELISA did not detect bsab activity but does detect the bsab mouse and rabbit 
Fab' regions.
2.8.10. ELISA for the detection of human IgG in plasma
96 well microtitre plates were coated overnight at 4°C or for two hours at room 
temperature (RT) with lOOpl of a 10pg/ml solution of goat anti-human IgG in 
carbonate/bicarbonate, (0.03M NaHC03, 0.01M Na2C03), buffer, pH 9.6. The plates 
were then washed five times with 0.15M PBS, pH 7.2 containing 0.05% (v/v) Tween 
20, and once in 0.15M PBS, pH 7.2, (the plates were washed after each subsequent 
incubation step in a similar manner). The plates were then blocked for 1 hour at 37°C 
with a 2% (w/v) solution of BSA made up in 0.15M PBS, pH 7.2. In the next step 
samples were added to the wells in duplicate. These consisted of commercial human 
IgG (O-lOpg/ml) normal human plasma and plasma from patients with B-CLL. Plasma 
samples were diluted 1:5000 in the case of normal human plasma and 1:1000 in the 
case of B-CLL patient plasma in 0.15M PBS, pH 7.2. The plates were incubated for 
two hours at RT. Antibody presence was detected using a 1:5000 dilution of alkaline 
phosphatase-conjugated goat anti-human antibody made up in 0.15M PBS, pH 7.2, 
which was incubated on the plate for two hours at RT. A coloured product was 
obtained and detected as described in Section 2.8.1.
2.9. Histochemical staining of cells on cytospin smears
Morphological staining was performed on HL60, K562, T24, GCCM, CLL cells and 
normal human peripheral blood cells. lOOpl of a 0.5xl05/ml cell suspension made up 
in 0.15M PBS, pH 7.2 was centrifuged at 50Qrpm for 2-3 minutes onto a clean glass 
slide, using a Heraeus Sepatech cytocentrifuge. The cells were allowed to air-dry for 
20 minutes and stained immediately or stored at -20°C for up to 6 months. Cells 
which had been stored at -20°C were allowed to thaw at RT for 30 minutes prior to 
use. The stains used were methylene blue and eosin, (Rapi-diff II, Triple stain set, 
Diagnostic Developments). Stained cells were mounted with coverslips using DPX 
mountant, (BDH).
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2.9.1. Immunocytochemical staining of cells using bispecific antibody
Cytocentrifuged samples were removed from the -20°C freezer and allowed to air-dry 
at room temperature. The cells were fixed in acetone, absolute alcohol and 
paraformaldehyde at a ratio of 19:19:2 for 30 seconds, and washed in a Tris buffered 
bath consisting of 0.05M Tris buffer, pH 7.6, for 5 minutes. After fixation the 
preparations must be kept moist at all times. The slides were removed from the Tris- 
buffered bath and the area around the smear was dried with a tissue. The slides were 
incubated for 5 minutes at room temperature with a 3% (v/v) solution of hydrogen 
peroxide made up in methanol. This step blocks endogenous peroxidase activity. To 
inhibit the non-specific binding of protein the specimens were incubated for 20 
minutes at room temperature with a 2% (w/v) solution of BSA, made up in 0.15M 
PBS, pH 7.2. Excess blocking reagent was tapped off carefully. The samples were 
washed as before, in a Tris-buffered bath for 5 minutes. The bispecific antibody, at 
a concentration of lOpg/ml in 0.15M PBS, pH 7.2, was applied to the specimens and 
the slides were then incubated for 30 minutes at room temperature. The slides were 
washed as before in a Tris-buffered bath for 5 minutes. The specimens were then 
incubated for 30 minutes at room temperature with a lOpg/ml solution of HRP, made 
up in 0.15M PBS, pH 7.2. The slides were washed as before and an insoluble product 
was developed using a 0.066% (w/v) solution of 3,3’-di-aminobenzidine, (DAB), made 
up in 0.05M Tris-buffered saline. The specimens were counterstained for 1 minute 
using a 2% (w/v) solution of methylene green made up in ultrapure water. Stained 
cells were mounted with coverslips using DPX mountant as described in Section 2.9.
2.9.2. Immunocytochemical staining of cells using a HRP-labelled anti-mouse IgG 
secondary antibody to detect G12 whole antibody
The specimens were treated in a similar manner to that described in Section 2.9.1. 
Dilutions of the G12 purified antibody ranging from l-20pg/ml were made up in 
0.15M PBS, pH 7.2, and applied to the specimens and the slides were then incubated 
for 30 minutes at room temperature. The slides were washed as before in a Tris- 
buffered bath for 5 minutes. The specimens were then incubated for 30 minutes at 
room temperature with goat anti-mouse IgG peroxidase-conjugated antibody, made up 
in 0.15M PBS, pH 7.2. The slides were washed as before and an insoluble product
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was developed using DAB as described in Section 2.9.1. The specimens were 
counterstained using a 2% (w/v) solution of methylene green made up in ultrapure 
water. Stained cells were mounted with coverslips using DPX mountant as described 
in Section 2.9.
2.9.3. Immunocytochemical staining of cells using Dako PAP kit
All reagents with the exception of the primary antibody were supplied in the kit. The 
specimens were treated in a similar manner to that described in Section 2.9.1. 
Dilutions of the G12 purified antibody ranging from lpg-20pg/ml were made up in 
0.15M PBS, pH 7.2, and applied to the specimens and the slides were then incubated 
for 30 minutes at room temperature. The slides were washed as before in a Tris 
buffered bath for 5 minutes. The specimens were then incubated for 30 minutes at 
room temperature with two drops of anti-mouse IgG and washed as before in a Tris 
buffered bath for 5 minutes. The specimens were then incubated with peroxidase anti­
peroxidase complex. The slides were washed as before and an insoluble product was 
developed using DAB. The specimens were counterstained using a 2% (w/v) solution 
of methylene green made up in ultrapure water. Stained cells were mounted with 
coverslips using DPX mountant as described in Section 2.9.
2.10. MTT bioassay for IL-6
lxlO4 B9 cells were cultured on 96 well culture trays for 2-3 days in complete 
medium supplemented with 5% (v/v) T24-CM (diluted a further 1:100 in complete 
medium) CLL-DMEM, NHP-DMEM, rhIL-6 (O-lOpg/ml in complete medium), or 
complete medium, (blank). On day 2/3 a 5mg/ml solution of MTT was made up in 
0.15M PBS, pH 7.2 and filter sterilized. 20j.il of this solution was added to each well 
and the plates were incubated for 4 hours at 37°C. lOOpl of 10% (w/v) sodium dodecyl 
sulphate, (SDS), SDS-0.01 N HC1 was added to each well and incubated for a further 
4 hours at 37°C, (until all the crystals were dissolved). Absorbance was read at 560nm 
using a Titertek Multiscan automatic plate reader.
CLL-CM and NHP-CM were also examined for IL-6 activity.
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2.11. SDS-polyacrylamide gel electrophoresis
Antibody fragments were subjected to sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using a modified procedure to that described by Laemmli 
(1970). Proteins were separated on a resolving gel containing 10% (w/v) acrylamide, 
0.33% (w/v) bis-acrylamide, 0.75M Tris, 0.2% (w/v) SDS, 0.1% (v/v) TEMED and 
0.1% (w/v) ammonium persulphate, pH 8.8. A stacking gel consisting of 3.5% (w/v) 
acrylamide, 0.08% (w/v) bis-acrylamide, 0.25% (w/v) Tris, 0.2% (w/v) SDS and 
0.08% TEMED, 0.08% (w/v) ammonium persulphate pH 6.8 was used, 0.25% (w/v). 
The electrode buffer contained 0.025M Tris, 0.192M glycine and 0.1% (w/v) SDS 
prepared in distilled water. Samples for electrophoresis were dissolved at a 
concentration of lmg/ml in solubilization buffer consisting of 0.062M Tris, 2.0% (w/v) 
SDS, 10% (w/v) glycerol and 0.001% (w/v) bromophenol blue. 0.5% (v/v) 2- 
mercaptoethanol was used when reducing conditions were required. The samples were 
boiled for between 2-3 minutes. 10-20pl of these solutions were applied to the gel. 
The gel was electrophoresed in electrode buffer, at 100mA using a Biorad vertical 
electrophoresis system. Gels were stained for 30 minutes in 0.05% (w/v) Comassie 
Brilliant blue in acetic acid:water:methanol (1:10:8) and destained overnight in the 
same solvent system.
2.12. HPLC analysis of proteins
A 20pl volume of protein diluted to lmg/ml in 0.15M PBS, pH 7.2, was applied to 
a Waters Protein PAK 300 SW, (7.8x300pM) column which was pre-equilibrated with 
0.1M phosphate, pH 7.2. A flow rate of 0.5 ml/min used and protein was monitored 
by determining absorbance at 280nm.
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Chapter 3
Production of Bispecific Antibodies
3.1. Production of bispecific antibodies
As outlined in the introduction (Section 1.2.) bsabs can be made biologically, 
chemically and genetically. We have used both biological and chemical methods to 
synthesise bsabs with dual specificities for HRP and CLL cells. The bsabs have been 
used in the development of ELISAs and immunocytochemical techniques. The 
methods employed are outlined briefly in the following section. Triomas were made 
biologically by the fusion of HRP-immunized rabbit and mouse splenocytes with 
HAT-s G12 cells. G12 hybridoma cells secrete antibodies reactive with CLL cells. The 
antigen recognised by the G12 antibody has a MW of 69,200D. HAT-sensitivity was 
induced by mutagenesis using ethyl methanosulfonate (EMS), or, alternatively, by 
growing the cells in increasing concentrations of 8-aza. All efforts to induce HAT- 
sensitivity in E5, another hybridoma cell line secreting antibodies reactive with CLL 
cells, were unsuccessful.
Both hybridoma cell lines E5 and G12 also produce antibody reacting with the K562 
cell line and, therefore, this cell line was chosen for routine assaying of mAb activity. 
Supernatants from the triomas formed were examined by ELISAs specific for the 
K562 cell line and HRP individually and for bispecificity to both antigens.
Bsab were also synthesised by chemical methods (Glennie etal., 1987). This involves 
chopping up the parent antibodies to form Fab' fragments which were then 
reconstituted to form bispecific F(ab'y)2.
The principle of using bsab as a detection system as opposed to more conventional 
ELISAs is outlined in Figure 3.1. A single bsab is capable of linking the cell and the 
detector molecule, HRP. Theoretically this could be achieved with the HRP pre-bound 
to the bsab followed by its addition to the cell or the the bsab could be added to the 
cell in its native state and followed by addition of the HRP. In the system described 
here the former approach proved more successful. This compares favourably with 
conventional detection systems which require enzyme-conjugated anti-tumour 
antibodies or peroxidase anti-peroxidase, PAP, and alkaline phosphatase anti-alkaline 
phosphatase, APAAP, amplification systems.
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Figure 3.1.
The above diagram depicts the methods used to detect antigenic determinants on cells. 
The bispecific antibody detection system as represented in (a) has been used 
successfully in ELISA and immunohistrochemistry. A more conventional system using 
an enzyme-conjugated secondary antibody which is capable of binding to the anti­
tumor antibody is represented in (b). The final system (c) represents the peroxidase 
anti-peroxidase complex which is used routinely as an amplification system during 
immunohistochemical procedures.
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3.2. Biological production
Biological production of bsabs involves manipulation of the somatic cell hybridization 
techniques first developed by Cotton and Milstein (1973) and Kohler and Milstein 
(1975). Reading et al. (1981) reported on the fusion of hybridomas to form quadromas 
which secrete bispecific antibodies. The method chosen in our work was to fuse 
hybridomas directly to antibody producing splenocytes to form triomas. One of the 
first obstacles to be overcome using this method was the selection of hybridoma cells 
for use in cell fusions. The 2 methods chosen were either to grow the hybridomas in 
medium containing the drug 8-aza or to mutagenise the cells using EMS. Efforts to 
produce a quadroma (fusion of the G12 hybridoma with a hybridoma cell line 
secreting anti-HRP antibodies) were hampered by an outbreak of the mouse hepatitis 
virus (MHV) in the animal house facility. The hybridomas producing anti-HRP 
antibodies (IgG class) came in contact with infected animals when ascitic fluid was 
being produced and all further aspects of this work were halted.
Various other properties which are used in the selection of hybridomas for use in the 
formation of triomas and quadromas involve the induction of sensitivity or resistance 
in the hybridomas to drugs (Staerz and Bevan, 1986; Suresh et al., 1986; De Lau et 
al., 1989). Other properties such as the labelling of the hybridomas with fluorescent 
markers have also been applied (Karawajew et al., 1987; Shi et al., 1991; Jantscheff 
et al., 1993). These methods have been discussed more fully in the introduction 
(Section 1.2).
3.2.1. Induction of HAT-sensitivity in E5 and G12 hybridoma cells using 8-
azaguanine
In order to induce HAT-sensitivity in the hybridomas G12 and E5 the cells were 
grown in progressively increasing concentrations of 8-aza (ljjg-20pg/ml) made up in 
complete medium.
Initially the E5 cells were seeded in 24 well culture trays in Opg/ml, 2pg/ml and 
4pg/ml 8-aza in complete growth medium [Table 3.2.1.(a)]. Each drug concentration 
was carried out in duplicate. Cells were counted on days 4 and 10. Cells growing in 
2pg/ml 8-aza were seeded on day 4 in higher concentrations of the drug. The cells
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were seeded in complete medium containing the following concentrations of 8-aza, 
Opg/ml, 4pg/ml, 6pg/ml and 8pg/ml [Table 3.2.1.(b)]. On day 8 only cells seeded in 
0 and 4pg/ml of drug were viable. Cells growing in 4pg/ml 8-aza were taken and 
seeded in higher concentrations of drug. The concentrations chosen on this occasion 
were Opg/ml, 4pg/ml, 6pg/ml and 8pg/ml [Table 3.2.1.(c)]. On day 16 cells growing 
in 8pg/ml of 8-aza were seeded in higher concentrations of the drug. Up to 20pg/ml 
of the drug was used on this occasion [Table 3.2.1.(d)]. On day 30 cells were found 
to grow in all of the chosen concentrations (0, 12, 16 and 20pg/ml 8-aza). When 
examined for HAT-sensitivity [Table 3.2.1.(e)] the cells were still HAT-r.
The experiment was repeated using fresh E5 cells. On day 0 cells were seeded in 24 
well culture trays containing 0, 2, 4, 6, 8 and lOpg/ml 8-aza [Table 3.2.1.(f)]. After 
10 days cells in the highest concentration were dead. The cells growing in 6pg/ml 8- 
aza were then taken and seeded in 0, 6, 10, 12, 14 and 16pg/ml 8-aza [Table
3.2.1.(g)]. On day 20 the plates were examined and all wells had viable cells. Cells 
growing in the highest concentration of 8-aza, 16pg/ml 8-aza, were taken and grown 
in 0, 16, 20 24, 28 and 32pg/ml of 8-aza [Table 3.2.1.(h)]. Cells growing in 24pg/ml 
of the drug were examined for HAT-sensitivity on day 30 as shown in [Figure
3.2.1.(i)]. All cells were still HAT-r.
Induction of HAT-sensitivity in G12 cells proved to be far easier. On day 0 the cells 
were seeded in 0, 8, 14, and 20pg/ml 8-aza [Table 3.2.1.(j)] in complete medium. 
After 20 days only cells growing in 0 and 8pg/ml 8-aza were viable. Cells growing 
in 8pg/ml 8-aza were taken and seeded in 0, 12, 16 and 20pg/ml 8-aza in complete 
growth medium [Table 3.2.1.(k)j. On day 30 cells were growing in all wells. The cells 
growing in 20pg/ml 8-aza were HAT-s [Table 3.2.1.(1)] and maintained their ability 
to react with K562 cells [Table 3.2.1.(m)].
3.2.2. Induction of HAT-sensitivity in GI2 cells using EMS
HAT-sensitivity was also induced in the hybridoma G12 using the mutagen EMS. The 
concentrations of EMS causing a 50% kill of G12 cells were established. G12 cells 
were seeded out in duplicates at a concentration of lx l04cells/well on 24 well culture 
trays. The concentration of EMS ranged from 0-180pg/ml of complete medium. The
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concentration resulting in a 50% kill of the cells was 20pg EMS/ml of complete 
medium [Table 3.2.2.(a)].
The concentration of the selection agent (8-aza) required to cause a 100% kill of wild 
type hybridoma cells was also established. The cells were seeded at a concentration 
of lxlO4 cells/well on 24 well plates in duplicates in complete medium containing a 
range of concentrations of 8-aza (0-20pg/ml). The concentration of 8-aza resulting in 
a 100% kill of hybridoma cells was 16pg 8-aza/ml of complete medium [Table 
3.2.2.0?)].
Once the concentrations of EMS resulting in a 50% kill and that of 8-aza resulting in 
a 100% kill of hybridoma cells were established the cells were mutagenised in 
complete medium containing 20pg/ml EMS [Table 3.2.2.(c)] and new HAT-s 
phenotypes were selected with 16pg/ml of 8-aza. The concentration of 8-aza was 
adjusted to 16pg/ml slowly over the next 11 days [Tables 3.2.2.(d,e, & f)]. These cells 
were then examined for their ability to grow in HAT-containing medium [Table
3.2.2.(g)]. The G12 cells were HAT-s and the antibody secreted by these cells 
maintained its ability to bind K562 cells [Table 3.2.2.(h)].
3.2.3. Somatic cell fusions
These involved the fusion of HAT-s G12 cells with rabbit and mouse splenocytes 
which secreted anti-HRP antibodies. All newly formed triomas were examined by 3 
separate ELISAs specific for anti-K562 activity, anti-HRP activity and bsab activity. 
Five of these involved the fusion of HAT-s G12 cells and in vitro immunized rabbit 
anti-HRP splenocytes. The in vitro immunization was necessary because the rabbit had 
been given a final in vivo immunization two weeks prior to being sacrificed which 
maximised the levels of antiserum to HRP but resulted in splenocytes which were in 
the wrong phase for antibody production. The G12 HAT-s cells were grown for a 
week prior to cell fusion in medium containing 3% FCS and 3% rabbit serum. The 
cells were fused at a 5:1 ratio of splenocytes to G12 HAT-s. The numbers of triomas 
formed are shown in [Table 3.2.3.(a)]. The triomas formed here were found to grow 
extremely slowly and the supernatants could not therefore be tested for antibody 
production until day 34. 3.5% of triomas formed produced antibody reactive with HRP
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but a large majority (95%) only exhibited reactivity with the K562 cell line. No bsab 
producing triomas were formed.
Four of the final 8 cell fusions involved fusion of G12 HAT-s cells in which HAT- 
sensitivity had been induced using 8-aza and the final 4 involved the fusion of 
mutagenised G12 cells [Table 3.2.3.(b & c)] respectively. All of these 8 fusions 
involved immunized mouse splenocytes. In the first 4 fusions 2.8% of the total 
number of triomas formed secreted antibody reactive with HRP and 95% of the 
triomas secreted antibody reactive with the K562 cell line. In the final 4 fusions the 
the figures were similar in that 2.6% of the total number of triomas produced against 
against HRP and 95% were against the K562 cell line. No bsab was detected in any 
of the 8 cell fusions.
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E5 cell growth in a range of concentrations of 8-aza in DMEM.S5. 
The cells were seeded at SxlOVwell
Day no. Opg/ml 8-aza 2pg/ml 8-aza 4pg/ml 8-aza
0 3xl04 3xl04 3xl04
4 5xl04 lxlO4 0.8xl04
10 8xl04 4xl04 3xl04
Table 3.2.1.(a). Induction of HAT-sensitivity was performed by growing the cells in 
increasing concentrations of 8-aza. Initially E5 cells were seeded at 3X104 cells/well 
in varying concentrations of 8-aza.
Cell counts were performed on day 4 and it is observed that cells growing in medium 
containing 8-aza experience an initial cell kill followed by recovery.
On day 4 cells from the wells containing 2pg/ml 8-aza were removed and seeded in 
higher concentrations of 8-aza [Table 3.2.1.(b)]
E5 cell growth in a range of concentrations of 8-aza in 
DMEM.S5. The cells were seeded at lx l0 3/well
Day no. Oug/ml 8-aza 4pg/ml 8-aza 6pg/ml 8-aza 8pg/ml 8- 
aza
4 lxlO3 lxlO3 lxlO3 lxlO3
8 4xl03 2xl03 dead dead
Table 3.2.1.(b). E5 cells which had been growing in 2pg/ml 8-aza [Table 3.2.1.(a)] 
were seeded at lxlO3 cells/well in up to 8pg/ml 8-aza.
On day 8 cells from the wells containing 4pg/ml 8-aza were removed and seeded in 
higher concentrations of 8-aza [Table 3.2.1.(c)]. Cells growing in 6 and 8pg/ml 8-aza 
have died.
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E5 cell growth in a range of concentrations of 8-aza in 
DMEM.S5. The cells were seeded at lx l03/well
Day no. Opg/ml 8-aza 4pg/ml 8-aza 6pg/ml 8- 
aza
8pg/ml 8- 
aza
10 lxlO3 lxlO3 lxlO3 lxlO3
16 lxlO4 8xl03 5xl03 lxlO3
Table 3.2.1.(c). E5 cells which had been growing in 4pg/ml 8-aza [Table 3.2.1.(b)] 
were seeded at lxlO3 cells/well in up to 8pg/ml 8-aza.
On day 16 cells were viable in all of the chosen concentrations of 8-aza. Cells were 
taken from the wells containing 8pg/ml 8-aza and seeded in higher concentrations of 
8-aza [Table 3.2.1.(d)].
E5 cell growth in a range of concentrations of 8-aza in 
DMEM.S5. The cells were seeded at lx l03/well
Day no. Opg/ml 8-aza 12pg/ml 8-aza 16pg/ml 20pg/ml 8- 
aza
16 lxlO3 lxlO3 lxlO3 lxlO3
20 4xl03 0.3xl03 0.6xl03 0.4xl03
25 7xl03 3xl03 3xl03 0.7xl03
30 lxlO4 2.3xl03 4xl03 2xl03
Table 3.2.1.(d). E5 cells which had been growing in 8pg/ml 8-aza [Table 3.2.1.(c)] 
were seeded at lxlO3 cells/well in up to 20pg/ml 8-aza. Cell counts were recorded on 
days 20 and 25 and all wells had cell viability.
On day 30 cells from the wells containing 20pg/ml 8-aza were grown in HAT- 
supplemented medium [Table 3.2.1.(e)].
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E5 cell growth in a range of concentrations of HAT- 
supplemented medium. The cells were seeded at 2xl03/well
Day no. Ox HAT 2x HAT 4x HAT
30 2xl03 2xl03 2xl03
35 4xl03 3xl03 3xl03
39 8xl03 6xl03 7xl03
Table 3.2.1.(e). Growth of E5 cells seeded at 2xl03 cells/well in varying 
concentrations of HAT. The cells were expected to be HAT-s as they grew in medium 
containing up to 20pg/ml of 8-azaguanine. On examination, however, the cells were 
found to be HAT-r. The experiment was repeated [Table 3.2.1.(f)]. 
lx HAT =2.2mg/ml aminopterin, 0.0048mg/ml thymidine and 0.13mg/ml 
hypoxan thine.
E5 cell growth in a range of concentrations of 8-aza in 
DMEM.S5. The cells were seeded at 2xl07well
Day Opg/ml 2pg/ml 4pg/ml 6pg/ml 8pg/ml lOpg/ml
no. 8-aza 8-aza 8-aza 8-aza 8-aza 8-aza
0 2xl04 2xl04 2xl04 2xl04 2xl04 2xl04
10 1x10s 5xl04 3xl04 lxl 04 dead dead
Table 3.2.1.(f). Fresh E5 cells were seeded at 2xl04 cells/well in varying 
concentrations of 8-aza.
On day 10 cells from the wells containing 6pg/ml 8-aza were removed and seeded in 
higher concentrations of 8-aza [Table 3.2.1.(g)].
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E5 cell growth in a range of concentrations of 8-aza in DMEM.S5. The
cells were seeded at lx l03/well.
Day no. Opg/ml
8-aza
6pg/ml
8-aza
lOpg/ml 8-
aza
12pg/ml
8-aza
14pg/ml
8-aza
16pg/ml
8-aza
10 lxlO3 lxlO3 lxlO3 lxlO3 lxlO3 lxlO3
20 lxlO4 6xl03 6xl03 6xl03 4xl03 2xl03
Table 3.2.1.(g). E5 cells which had been growing in 6pg/ml 8-aza [Table 3.2.1.(f)] 
were seeded at lxlO3 cells/well in up to 16pg/ml 8-aza.
On day 20 cells from the wells containing 16pg/ml 8-aza were removed and seeded 
in higher concentrations of 8-aza [Table 3.2.1.(h)].
E5 cell growth in a range of concentrations of 8-aza in DMEM.S5. Cells 
were seeded at 4xl02/well.
Day Opg/ml 16pg/ml 20pg/ml 8- 24pg/ml 8- 28pg/ml 32pg/ml
no. 8-aza 8-aza aza aza 8-aza 8-aza
20 4xl02 4xl02 4xl02 4xl02 4xl02 4xl02
30 lxlO4 lxlO3 5xl02 5xl02 dead dead
Table 3.2.1.(h). E5 cells which had been growing in 16pg/ml 8-aza [Table 3.2.1.(g)] 
were seeded at 4xl02 cells/well in up to 32pg/ml 8-aza. On day 30 cell counts 
revealed the presence in wells containing up to 24pg/ml of 8-aza.
On day 30 cells from the wells containing 24ug/ml 8-aza were grown in HAT- 
supplemented medium [Table 3.2.l.(i)].
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E5 cell growth in a range of concentrations of HAT-supplemented 
medium. Cells were seeded at 0.8xl02 /well.
Day
no.
Ox HAT lx HAT 2x HAT 4x HAT 6x HAT 8x HAT
30 0.8xl02 0.8x102 0.8X102 0.8X102 0.8X102 0.8xl02
40 lxlO3 lxlO3 lxlO3 9xl02 7xl02 9xl02
Table 3.2.1.(i). Growth of E5 cells seeded at 0.8X102 cells/well in varying 
concentrations of HAT. The cells were expected to be HAT-s as they grew in medium 
containing up to 24pg/ml of 8-azaguanine. On examination, however, the cells were 
found to be HAT-r.
lx HAT =2.2mg/ml aminopterin, 0.0048mg/ml thymidine and 0.13mg/ml 
hypoxanthine.
G12 cell growth in a range of concentrations of 8-aza in 
DMEM.S5. Cells were seeded at 2xl03/well.
Day no. Opg/ml
8-aza
8pg/ml
8-aza
14pg/ml
8-aza
20pg/ml 8-
aza
0 2xl03 2xl03 2xl03 2xl03
10 lxlO4 2xl03 2xl03 0.8xl03
20 5xl04 l.lxlO3 dead dead
30 lxlO4 4xl03 dead dead
Table 3.2.1.(j). Induction of HAT-sensitivity in G12 cells was performed by growing 
the cells in increasing concentrations of 8-aza. Initially G12 cells seeded at 2xl03 
cells/well in varying concentrations of 8-aza.
On day 20 cells from the wells containing 8pg/ml 8-aza were removed and seeded in 
higher concentrations of 8-aza [Table 3.2.1.(k)].
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G12 cell growth in a range of concentrations of 8-aza in 
DMEM.S5. Cells were seeded at 0.5xl03/well.
Day no. Opg/ml 8- 
aza
8-pg/ml 8- 
aza
16pg/ml 8-
aza
20pg/ml 8- 
aza
20 0.5xl03 0.5xl03 0.5xl03 0.5xl03
30 Confluent
cno'x 6xl03 4xl03
Table 3.2.1.(k). G12 cells which had been growing in 8pg/ml 8-aza [Table 3.2.1.(j)] 
were seeded at 0.5xl03 cells/well in up to 20pg/ml 8-aza.
On day 30 cells from the wells containing 20pg/ml 8-aza were grown in HAT- 
supplemented medium [Table 3.2.1.(1)].
Cell growth in a range of concentrations of 
HAT-supplemented medium
Day no. Ox HAT 2x HAT 4x HAT 8x HAT
30 lxlO3 lxlO3 lxlO3 lxlO3
35 4xl03 dead dead dead
Table 3.2.1.(1). Growth of G12 cells seeded at lxlO3 cells/well in varying 
concentrations of HAT. On day 35 the cells growing in HAT-supplemented medium 
were all dead indicating that the cells are HAT-s.
lx HAT =2.2mg/ml aminopterin, 0.0048mg/ml thymidine and 0.13mg/ml
hypoxanthine.
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Sample OD + SD @ 560nm
G12 HAT-s 0.740 ±  0.023
OKT8 0.000 + 0.000
DMEM.S5 0.000 + 0.000
PBS (blank) 0.000 + 0.000
Table 3.2.1.(m). Supernatant from HAT-s G12 cells was examined by ELISA to detect 
reactivity of the antibody secreted by G12 cells with the K562 cell line. Supernatants 
from the hybridoma OKT8 was also examined. Samples were tested as neat 
supernatant.
SD - Standard deviation, n = 3.
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Cell no. (xlO4)
Cone EMS (pg/ml 
complete medium)
Day 1 Day 4
0 5 10.00
10 5 7.5
20 5 5.0
40 5 0.00
60 5 0.00
80 5 0.00
100 5 0.00
120 5 0.00
140 5 0.00
160 5 0.00
180 5 0.00
Table 3.2.2.(a). The concentration of the mutagenic agent EMS causing a 50% kill of 
G12 cells was established by growing the cells in a range of concentrations of the 
mutagen (0-180|jg/ml) in complete medium. The concentation causing a 50% kill was 
20pg/ml of EMS. New phenotypes were selected using 8-aza.
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Cone. 8-azaguanine (pg/ml of complete 
medium)
Cell no. (xlO4)
0 1.00
2 0.80
4 0.48
6 0.41
8 0.32
10 0.30
12 0.19
14 0.20
16* 0.00
18 0.00
20 0.00
Table 3.2.2.(b). The concentration of 8-aza which caused a 100% kill of wild type 
G12 cells was established. G12 cells were grown in complete medium containing 0- 
20pg/ml 8-aza. G12 cells which had been mutagenised with EMS were selected for 
new HAT-s phenotypes using 8-aza at a concentration which causes a 100% kill of 
wild-type cells.
* 16pg/ml of 8-aza caused a 100% kill of wild type G12 hybridoma cells.
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Cell number
Cone. EMS (pg/ml complete medium) Day 1 Day 4
0 2x103 4.00x103
15 2xl03 2.50xl03
20 2xl03 1.90xl03
Table 3.2.2.(c). G12 cells were mutagenised using EMS. G12 cells were seeded in 24 
well plates in duplicates containing 0, 15 & 20pg/ml EMS. The concentration of EMS 
resulting in a 50% kill of hybridoma cells was 20pg/ml of EMS in complete medium. 
After 3 days the cells in all the wells were counted. Cells growing in 20pg/ml 8-aza 
were selected for HAT-sensitivity using 8-aza [Table 3.2.2.(d-f)].
Cell growth in a range of concentrations of 8-aza
Day no. 0pg/ml 8-aza 2pg/ml 8-aza 4pg/ml 8-aza
3 2xl03 2xl03 2xl03
6 4xl04 2.8xl03 2.5xl03 *
Table 3.2.2.(d). Three days after mutagenesis the G12 cells were seeded at 
2xl03cells/well in varying concentrations of the selection agent 8-aza.
* On day 6 cells were taken from the wells containing 4pg/ml 8-aza and seeded in 
higher concentrations of 8-aza [Table 3.2.2.(e)].
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Cell growth in a range of concentrations of 8-aza
Day no. Opg/ml 8-aza 4pg/ml 8-aza 8pg/ml 8-aza
6 5xl02 5xl02 5xl02
10 lxlO3 7xl02 7xl02
Table 3.2.2.(e). The mutagenised G12 cells were seeded in up to 8pg/ml of 8-aza. On 
day 10 cells were removed from the wells with 8pg/ml of 8-aza and seeded at 
5xl02cells/well in up to 16pg/ml of 8-aza.
Cells were taken from these wells and seeded in up to 16pg/ml of 8-aza. This is the 
concentration of 8-aza which causes a 100% kill of hybridoma cells and, therefore, 
only the newly formed phenotypes which are 8-aza-resistant should suvive [Table 
3.2.2. (g)].
Cell growth in a range of concentrations of 8-aza
Day no. Opg/ml 8-aza 8pg/ml 8-aza 16pg/ml 8-aza
10 2xl02 2xl02 2xl02
14 5xl02 4xl02 3xl02
Table 3.2.2.(g). The G12 cells were seeded in up to 16pg/ml of 8-aza. This is the 
concentration of 8-aza which causes a 100% kill of hybridoma cells and, therefore, 
only the newly formed phenotypes which are 8-aza-resistant should survive.
On day 14 cells were removed from the wells with 16pg/ml of 8-aza and grown in 
HAT-supplemented medium.
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Cell growth in a range of concentrations of HAT- 
supplemented medium
Day no. Ox HAT 2x HAT 4x HAT 8x HAT
14 6xl02 6xl02 6xl02 6xl02
20 lxlO3 dead dead dead
Table 3.2.2.(g). Mutagenised cells which had been selected for HAT-sensitivity using 
8-aza were examined for their ability to grow in HAT-containing medium. The cells 
were seeded at 6X102 cells/well in varying concentrations of HAT. On day 20 the cells 
were examined for viability and were all dead and, therefore, HAT-s. These cells were 
now ready for to be used in cell fusions to form triomas.
lx HAT =2.2mg/ml aminopterin, 0.0048mg/ml thymidine and 0.13mg/ml hypoxanthine
Sample OD + SD @ 560nm
G12 HAT-s (mutagenesis) 0.610 + 0.020
OKT8 0.000 ±  0.000
DMEM.S5 0.000 ±  0.000
PBS (blank) 0.000 ±  0.000
Table 3.2.2.(h). Supernatant from the mutagenised HAT-s G12 cells were examined 
by ELISA to detect reactivity of the antibody secreted by G12 cells with the K562 cell 
line. Supernatant from the OKT8 hybridoma was also examined. Samples were tested 
as neat supernatant.
SD - Standard deviation, n = 3.
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Fusion
number
No.
hybrids/480
wells
HRP +ve K562 +ve HRP/K562
+ve
Fusion 1 114 2 111 0
Fusion 2 93 3 90 0
Fusion 3 118 3 114 0
Fusion 4 68 3 64 0
Fusion 5 130 8 120 0
Total 523/2400
wells
19/523
triomas
499/523
triomas
0/523
triomas
Table 3.2.3.(a). HAT-s G12 hybridoma cells were fused with rabbit splenocytes 
secreting anti-HRP antibodies. The G12 cells used were rendered HAT-s using 8-aza. 
Specific antibody was detected using three ELISAs two of which detected both 
parental antibodies and a third which detected the bsab (Section 2.8). The total 
numbers of triomas formed and their various reactivities are given above. No bsab was 
detected in any of the 5 cell fusions.
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Fusion
number
No.
hybrids/480
wells
HRP -i-ve K562 +ve HRP/K562
+ve
Fusion 1 106 3 99 0
Fusion 2 112 4 105 0
Fusion 3 81 4 77 0
Fusion 4 88 0 87 0
Total 387/1920
wells
11/387
triomas
368/387
triomas
0/387
triomas
Table 3.2.3.(b). HAT-s G12 hybridoma cells were fused with mouse splenocytes 
secreting anti-HRP antibodies. The G12 cells used were rendered HAT-s using 8-aza. 
Specific antibody was detected using three ELISAs two of which detected both 
parental antibodies and a third which detected the bsab (Section 2.8.). The total 
numbers of triomas formed and their various reactivities are given above. No bsab was 
detected in any of the 4 cell fusions.
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Fusion
number
No.
hybrids/480
wells
HRP +ve K562 +ve HRP/K562
+ve
Fusion 1 119 3 111 0
Fusion 2 84 1 81 0
Fusion 3 73 2 70 0
Fusion 4 74 3 71 0
Total 350/1920
triomas
9/350 triomas 333/350
triomas
0/350 triomas
Table 3.2.3.(e). HAT-s G12 hybridoma cells were fused with mouse splenocytes 
secreting anti-HRP antibodies. The G12 cells used were rendered HAT-s using EMS. 
Specific antibody was detected using three ELISAs two of which detected both 
parental antibodies and a third which detected the bsab (Section 2.8.). The total 
numbers of triomas formed and their various reactivities are given above. No bsab was 
detected in any of the 4 cell fusions.
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3.3. Chemical production of bsabs
Bsabs have been made chemically using the method of Glennie et al. (1987). F(ab'y)2 
fragments formed by peptic digests of both parental antibodies were reduced to FabSH 
with 2-mercaptoethanol. One FabSH species was maleimidated with the bifunctional 
cross-linking agent o-phenylenedimaleimide to yield FabMAL which has free 
maleimide groups. The FabMAL and FabSH were then reacted together to form bsab. 
The method prevents any parental antibody recombinations. As already outlined in the 
introduction (Section 1.1) the method of Glennie et al. (1987) has been used 
successfully by a number of researchers, for delivery of the immunotoxin saporin to 
tumour cells (Flavell et al., 1991; Flavell et al., 1992; French et al., 1992) and for 
targeting T-lymphocytes to tumour cells (Mezzanzanica et al., 1991).
3.3.1. Production and purification of antiserum to HRP
Polyclonal anti-HRP antisera were produced in a New Zealand White male rabbit. A 
titre of 1:100,000 was achieved using a HRP-specific ELISA [Table 3.3.1.]. The 
antisera was purified by (NH4)2S04 precipitation and affinity chromatography using 
a 1ml Protein A column.
3.3.2. Characterization of anti-HRP antiserum by ELISA
The antisera was examined for cross reactivity with a range of other enzymes [Table
3.3.2.]. No cross reactivity of anti-HRP antibody with hexokinase, P-galactosidase or 
lactate dehydrogenase was observed.
3.3.3. Characterization of anti-HRP antiserum by HPLC
Whole normal rabbit serum, antiserum to HRP and various purified protein fractions 
were analysed by HPLC. The PAP complex formed on reacting the anti-HRP and HRP 
was also examined by HPLC. The retention times of a range of protein standards are 
shown in [Table 3.3.3.] and these allowed for the identification of the proteins present 
in various samples.
HPLC chromatographic profiles of (NH4)2S04 purified antiserum to HRP [Figure
3.3.3.(a)] revealed a major peak at 15 minutes and a smaller peak at 9 minutes. These 
represent IgG and IgM, respectively. Further purification on a Protein A column again
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shows a large peak at 15 minutes and a lesser peak at 22 minutes. The latter could be 
due to the leaching of protein A from the column [Figure 3.3.3.(b)]. The HPLC 
chromatographic profile of antiserum incubated with HRP [Figure 3.3.3.(d)] revealed 
a peak with a retention time of 12 minutes. This is representive of the PAP complex 
which has a molecular weight of approximately 432,000 daltons. This compares 
favorably with the individual retention times of peroxidase and the purified antibody, 
which are 17 minutes and 15 minutes, respectively [Figures 3.3.3.(a & c)]. The 
chromatographic profile of peroxidase incubated with normal rabbit serum was 
performed and no shifts in the parental peaks were observed [Figure 3.3.3.(e)].
3.3.4. Characterization of anti-HRP antiserum by SDS electrophoresis
SDS-Page analysis under non-reducing conditions was used to detect purity of the 
protein A purified antisera (Figure 3.3.4.]. A single large band with a MW of 
approximately 150KD representative of IgG is present.
Titre OD + SD @ 620nm
1:1000 antiserum 1.300 + 0.049
1:10,000 antiserum 1.276 ±  0.076
1:100,000 antiserum 0.539 ±  0.253
1:10 Normal rabbit serum 0.221 + 0.210
PBS (blank) 0.000 ±  0.000
Table 3.3.1. The titre of anti-HRP antiserum was assessed by ELISA. A sufficient 
signal was obtained using a titre of 1:100,000. All serum dilutions were performed in 
0.15M PBS, pH7.2.
SD - Standard deviation, n = 3.
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OD + SD @ 620nm
Sample HRP LDH Hexokinase ß-Gal
1:10,000 anti-HRP 0.806 + 
0.020
0.000 0.000 0.000
1:100 normal rabbit serum 0.000 + 
0.000
0.000 + 
0.000
0.000 + 
0.000
0.000 + 
0.000
PBS 0.000 + 
0.000
0.000 + 
0.000
0.000 + 
0.000
0.000 + 
0.000
Table 3.3.2. Cross-reactivity of rabbit anti-HRP antibodies with various enzymes. 
LDH:- lactate dehydrogenase, ß-Gal:- ß-Galactosidase. Antiserum dilutions were made 
up in 0.15M PBS, pH7.2.
SD - Standard deviation, n = 3.
Protein Molecular weight Retention time 
(mins)
IgM 900,000 9
IgG 150,000 15
HRP 44,000 18
Table 3.3.3. The retention times of a range of commercial proteins were determined 
by HPLC. The column used was a lOpM Protein Pak SW 300 column with a mobile 
phase of 0.1M phosphate buffer, pH 7.0, with a flow rate of 0.5ml/min. Absorbance 
due to proteins was detected at 280nm.
1 0 0
Time (mina)
Figure 3.3.3.(a).
HPLC chromatogram of rabbit antisera to HRP (lmg/ml), after (NH4)2S04 
precipitation. The column used was a lOpM Protein Pak SW 300 column with a 
mobile phase of 0.1M phosphate buffer, pH 7.0, and flow rate of 0.5ml/min. 
Absorbance due to protein was detected at 280nm. Two peaks were detected. One 
peak had retention time of 15mins and was IgG, the second protein peak with a 
retention time of 9 mins was that of IgM.
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Figure 3J.3.(b).
HPLC chromatogram of antisera to HRP after purification on a Protein A affinity 
column. The column used was a lOpM Protein Pak SW 300 column with a mobile 
phase of 0.1 M phosphate buffer, pH 7.0, and a flow rate of 0.5ml/min. Absorbance 
due to protein was detected at 280nm. Two peaks were detected. One peak had a 
retention time of 15mins and was IgG, the protein peak with a retention time of 
22mins could be that of protein A which has leached from the column.
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Figure 3.3.3.(c).
HPLC chromatogram of HRP, (lmg/ml). The column used was a lOpM Protein Pak 
SW 300 column with a mobile phase of 0.1 M phosphate buffer, pH 7.0, and a flow 
rate of 0.5ml/min. Absorbance due to protein was detected at 280nm. A large protein 
peak is present with a retention time of approximately 17mins.
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Figure 3.3.3.(d).
HPLC chromatogram of affinity-purified rabbit antisera to HRP, (1 mg/ml), incubated 
with HRP, (lmg/ml), for 30mins at 37°C. The column used was a lOpM Protein Pak 
SW 300 column with a mobile phase of 0.1M phosphate buffer, pH 7.0, and a flow 
rate of 0.5ml/min. Absorbance due to protein was detected at 280nm. One major peak 
was detected with a retention time of 12mins. This is representative of the peroxidase 
anti-peroxidase complex which has a MW of 432,000D (MWs: IgG = 150,000D, HRP 
= 44,000D). Smaller broad peaks are present with a retention time of 25mins and 
could be representative of denatured proteins.
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Figure 3.3.3.(e).
HPLC chromatogram of normal rabbit serum, (1 mg/ml), incubated with HRP, 
(lmg/ml), for 30mins at 37°C. The column used was a lOpM Protein Pak SW 300 
column with a mobile phase of 0.1 M phosphate buffer, pH 7.0, and a flow rate of
0.5ml/min. Absorbance due to proteins was detected at 280nm. This chromatogram 
should be compared to those obtained for HRP (Figure 3.3.3.c), and for HRP 
incubated with rabbit antisera to HRP. The protein peaks of interest are present at 
15mins and 17mins. These are representative of normal rabbit IgG and HRP. No 
change in the retention was observed, hence, no interaction of HRP and normal rabbit 
IgG has taken place. Other smaller protein peaks which are present are from the rabbit 
serum.
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Figure 3.3.4.
SDS-Page electrophoresis of purified antibodies (MW: 150,000D) and F(ab'y)2 
fragments (MW: 100,000). Lane 1 contains molecular weight markers. Lanes 2 and 
4 are the anti-HRP F(ab'y)2 and anti-HRP whole antibody molecules respectively and 
lanes 3 and 5 are the G12-F(ab'y)2 and G12 whole antibody molecules, respectively. 
Electrophoresis was performed under non-reducing conditions.
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3.3.5. G12 antibody production and purification
G 1 2  m onoclonal antibody w as purified  from  ascites by (N H ^ S C ^  precipitation and 
affin ity chrom atography using a 1m l protein A column.
3.3.6. Characterization of G12 antibody by ELISA
The reactivities o f  the m A bs G 1 2  and E 5  against various ce ll lines and human cancers 
w as exam ined by E L IS A  [Tables 3 .3 .6 .(a  &  b)J. Both G 1 2  and E 5  w ere found to be 
reactive with the K 5 6 2  and G C C M  cell lines [Table 3 .3 .6 .(a)]. N o reactivity w as 
detected with the T 24  and H L 6 0  ce ll lines. H9 and H 1 2  are hybridom as w hich also 
secrete antibody reactive with C L L  cells w ere negative on all ce ll lines exam ined. All 
4 antibodies reacted p o sitive ly  with six  C L L  sam ples when exam ined by E L IS A  
[Table 3 .3 .6 .(b)].
3.3.7. Characterization of G12 antibody by HPLC
H P L C  analysis w as also carried out on the (NH4)2S 0 4 and protein A  purified  fractions 
[Figures 3 .3 .7 .(a &  b)].
H P L C  chrom atographic profiles o f  (NH 4)2S 0 4 purified ascitic flu id  containing antibody 
[Figure 3 .3 .7 .(a)] revealed  a m ajor peak at 1 5  minutes and a sm aller peak at 9 
minutes, these represent Ig G  and Ig M , respectively. Further purification on a protein 
A  colum n show s a single large peak at 1 5  minutes [Figure 3 .3 .7 .(b)]. A sm aller peak 
at 2 3  minutes could be due denatured proteins or protein w hich has leached from  the 
column.
3.3.8. Characterization of G12 antibody by SDS-electrophoresis
S D S-P ag e  analysis under non-reducing conditions w as used to detect purity o f  the 
protein A  purified  G 1 2  m A B  [Figure 3 .3 .4 .] . A  single large band with a M W  o f
approxim ately 150 ,000 D  is present. This w ould be representative o f  IgG .
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OD +  SD  @  560nm
Sam ple K 5 6 2 G -C C M T 24 H L60
G 1 2 0 .580  ±  0 .020 0 .2 7 0  +  0 .0 0 1 0.000 + 
0.000
0.000 + 
0.000
E 5 0.403 ±  0 .0 37 0 .28 5  + 0 .0 0 1 0.000 ±  
0.000
0.000 + 
0.000
H9 0.000 ±  0.000 0.000 + 0.000 0.000 + 
0.000
0.000 + 
0.000
H 12 0.000 +  0.000 0.000 +  0.000 0.000 + 
0.000
0.000 + 
0.000
D M E M .S 5 0.000 ±  0.000 0.000 + 0.000 0.000 + 
0.000
0.000 + 
0.000
P B S 0.000 ±  0.000 0.000 +  0.000 0.000 + 
0.000
0.000 + 
0.000
Table 3 .3 .6 .(a). R eactivity  o f  a panel o f  the antibodies produced by the hybridom as 
G 1 2 ,  E 5 , H 9 and H 12  w ith various ce ll lines (K 56 2 , G -C C M , T 24  &  H L60). The 
E L IS A s  w ere perform ed on 96 w ell m icrotitre plates to w hich the ce ll lines had been 
prebound as described in Section 2 .8 .4 . The sam ples w ere exam ined as neat
supernatants.
SD  - Standard deviation, n =  3.
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OD + SD  @  620nm
C ell
type
G 1 2 E 5 H9 H 12 D M E M .S 5
C L L  1 0 .420  + 
0.004
0 .3 5 5  +  
0 .0 13
0 .238  + 
0 .0 12
0 .20 3  + 
0.003
0.000 + 
0.000
C L L  2 0.308 + 
0.003
0 .18 0  + 
0 .002
0.200 + 
0 .002
0 .207  +  
0 .007
0.000 + 
0.000
C L L  3 0 .2 10  +  
0 .002
0 .36 2  + 
0 .0 0 1
0 .260  ±  
0 .0 15
0.209 +  
0 .002
0.000 +
0.000
C L L  4 0.398  + 
0 .020
0 .18 4  + 
0 .007
0 .2 30  +  
0.004
0 .220  + 
0 .0 0 1
0 .000 + 
0.000
C L L  5 0 .3 3 3  +  
0.006
0 .2 2 7  +  
0.006
0 .220  + 
0.007
0.200  +  
0.003
0.000 + 
0.000
C L L  6 0 .4 10  +  
0 .0 13
0 .2 50  + 
0.006
0 .230  + 
0.005
0 .2 10  + 
0 .0 0 1
0.000 + 
0.000
Table 3 .3 .6 .(b). R eactiv ity  o f  the antibodies produced by the hybridom as G 1 2 ,  E 5 , H9 
and H 12  with C L L  cells by E L IS A . The E L IS A s  w ere perform ed on 96 w ell 
microtitre plates to w hich the C L L  cells had been pre-bound as described in Section 
2.8 .4 . The sam ples w ere exam ined as neat supernatants.
SD  - Standard deviation, n =  3.
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Figure 3.3.7.(a).
HPLC chromatogram G12 ascitic fluid, (lmg/ml) after (NH4)2S04 precipitation. The 
column used was a lOpM Protein Pak SW 300 column with a mobile phase of 0.1M 
phosphate buffer, pH 7.0, and a flow rate of 0.5ml/min. Absorbance due to proteins 
was detected at 280nm. Two peaks were detected. An IgG protein peak is present with 
a retention time of approximately 15 minutes. The smaller protein peak eluted in the 
void volume with a retention time of 9 minutes is that of IgM.
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Figure 3.3.7.(b).
HPLC chromatogram of G12 ascitic fluid, (lmg/ml), after purification on a Protein A 
affinity column. The column used was a lOpM Protein Pak SW 300 column with a 
mobile phase of 0.1M phosphate buffer, pH 7.0, and a flow rate of 0.5ml/min. 
Absorbance due to proteins was detected at 280nm. The protein peak with a retention 
time of 15mins is that of IgG. A small protein peak with a retention time of 23mins 
could be that of denatured proteins or that of protein A which has leached from the 
column.
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3.4. Reconstitution of Fab' fragments to form F(ab'y)2
F ab ' fragm ents w ere m ade from  purified G 1 2  m A B  and anti-H RP antiserum  as 
described in Section 2 .7 . These w ere reconstituted to form  bsab using the m ethod o f 
G lennie et al. ( 19 8 7 ).
These F(ab 'y)2 bsabs w ere characterized by E L IS A , im m unocytochem istry, SD S- 
electrophoresis and H P L C .
3.4.1. Characterization of F(ab'y)2 bsab by ELISA
The bsab and the w hole antibody secreted by the hybridom a G 1 2  exhibited sim ilar 
binding patterns when exam ined  by E L IS A  [Table 3 .4 . 1 . (a)]. O f the cell lines 
exam ined both G 1 2  and bsab reacted with K 5 6 2  and G C C M . Both  also reacted with 
7 C L L  sam ples and w ere negative for 3  normal peripheral b lood sam ples. The E L IS A  
used to detect reactivity o f  G 1 2  m A B  is outlined in [Figure 3 .1 .(b )] and that used to 
detect reactivity o f  bsab is  outlined in [Figure 3 . 1 . (a)].
The bsab w as also analysed by an E L IS A  w hich detected m ouse and rabbit IgG  since 
the bsab had F a b ' fragm ents derived from  both sources [Table 3 .4 .1.(b )].
3.4.2. Characterization of F(ab'y)2 by HPLC
H P L C  chrom atographic profiles o f  both G 1 2  and anti-H RP F a b ' fragm ents revealed 
a single peak with a retention time o f  2 2  minutes in both cases [Figures 3 .4 .2 .(a &  b)]. 
T he reconstituted F(ab 'y )2 w as present as a large peak  at 16  minutes [Figure
3.4 .2 .(c)]. A  sm aller peak at 2 2  minutes is probably unreacted F a b ', fragm ents.
3.4.3. Characterization of F(ab'y)2 bsab by SDS electrophoresis
S D S-P age  analysis under non-reducing conditions w as used to detect purity and M W  
o f the F(ab 'y)2 reconstituted bsab [Figure 3 .4 .3 .] .
3.4.4. Characterization of F(ab'y)2 bsab by immunocytochemistry
K 5 6 2 , T 24, H L 6 0 and C L L  w ere stained h istochem ically using m ethylene blue and 
eosin [Figures 3 .4 .4 .(a  and b)]. The cells w ere also exam ined im m unocytochem ically 
fo r antigenic reactivity using the bsab. In all 6 C L L  sam ples w ere tested. H L60, K 5 6 2 , 
T 2 4  and norm al lym phocytes all tested negative w hereas all 6 C L L  sam ples w ere
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positive [Figure 3 .4 .4 .(c  and d)J. Im m unocytochem ical staining w as also performed 
using firstly  a com m ercial D ako PA P  kit [Table 2 . 1 . 1 . ]  and secondly a H RP- 
conjugated goat anti-m ouse IgG  antibody. In the latter 2 cases whole G 1 2  antibody 
w as used as a prim ary binding antibody to the im m obilized ce lls  [Figure 3 .1 .( b  &  c)]. 
Neither o f  the latter 2  methods w ere capable o f  detecting antigen using 
im m um ocytochem ical techniques.
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Sam ples: OD +  S D  @  405nm
C ell type D M E M .S 5 P B S G 1 2 F(ab 'y)2
K 5 6 2 0.000 0.000 0 .39 0  +  0.004 0 .297  +  0 .023
G C C M 0.000 0.000 0 .2 18  +  0 .0 17 0 .34 3  +  0.028
C L L  1 0.000 0.000 0.440 ±  0 .007 0.260  + 0 .0 15
C L L  2 0.000 0.000 0 .19 7  +  0 .0 15 0 .15 7  +  0 .023
C L L  3 0.000 0.000 0 .15 2  +  0 .0 16 0 .37 0  +  0 .0 10
C L L  4 0.000 0.000 0 .34 2  +  0 .0 17 0 .369  +  0 .020
C L L  5 0.000 0.000 0 .14 5  +  0 .0 12 0 .20 3  +  0 .020
C L L  6 0.000 0.000 0 .2 36  + 0 .0 0 1 0 .3 2 7  +  0 .020
C L L  7 0.000 0.000 0.404 +  0.006 0 .3 2 1  +  0.004
P B L  1* 0.000 0.000 0.000 0.000
P B L  2 * 0.000 0.000 0.000 0.000
P B L  3 * 0.000 0.000 0.000 0.000
Table 3 .4 . 1 . (a). R eactiv ity  o f  G 1 2  w hole antibody and F(aby')2 bsab with 7 C L L  
sam ples, norm al peripheral blood lym phocytes and various ce ll lines. Both G 1 2  w hole 
antibody and F(aby')2 w ere used at a  concentration o f  lOjag/ml in P B S . The E L IS A s  
used to detect the G 1 2  w hole antibody and the bsab are outlined in Sections 2 .8 .5 . and 
2.8.8.
SD  - Standard deviation, n =  3.
* N orm al peripheral blood lym phocytes
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Sam ple OD +  SD  @  620nm
B sab  F(ab 'y)2 0 .3 2 2  ±  0 .002
G 1 2  antibody 0.000
R abbit anti-H RP antibody 0.000
P B S  (blank) 0.000
Table 3 .4 .1.(b ). C hem ically  form ed bsabs w ere m ade using rabbit and m ouse IgG  
F a b ' fragm ents. A n  E L IS A  detecting rabbit and m ouse F ab ' sim ultaneously w as 
perform ed to v e rify  that both o f  these arms w ere in fact present in the n ew ly  form ed 
bsab. Anti-m ouse Ig G  w as im m obilized onto a 96 w ell microtitre plate. The bsab w as 
then added. The bsab w as detected using an alkaline phosphatase-conjugated goat anti­
rabbit Ig G  antibody.
SD  - Standard deviation, n =  3.
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Figure 3.4.2.(a).
HPLC chromatogram of rabbit anti-HRP antibody Fab’ fragment. The column used 
was a lOpM Protein Pak SW 300 column with a mobile phase of 0.1M phosphate 
buffer, pH 7.0, and a flow rate of 0.5ml/min. Absorbance due to proteins was detected 
at 280nm. A protein peak with a retention time of 22 minutes is present. This 
corresponds to the Fab’ molecule.
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Figure 3.4.2.(b).
HPLC chromatogram of G12 antibody Fab’ fragment. The column used was a lOpM 
Protein Pak SW 300 column with a mobile phase of 0.1 M phosphate buffer, pH 7.0, 
and a flow rate of 0.5ml/min. Proteins were detected at 280nm. A protein peak with 
a retention time of 22 minutes is present. This corresponds to the Fab’ molecule.
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Figure 3.4.3.
HPLC chromatogram of the bsab F(ab'y)2 formed during reconstitution of rabbit anti- 
HRP and G12 antibody Fab' fragments using a lOpM Protein Pak SW 300 column 
with a mobile phase of 0.1M phosphate buffer, pH 7.0, and a flow rate of 0.5ml/min. 
Proteins were detected at 280nm. Protein peaks with Rts of approximately 16 minutes 
and 22 minutes are present. The peak at 16 minutes is thought to be that of the bsab 
which would have a molecular weight of approximately lOOkD and the second with 
a retention time of 22 minutes that of unreacted Fab' fragments (See discussion 
section 3.4.5.)
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Figure 3.4.3.
SDS-Page electrophoresis of HRP (lane 2, MW: 44,000D), reconstituted F(ab'Y)2 
bispecific antibody (lane 3, MW: 100,000) and purified anti-HRP antiserum (lane 4, 
MW: 100,000). Lane 1 contains molecular weight markers. Electrophoresis was 
performed under non-reducing conditions.
119
(a) (b)
(c)
Figure 3.4.4.(a).
Histochemical staining of (a) K562, (b) T24 and (c) HL60 cytocentrifuged cell 
preparations using methylene blue and eosin as described in Section 2.9. 
(Magnification x 40).
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Figure 3.4.4.(b).
Histochemical staining of cytocentrifuged cell preparations from the peripheral blood 
lymphocytes of (a) normal healthy volunteers and (b) patients with CLL using 
methylene blue and eosin as described in Section 2.9.
(Magnification x 40).
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Figure 3.4.4.(c).
Immunohistochemical staining of (a) K562, (b) T24, (c) HL60 and (d) normal 
peripheral blood lymphocyte (PBL) cytocentrifuged cell preparations using chemically 
synthesised ‘G12 anti-CLL crossed with anti-HRP’ bsab counterstained with methylene 
green as described in Section 2.9.1. All samples are negative.
(Magnification x 40).
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Figure 3.4.4.(d).
Tmmunohistochemical staining of cytocentrifuged cell preparations from (a) the 
peripheral blood lymphocytes of normal healthy volunteers and (b, c & d) the 
peripheral blood lymphocytes of 3 patients with CLL using chemically synthesised 
‘G12 anti-CLL crossed with anti-HRP’ bsab counter stained with methylene green as 
described in Section 2.9.1. Positive cells stain brown. The CLL samples stain 
positively with the bsab.
(Magnification x 40).
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3.4.5. Discussion
Biological production of triomas was very time consuming. Production of hybridomas 
using normal somatic cell fusion involves raising a sufficient titre in the immunized 
animal, a procedure which in itself is highly variable with regard to time (Baumgarten 
1992). These splenocytes are then fused to myeloma cells. Newly formed hybridomas 
are then assayed for specific antibody production. The time scale involved in the 
biological production of bsabs is increased by the need to back select for HAT- 
sensitivity in the hybridomas cells. Two methods were used to back select for HAT- 
sensitivity. Firstly, the hybridoma cells were grown in increasing concentrations of 8- 
aza and secondly the cells were mutagenised using EMS and new phenotypes were 
selected using 8-aza as a selection agent. The fusion frequencies of HAT-s G12 cells 
with immunized splenocytes was quite satisfactory. The resulting antibodies secreted 
from the triomas were either anti-K562 or anti-HRP parental antibodies. No bsabs 
were formed.
Newly formed triomas can potentially secrete 10 reassociated antibody types (Nolan 
and O’Kennedy 1991). The relative quantities of each of these ten is dependent on 
whether reassociation is random or non-random. The exact nature of heavy and light 
chain reassociation has been well studied. Milstein and Cuello (1984) demonstrated 
that among antibodies secreted by hybrid-hybridomas there was a preferential 
association of homologous heavy and light chains. This would be advantageous to the 
production of bsabs. De Lau et al. (1989) on the other hand reported that the 
homologous reassociation of heavy and light chains of 8 quadromas examined was 
favoured only in a minority of cases. Generally heavy and light chain reassociation 
was random. One of the quadromas produced was developed from parental 
hybridomas secreting antibodies to bovine IgG and HRP. Analysis of the secreted 
antibody species revealed that reassociation of the anti-HRP light chain with heavy 
chains was absolutely heterologous. Reassociation of the bovine anti-IgG light chain 
showed no such constraints. No anti-HRP antibody activity and therefore no bsab 
activity was detected. The implication of these results is that when antibodies are 
produced by B-cells the reassociation of homologous chains is not a property which 
is selected. This would not favour bsab production.
Given that the majority of triomas formed in the work described here secrete
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antibodies reactive with the K562 cell line it can be taken that the reassociation of 
heavy and light chains is such that the binding pattern of newly formed antibodies is 
dominated predominantly by heavy and light chains from the G12 hybridoma. It has 
been demonstrated that the heavy chain alone can bind antigen (Collet et al., 1989; 
Sastry et al., 1992). Therefore any reassociated antibody with an anti-K562/CLL heavy 
chain could bind the antigen. Less stable reassociated antibodies such as the anti-HRP 
antibodies may be overgrown at an early stage post-fusion by more stable triomas 
secreting anti-K562 antibodies.
The triomas formed by the fusion of mouse HAT-s G12 cells and rabbit splenocytes 
(secreting antibodies to HRP) are of particular interest because the resultant cells are 
chimeric in nature. It was required that these splenocytes receive an in vitro 
immunization. This was necessary because the splenocytes had been isolated 2 weeks 
subsequent to the final in vivo immunization which facilitated maximum antiserum 
levels to HRP but meant that the splenocytes were in the incorrect growth phase for 
antibody production by fusion. The in vitro immunization system used was developed 
previously in our laboratory for application to a murine system and its use here is the 
first occasion it has been applied to the development of an immune response in 
rabbits. The fusion of rabbit splenocytes with mouse myeloma or hybridoma cells can 
be more advantageous in some cases than the fusion of mouse splenocytes with mouse 
myeloma/hybridoma cells. Mice may not always be the most suitable animal in which 
to stimulate an immune response. Hyperimmunization of rabbits is often more 
practical, therefore, the chimeric mouse-rabbit system is better in these cases for mAb 
production. Due to the difficulties in raising an immune response in mice to group A 
Streptococcus Raybould and Takahashi (1988) developed rabbit-mouse hybridomas 
using the splenocytes of a hyperimmunized rabbit. The resultant chimeric cells 
secreted rabbit antibodies to group A Streptococcus. Given that the trioma produced 
in our work is of such a nature their exists the potential that this system could be used 
to produce bsabs in cases where a mouse antibody response is either not possible or 
difficult to obtain. The anti-HRP antiserum obtained from the rabbit was used for the 
production of bsabs using chemical procedures. Therefore, the use of rabbits in the 
course of this work allows for the production of bsabs firstly by chemical methods 
using the anti-HRP antiserum and secondly by biological methods using the isolated
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splenocytes in somatic cell fusions to form triomas. The splenocytes may be used 
immediately or stored in liquid nitrogen indefinitely. It may be necessary that the 
splenocytes receive an in vitro immunization depending on when the animal received 
its final antigenic boost.
Another feature of the mouse-rabbit triomas is that they required normal rabbit serum 
to be included in the growth medium post fusion. It was observed that this altered the 
morphology of the fused cells to one of a fibroblastic type-cell. When parental G12 
cells were grown in medium supplemented with normal rabbit serum they too 
exhibited this altered morphology. The triomas grew extremely slowly and were more 
unstable than mouse-mouse triomas.
To facilitate bsab production by triomas it may be necessary in the future to optimise 
the growth conditions used to culture the cells. The next chapter deals with the 
influence of the growth conditions on hybridoma growth at the clonal stage. Perhaps 
more defined growth medium would allow for production of triomas which secrete 
stable bsab.
Chemical methods proved more successful in the production of bsabs. A bsab was 
readily formed and was fully functional for both antigens as determined by ELISA and 
immunocytochemistry. Antiserum to HRP was produced in a New Zealand White male 
rabbit (Cahill et al., In press). A titre of 1:100,000 was achieved. The antibody 
produced by the hybridoma G12 was obtained from ascitic fluid. Both antibodies were 
affinity purified on Protein A columns prior to use. The resultant bsab was stable for 
up to six months when stored at 4°C. Stability of the bsab may be dependent on the 
relative stabilities of the parental antibodies both of which were very stable.
The bsab proved more efficient than the whole anti-tumour antibody when applied to 
immunocytochemical techniques. Immunocytochemical staining of cells using the 
whole G12 antibody in a PAP kit and in a direct stain using an anti-mouse IgG 
enzyme-conjugated antibody proved unsuccessful. The reactivity of the bsab was 
slightly altered when used in the immunocytochemical system as opposed to the 
ELISA. Whereas in the ELISA the bsab reacted with the K562 and GCCM cell lines 
as well as CLL cells, in the immunocytochemical system the cross-reativity with the 
human tumour cell lines was eliminated, only reactivity with the CLL cells was 
obtained. Optimal functioning required that the HRP be added after the bsab was
126
reacted with the cells. Addition of the bsab with pre-bound HRP resulted in poor 
binding of the bsab complex. Milstein and Cuello (1984) reported that bsabs used in 
immunocytochemical techniques had reduced non-specific binding compared to more 
conventional immunoenzymatic techniques. These authors also highlight the 
importance of penetration of the bsab. For example, their bsab which detected both 
HRP and extrahypothallmic somatostatin was incapable of functioning when the bsab 
was applied to samples with the pre-bound HRP. When the bsab was added first 
followed by addition of the HRP staining was obtained. The size of the bsab was 
150,000D and that of the bsab with HRP bound would be approximately 190,000D. 
This difference in MW was enough to interfere with binding of the bsab. This 
manipulation of procedure would not be possible in conventional systems where the 
functional agents are conjugated to antibodies. In the present study the MWs of the 
F(ab'y)2 bsab and Fab' were analyzed using HPLC and SDS polyacrylamide gel 
electrophoretic techniques. The approximate MWs would be in the region of 100,000D 
and 50,000D for F(ab'y)2 bsab and Fab', respectively. SDS-electrophoresis revealed 
that the molecular weigth of the F(ab'y)2 bsab was approximately 100,000D as 
expected. HPLC analysis revealed that the retention times obtained for F(ab'y)2 bsab 
and Fab' fragments were 16 and 22 minutes respectively. This is unusual because the 
retention time of HRP which has a MW of 44,000D is 17 minutes. The cause of such 
an observation could be due to the loss of the light from the F(ab'y)2 bsab and Fab' 
fragments. Although this would alter the MW the functioning of the bsab would not 
neccessarily be altered because as already discussed the light chain may not be 
required for antigenic binding (Collet et al., 1989; Sastry et al., 1992). The various 
reduction steps involved in the chemical production of bsabs could reduce the stability 
of the thiol bonds linking the light and heavy chains. Loss of the light chains may 
actually increase binding of bsab to antigen because the smaller molecule can 
penetrate antigen more readily (Milstein and Cuello 1984).
Some of the obvious drawbacks in the chemical production of bsabs are the large 
amounts of parent antibodies required for their synthesis and the fact that, unlike 
biologically made bsabs, a continuous supply of bsab is not readily available. Some 
of their advantages include the fact that their production method allows for 
purification by size, this would not be the case with biologically made bsabs where
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up to 10 different heavy and light chain rearrangements are possible and all newly 
formed antibodies are of equivalent size. Purification of bsabs would therefore involve 
at least two affinity purification procedures. The large amounts of antibodies required 
during chemical procedures can be overcome if facilities are available which allow for 
the production of large quantities of antibodies such as animal houses where ascites 
can be raised in mice and polyclonal antiserum developed in rabbits and large cell 
culture facilties for the production of antibody in cell culture supernatants.
The use of bsabs in vitro for ELISA and immunocytochemical techniques is quite 
promising. This is mainly due to the fact that once they are made they can be used in 
their native states. Their is no need to humanize them as is the case for bsabs with 
potential therapeutic applications.
There are several advantages of bsabs over mAbs. Bsabs work in a single step so 
reducing the time required to perform the assay. The dependency on and cost of, 
commercial labelled antibodies are eliminated. Biologically produced bsabs are active 
in their native state. No chemical alterations are required once the bsabs are made in 
order to bind the functional agent and the target cell. This is important as chemical 
modification may reduce the activity of the antibody or the functional agent which is 
being coupled. Although production of the bsab made here involved chemical 
modification of both parental antibodies these modifications were very site-specific. 
For example, the pepsin digestion of parental antibodies was followed by the reduction 
of thiol groups to yield the Fab' fragments. These modifications were not near the 
antigen binding site and, therefore, the antigen binding capability of the bsab should 
be unaffected. Conjugation of enzymes to whole antibodies is usually performed using 
accessible lysine residues and is therefore less specific than the conjugation procedure 
used to produce bsabs.
Bsabs do not require that the functional agent be bound prior to their administration. 
This allows pre-localization of the bsab at the target site prior to the addition of the 
functional agent. This may be of benefit in situations where penetration of the 
bsab/antibody to the antigic site hindered. This has been outlined in more detail above 
(Milstein and Cuello, 1984). An added advantage of the bsab produced here was that 
it performed in both ELISA and immunocytochemical based systems. Although
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ELISAs are very useful for determining antigenic determinants on cell surfaces the 
result is obtained as an absorbance measurement spectrophotometrically. 
Immunocytochemistry on the other hand allows for the microscopic visualisation of 
samples. These samples can be stored indefinitely.
Potentially, bsabs could find applications in the area of biosensors. A biosensor 
consists of a biological material that is responsive to the property or substance being 
sensed, in contact with a suitable transducing element that is needed to convert the 
signal sensed into a signal that can be easily processed. The specific and sensitive 
nature of antibody-antigen interaction provides the biosensing mechanism of 
immunosensors. The transducing mechanisms can be be based on for example 
electochemical and optical detection. Bsabs with one arm specific for an enzyme 
which produces electroactive product can be utilised in electrochemical 
immunosensors (Boitieux et al., 1984). Difficulties which may arise in these systems 
include failure of the antibody-enzyme to penetrate the antigenic determinant due to 
the sheer bulk of the complex and difficulties in conjugating the enzyme to the 
antibodies. In such cases the use of bsabs with one reactive with an enzyme could 
alleviate such problems.
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Chapter 4
Optimal growth conditions 
for hybridoma cells
4. Growth patterns of hybridomas at the clonal stage 
4.1 Introduction
Hybridoma growth is usually aided by the presence of exogenous growth factors or 
feeder layers in the culture medium. One such factor is interleukin-6 (IL-6) which is 
also known as hybridoma growth factor (HGF). Various hybridoma cloning products 
are available commercially. For example ‘Sigma Chemical Company’ have on offer 
conditioned medium (CM) from Giant Cell Tumour, EL4-IL2 and J774A.1 cells and 
hybridoma enhancing supplements with macrophage-like and thymoma cell origins. 
IL-6 is essential for differentiation of activated B-cells into antibody-producing cells, 
but it is not involved in the growth/proliferation of B-cells (Kishimoto, 1989). 
Factors such as B-cell growth factor (BCGF) are involved in the actual 
growth/proliferation of activated B-cells. IL-6, is, however, a growth factor required 
for myeloma/plasmacytoma cells (Kishimoto, 1989). Whether or not myeloma cells 
used routinely in cell fusions are IL-6-dependent may be dependent on the growth 
medium used in individual laboratories. According to Sugasawara (1988) (i) the 
cloning efficiency of IL-6 dependent hybridomas increases with the addition of IL-6 
to basal medium and (ii) the total number hybridomas (antibody-positive and negative) 
post fusion are increased in the presence of IL-6, indicating that the IL-6 is involved 
in differentiation and proliferation of hybridomas. Bazin and Lemieux (1989) observed 
that IL-6 has a much more beneficial effect on the overall number of antibody- 
producing hybridomas post fusion rather than on the overall number of hybridomas 
formed. This indicates that IL-6 is involved in differentiation rather than proliferation 
of B-cell hybridomas. These reporters go on to state that the actual number of 
hybridomas formed may depend on the FCS batch. Aarden et al. (1985) report that 
IL-6 dependency may be induced. They suggest that during fusions hybridomas 
become HGF-dependent but may be readily selected for IL-6 independency in post 
fusion cloning steps.
Various authors have reported on the uses of feeder layers and CM in hybridoma 
technology (Butcher et al., 1983; Pintus et al., 1983; Sugasawara et al 1985; Long et 
al., 1988; King and Sartorelli, 1989; Perrson and Lemer, 1990). Their work and that 
of others on this research topic is summarised in Table 4.1.
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Growth factor Increased levels 
ofIg  +ve 
hybridomas
Increased
cloning
efficiency
References
IL-6/HGF + NR Bazin & Lemieux (1989)
IL-6 + + Sugasawara (1988)
IL-6 secreting myeloma cells + NR Harris et al. (1992)
ECGS & HECS NR + Pintus et al. (1983)
HUCS + + Westerwouldt et al. (1983)
MCM NR + Sugasawara et al. (1985)
ECGS NR -
L-CM (L-929 cell line) NR + Walker et al. (1986)
HUCS & Human plasma . + Van Mourik & Zeijlmaker
HGF& HECS + + (1986)
3T3/A31 feeder cells NR + Butcher et al. (1988)
IRM-90, MRC-5 & Vero 
feeder cells & ECGS-CM & 
MRC-5-CM.
+ NR Long et al. (1988)
Hela, splenocytes & 
macrophages feeder cells
■ NR
ESGF
ECGS
NR + King & Sartorelli (1989)
Sp2/0 ascitic fluid w/o FCS NR + Stewart & Fuller (1989)
Normal mouse serum + NR Perrson & Lemer (1990)
CM-C6 (Glioma cell line) NR + Gomathi et al. (1991)
Table 4.1. Examples of the effects on hybridoma growth of various conditioned medium, feeder cell 
layers and other supplements.
"+" Positive effect, Negative effect,
ECGS; Endothelial cell growth supplement, ESGF; Ewing sarcoma growth supplement, 
HECS; Human endothelial culture supernatant, HUCS; Human umbilical cord serum, 
MCM; Macrophage conditioned medium,
IMR-90 & MRC-5; Human fibroblast cell lines,
Vero; African green monkey kidney cells,
Hela; A clone of the epitheloid cell line,
C6; A glioma cell line.
NR; Not reported.
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In the work described here two aspects of hybridoma cell growth were examined. 
Firstly medium conditioned with recombinant human IL-6 (rhIL-6-CM) supernatant 
from a known IL-6-secreting cell line, T24 (T24-CM) or feeder layers were compared 
for their ability to enhance the cloning efficiency of established hybridomas. Antibody 
production in established clones was also examined.
In a second set of experiments media supplemented with human plasma obtained from 
healthy volunteers and from patients with chronic lymphocytic leukemia, CLL, were 
examined for their ability to enhance hybridoma clonal growth. As before supernatants 
from the newly formed clones were examined for their ability to produce antibody. 
CLL is a haematological neoplasm characterized by clonal proliferation of B-cells 
(Gale and Foon, 1987) which have a mature appearance but are functionally immature. 
There have been contradictory reports as to whether or not patients suffering from 
CLL produce increased levels of EL-6 (Freeman et al., 1988; Biondi et al., 1989; 
Schena et al., 1991; Aguilar-Santelises et al., 1992). If so, then culture medium 
conditioned with CLL plasma/serum, should increase the cloning efficiency of 
hybridomas.
Hybridomas are of B-cell origin. Therefore, how these cells respond to treatment with 
CLL plasma may mimic how the various cytokines present in plasma of patients with 
CLL effects the growth of their B-cells.
4.2. Hybridoma growth in IL-6-supplemented medium
CM and feeder layers were compared for their ability to enhance the cloning 
efficiency of 3 established hybridomas, G12, 14E5 and 7P41. Basal medium was 
conditioned with supernatant from the IL-6-secreting cell line, T24, at the following 
concentrations, 1.0%, 2.5%, 5% and 10% (v/v). When compared to conventional 
feeder layers of macrophages, thymocytes and splenocytes the numbers of clones 
formed by growing cells in T24-CM was not affected. The levels of IL-6 present in 
T24 supernatant was measured by an ELISA specific for IL-6 and MTT assay on IL- 
6-dependent B9 cells. Antibody production was detected in supernatants by ELISA 
and was found to be unaltered by any of the CM or feeder layers.
One of the hybridomas, G12, was taken and grown in a range of concentrations of 
rhIL-6. No increase in the numbers of clones formed was observed.
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4.2.1. Results
Feeder layers or T24-CM did not increase the cloning efficiency of hybridomas 
compared to basal medium [Table 4.2.1.(a)], indicating that the cloning efficiency of 
the hybridomas was not influenced by the presence of IL-6 or feeder layers in the 
medium. The results given are the total number of clones/288 wells as the cloning was 
carried out on 3 occasions. In the case of the hybridoma 7P41 the results ranged from 
56/288 using 5% T24-CM to 78/288 using macrophages as feeder layers. A similar 
pattern emerged for the other 2 hybridomas. For example, the cloning efficiency of 
the G12 hybridoma ranged from 88/288 to 103/288 in the case of 1% T24-CM and 
2.5% T24-CM, respectively. For the hybridoma 14E5 the results ranged from 82/288 
to 107/288 using 5% T24-CM and macrophages, respectively. Supernatants were taken 
from the clones and examined for antibody production by ELISA [Table 4.2.1.(b)]. No 
effect was observed on the numbers of mAb-producing clones in any of the medium 
or feeder layers examined. The concentration of IL-6 in T24 supernatant as determined 
by ELISA and MTT assays (both of which were specific for IL-6) was found to be 
approximately 15ng/ml [Figures 4.2.1.(a & b)]. Using this data it is possible to work 
out the concentration of IL-6 in all the T24-CM ranges.
The hybridoma G12 was taken and cloned at 1 cell/well using medium conditioned 
with recombinant human IL-6 (rh-IL-6) ranging from 50-700pg/ml. No effect on the 
numbers of clones formed was observed [Table 4.2.1.(c)].
It is interesting to note that although no increase was observed in cloning efficiency 
using rhIL-6-CM as compared to basal medium, the total number of clones formed in 
this set of cloning experiments [Table 4.2.1.(c)] far exceeds those formed in the first 
set of cloning results [Table 4.2.1.(a)]. For example, the numbers of clones formed 
using rhIL-6-CM ranged from 114/288 to 138/288 using 500pg and lOOpg/ml rhIL-6- 
CM, respectively. When G12 was cloned in T24-CM the numbers of clones ranged 
from 88/288 using 1% T24-CM to 103/288 using 5% T24-CM [Table 4.2.1.(a)]. This 
highlights the variablity which is associated with hybridoma growth at the clonal stage
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Supplement No.of 
clones of 
7P41/288 
wells
No. of 
clones of 
G12/28 8 
wells
No. of 
clones of 
14E5/288 
wells
Thymocytes 69 103 101
Macrophage 78 98 107
Splenocytes 66 101 ND
1% T24 (150pg/ml) * 68 88 93
2.5% T24 (375pg/ml)
*
60 103 99
5% T24 (750pg/ml) * 56 93 82
10% T24 
(1500pg/ml) *
63 102 90
5% FCS 66 95 86
Table 4.2.1.(a). Cloning of the hybridomas 7P41, G12 and 14E5 at 1 cell/well. The 
hybridomas were cloned out on 3 separate occasions. Therefore, the results given 
above represent the total number of clones formed in 288 wells. Supernatants were 
taken from the first set of cloning experiments and tested for antibody production by 
ELISA [Table 4.2.1.(b)].
* The concentrations of IL-6 in T24 supernatant listed above represents the 
concentration in whole medium.
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Supplement No. of 7P41 clones 
secreting mAB
No. of G12 clones
secreting
mAB
No. of 14E5 
clones secreting 
mAB
Thymocytes 54/69 67/103 89/101
Macrophage 56/78 61/98 86/107
Splenocytes 50/66 65/101 ND
1% T24 50/68 63/88 77/93
2.5% T24 46/60 72/103 84/99
5% T24 43/56 68/93 74/82
10% T24 50/63 63/102 77/90
5% FCS 50/66 67/95 72/86
Table 4.2.1.(b). Supernatants from the first set of cloning experiments were taken and 
examined for the presence of mAB by ELISA.
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Supplement No of clones/288 wells
50pg EL-6/ml * 136
lOOpg IL-6/ml * 138
200pg IL-6/ml * 127
300pg IL-6/ml * 135
400pg IL-6/ml * 121
500pg IL-6/ml * 114
600pg IL-6/ml * 121
700pg IL-6/ml * 122
5% FCS 136
Table 4.2.1.(c). The hybridoma, G12, was then taken and cloned at 1 cell/well in 
medium conditioned with a range of concentrations of rhIL-6.
* The concentrations of IL-6 listed above represent the concentration in whole 
medium.
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Figure 4.2.1.(a).
Standard curve for the determination of interleukin-6 (IL-6) using an ELISA specific 
for human IL-6 (Regression coefficient = 0.999). This was used to determine IL-6 
levels in normal human plasma, plasma of patients with Chronic Lymphocytic 
Leukemia (CLL) and T24-conditioned medium prepared from the T24 cell line.
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Figure 4.2.1.(b).
Standard curve for the determination of interleukin-6 (IL-6) using an MTT-based 
bioassay the IL-6 dependent cell line B9 (Regression coefficient = 0.999). This was 
used to determine IL-6 levels in normal human plasma, plasma of patients with 
Chronic Lymphocytic Leukemia (CLL) and T24-conditioned medium prepared from 
the T24 cell line.
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4.3 Hybridoma growth in plasma-supplemented medium
5% T24-CM, plasma-supplemented medium and feeder layers were compared for their 
ability to increase the cloning efficiency of established hybridomas. Basal medium, 
consisting of DMEM+5% Foetal Calf Serum (FCS) was supplemented with 5% (V/V) 
T24 supernatant, 5% T24-CM normal human plasma (NHP-DMEM) and plasma from 
patients with chronic lymphocytic leukemia (CLL-DMEM). When compared to 
conventional feeder layers of macrophages, thymocytes, splenocytes and to feeder CLL 
cells and 5% T24-CM it was discovered that the numbers of clones formed by 
growing hybridomas in CLL-DMEM was greatly enhanced. NHP-DMEM also 
enhanced the cloning efficiency. CM and plasma supplemented medium were 
examined for the presence of IL-6, which is also known as hybridoma growth factor 
(HGF). Of the eight CLL plasma samples examined only two had elevated IL-6 levels. 
Antibody production in established clones was examined by ELISA (Sections 2.8.1. 
and 2.8.2.) and to determine if antibody production was affected by the cloning media 
used. It was found that both the total numbers of clones produced and the number of 
antibody-producing clones were much higher using CLL-DMEM.
4.3.1. Results
The results indicate that basal medium conditioned with CLL plasma gave better 
results than conventional feeder layers NHP-DMEM and 5% T24-CM in hybridoma 
cloning work. In all eight CLL plasma samples were used as a supplement to basal 
medium, 4 in the first set of cloning experiments, CLL-DMEM A-D [Table 4.3.1.(a)], 
and 4 in the second set of cloning experiments, CLL-DMEM E-H [Table 4.3.1.(c)]. 
All CLL-DMEM enhanced the cloning efficiency of the hybridomas [Tables 4.3.1.(a 
& c)]. Each cloning efficiency experiment was carried on three separate occasions. 
Therefore, the results in each case are given as the total numbers of clones in 288 
wells.
In the first set of cloning experiments [Table 4.3.2.(a)], using the OKT8 hybridoma, 
CLL-DMEM was 4-5 fold more efficient for cloning than conventional feeder layers, 
4 fold more efficient than 5% T24-CM and 2.4 fold more efficient than NHP-DMEM. 
For the hybridoma 14E5, CLL-DMEM was 4-5 fold more efficient than feeder layers 
and 5% T24-CM, and 2-3 fold more efficient than NHP-DMEM and, finally, for the
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hybridoma Epl6, CLL-DMEM was 6 fold more efficient than feeder layers, 5 fold 
more efficient than 5% T24-CM and 1.6 fold more efficient than NHP-DMEM. 
Monoclonal antibody levels were measured in supernatants from all the established 
clones in the first set of cloning experiments. Due to the increase in the numbers of 
clones formed using CLL-DMEM, a corresponding increase in the number of 
antibody-producing clones is also observed [Table 4.3.1.(b)].
In the second set of cloning experiments a similar pattern emerged [Table 4.3.1.(c)]. 
CLL-DMEM was 3 fold more efficient for cloning 14E5 chybridoma cells than feeder 
layers and 5% T24-CM and two fold more efficient than NHP-DMEM. For the 
hybridoma Epl6 CLL-DMEM was 4-5 fold more efficient than feeder layers, 3-4 fold 
more efficient than 5% T24-CM and two fold as efficient as NHP-DMEM. Finally, 
for the hybridoma 7p41, CLL-DMEM was 3-4 fold more efficient than feeder layers, 
3 fold more efficient than 5% T24-CM and 1.5 times more efficient than NHP- 
DMEM.
The use of CLL cells as a feeder layer did not increase cloning efficiency [Table
4.3.1.(a)]. The feeder cells used were obtained from a patient who was found to have 
increased IL-6 levels (CLL plasma A). Sanchez et al. (1991) have reported enhanced 
cloning efficiency of heterohybridomas using CLL feeder cells, concluding that this 
may be due to an overall increase in secretion levels of several cytokines . All of the 
samples were examined for IL-6 levels using, firstly, an MTT-based bioassay on I n ­
dependent B9 cells [Figure 4.2.1.(a)], and secondly, an ELISA for rhIL-6 with a 
working range of 0.1-20ng/ml [Figure 4.2.1.(b)]. Of the 8 CLL samples two, CLL-A 
and CLL-D, tested postive for IL-6 in the MTT assay and the ELISA. CLL-A had 
1.3ng/ml IL-6 as determined by the MTT assay [Figure 4.2.1.(a)] and 1.5ng/ml IL-6 
as determined by ELISA [Figure 4.2.1.(b)]. CLL-D had 0.6ng/ml of IL-6 as 
determined by MTT assay [Figure 4.2.1.(a)], and 0.8ng/ml as determined by ELISA 
[Figure 4.2.1.(b)]. T24 supernatant was found to secrete approximately 15ng/ml IL-6 
by the MTT assay [Figure 4.2.1.(a)] and 15.6ng/ml IL-6 by ELISA [Figure 4.2.1.(b)]. 
Newly formed clones obtained using CLL-DMEM and basal medium are shown in 
Figure 4.3.1.(a).
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CLONING
MEDIUM
No. of clones of 
OKT8
No. of clones of 
14E5
No. of clones of 
Epl6
5% FCS 42 31 18
10%FCS 37 36 15
Splenocytes 36 48 18
Macrophage 45 30 12
Thymocytes 48 42 18
5% T24-CM 50 39 20
5% CLL serum 156 153 104
CLL-DMEM A 204 237 96
CLL-DMEM B 189 171 101
CLL-DMEM C 201 189 92
CLL-DMEM D 258 216 90
CLL feeder * 45 27 12
Normal human 
plasma
81 69 57
Table 4.3.1.(a). Results of cloning efficiency experiments with the hybridomas OKT8, 
14E5 and Epl6. Each cell line was cloned on 3 separate occasions. The numbers listed 
are the total numbers of clones growing in 288 wells. Supernatant from all clones 
formed here were examined for antibody production by ELISA [see Table 4.3.1. (c)]. 
CLL feeder * Here CLL cells were used as a feeder layer.
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Sample No. of OKT8 
clones
secreting mAB
No. of 14E5 
clones secreting 
mAB
No. of Epl6 
clones secreting 
mAB
5% FCS 33/42 22/31 10/13
10% FCS 30/37 28/36 12/15
Splenocytes 29/36 38/48 14/18
Macrophage 36/45 20/30 11/12
Thymocytes 40/48 27/42 14/18
T24-CM 38/50 26/39 16/20
CLL-DMEM A 153/204 154/237 78/96
CLL-DMEM B 147/189 117/171 79/101
CLL-DMEM C 161/201 138/189 69/92
CLL-DMEM D 217/258 162/216 75/90
CLL feeder cells 35/45 21/27 10/12
Normal numan 
plasma
61/81 50/69 48/57
Table 4.3.1.(b). The supernatants from all the clones (Table 4.3.1.a) formed were 
removed and assayed for antibody production by ELISA. As can be seen from the 
above data the higher numbers of clones formed using CLL-DMEM causes a 
corresponding increase in the numbers of antibody-producing clones.
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CLONING
MEDIUM
No. of clones of 
14E5
No. of clones of 
Epl6
No. of clones of 
7p41
5% FCS 35 18 25
10% FCS 38 21 29
Splenocytes 47 22 27
Macrophage 39 12 30
Thymocytes 42 22 25
5% T24-CM 44 25 31
CLL-DMEM E 111 89 90
CLL-DMEM F 190 120 122
CLL-DMEM G 108 61 90
CLL-DMEM H 140 106 82
Normal human 
plasma
68 43 62
Table 4.3.1.(c). Results of cloning efficiency experiments on the hybridoma 14E5, 
Epl6 and 7p41. Each cell line was cloned on 3 seperate occasions. The numbers listed 
are the total numbers of clones growing in 288 wells.
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(b)
Figure 4.3.1.(a).
Newly formed clones of hybridoma cells seeded at a cell concentration of 1 cell/well 
in growth medium. The cells were grown in (a) DMEM.S5 and (b) DMEM.S5 
supplemented with 5% CLL plasma.
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4.4. Discussion
The use of CM or feeder cells, which are essential aspects of hybridoma cell culture, 
have been discussed fully in the Introduction (Section 1.4) and are outlined in Table
4.1. CM has some clear advantages over the use of feeder cell layers. For example, 
the risk of contamination is reduced because the CM has either been grown in the 
laboratory and contamination can be checked prior to its use or the CM may be 
acquired commercially in which case the product would be for cell culture use only 
and checked for contamination. Very often the growth factors which are secreted by 
a cell line used as a source of CM are known. For example the T24 cell line secretes 
IL-6. In addition the requirement for animal use is eliminated as are the possibilities 
of infections derived from the animal feeder cell systems.
Some of the advantages of using IL-6 in the growth of hybridomas include increasing 
the proportion of antibody-producing hybridomas post fusion (Bazin and Lemieux, 
1989) and increasing the cloning efficiency of IL-6-dependent hybridomas 
(Sugasawara, 1988).
In the present study two aspects of hybridoma cell growth were examined. Firstly 
rhIL-6-CM, T24-CM, and feeder layers were compared and examined for their ability 
to enhance the cloning efficiency of hybridomas and to support antibody production. 
A range of concentrations of rhIL-6 and T24 supernatants were used. The presence of 
IL-6 was not a growth requirement for the hybridomas examined here. Antibody 
production in established clones was also found to be constant. In a second series of 
experiments, T24-CM, feeder layers and plasma-supplemented medium were examined 
and compared for their ability to enhance the cloning efficiency of hybridomas and 
to support antibody production.
DMEM supplemented with plasma from patients with Chronic Lymphocytic Leukemia 
(CLL) [CLL-DMEM] was found to increase the cloning efficiency of the hybridomas 
examined here (Quinlan and O’Kennedy In press). This is the first reported instance 
of such an effect and it may give clues as to how normal haematopoietic controls in 
patients with CLL are effected by aberrant cytokine production. The samples were 
examined by ELISA and an MTT assay for IL-6 and 2/8 were found to have elevated 
levels. This correlates with the first set of cloning experiments which indicated that 
the cloning efficiency of the hybridomas was IL-6-independent. The superiority of
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CLL-DMEM in cloning efficiency experiments could be due to an overall increase in 
cytokines in these patients. There have been mixed reports as to whether on not IL-6 
levels are increased in patients with CLL (Freeman et al., 1988; Biondi et al., 1989; 
Schena et al., 1991; Aguilar-Santelises et al., 1992). B-CLL have been shown to 
produce a range of cytokines. Kawamura et al. (1986) suggested that BCGF is a factor 
with a possible autocrine nature in B-CLL. Uggla et al. (1987) reported the 
spontaneous production of an IL-l-‘like’ growth factor by CLL cells and Schena et 
al. (1991) reported that B-CLL produce IL-la, IL-6, TNF-a and TGF-(3 which are 
consistent with the cytokines produced by normal mantle B-cells. It is conceivable that 
an increase in these and other cytokines which act on normal B-cells may be 
responsible for the growth promoting effect of the CLL plasma on the B-cell 
hybridomas. BCGF is needed for the normal growth of activated B-cells and this may 
fit the description of the factor enhancing the hybridomas used here.
When studying the effects of IL-6 on hybridoma cell growth a crucial factor may be 
the fact that IL-6-dependent and non-dependent hybridomas exist. This lends itself to 
the possibility of similar growth factors giving diverging results in different 
laboratories when used in cloning experiments, as can be seen in the case of ECGS. 
ECGS was found in some cases to be beneficial as a hybridoma growth factor (Long 
et al., 1988; Pintus et al., 1983) and in other cases to be ineffective (Butcher et a l ., 
1983; King and Sartorelli, 1989; Sugasawara et al., 1985). Freshly fused hybridomas 
are perhaps open to more influences in the medium than at any other stage. The new 
genetic material in a fused cell can be unstable and, therefore, dependency on growth 
factors may be induced here. Van Mourik and Zeijlemaker (1986) have demonstrated 
that culture medium supplemented with human umbilical cord serum and normal 
human serum did not promote the growth of hybridomas during cell fusions, whereas 
HGF and human endothelial cell supernatant did. All four supplements, however, were 
capable of supporting the growth of established hybridomas during cloning procedures 
indicating that growth conditions at this stage are less stringent.
As IL-6 is reported to increase the numbers of antibody-producing hybridomas post 
fusion, (Bazin and Lemieux, 1989) it is advisable to include it as a supplement in the 
culture medium at this stage. As a result these hybridomas may subsequently become 
dependent on IL-6 and it is therefore essential that IL-6 be included in the culture
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medium at this crucial stage of hybridoma growth post fusion.
In summary, the hybridomas examined here grow independently of IL-6. However, 
factors present in CLL plasma, and to a lesser extent NHP, are able to significantly 
enhance the cloning efficiency of hybridomas. We have only examined IL-6 as a 
possible growth factor involved in this process due to its reported beneficial effects 
on hybridomas (Sugasawara, 1988; Bazin and Lemieux, 1989). Other cytokines, 
perhaps in combination with IL-6, may be responsible for the observed effects. The 
anticoagulant tubes into which plasma is collected may be contaminated with 
endotoxin which may stimulate B-cells to secrete various cytokines (Riches et ah, 
1992). B-cells from both normal volunteers and CLL patients examined here could be 
stimulated to secrete cytokines in such a manner. The effect could be greatly amplified 
in patients with CLL due to the large numbers of circulating B-cells. A very important 
factor to consider when developing novel growth medium is the actual effect on the 
cellular function. Here the cells under investigation are hybridomas. It is therefore of 
vital importance that the plasma does not interfere with antibody production. Antibody 
production was detected by ELISA. Antibody production was not affected by the CLL 
plasma. However, given the increase in the total numbers of clones formed a similar 
increase in the number of antibody producing clones was obtained. This would be of 
greatest importance in the first cloning step post-fusion where each newly formed 
clone may secrete a unique antibody.
An important point to be taken from the results presented here is that if the optimum 
growth conditions can be identified for a particular hybridoma then this can greatly 
enhance the growth of the hybridoma cells. At large cell numbers this may not be of 
great importance but during times when the cells are under stress such as after 
recovery from liquid nitrogen or during the low cell numbers encountered during 
cloning procedures the microenvironment seems to influence the capacity of a cell to 
survive and at this stage the growth conditions are of greatest importance.
Given the commercial availability of recombinant cytokines further studies 
investigating the effects of the various cytokines present in CLL plasma on hybridoma 
cell growth both indvidually and in various combinations may indicate exactly which 
cytokines are responsible for the observed stimulatory effects. Highly defined novel
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hybriboma growth factors could thus be identified which be of high commercial value. 
In the work described here the effect of CLL plasma on hybridoma cell growth was 
examined. It is possible that the CLL plasma may act in a similar way on cell lines 
derived from various other cell types.
How these results relate to the progression of the disease is of particular interest since 
the clinical implications of elevated cytokine levels in these patients is unclear. 
Hybridomas are of B-cell origin. Therefore, the growth promoting ability of the 
plasma on hybridomas may be mimicked in vivo on cells of B-cell origin. Given that 
the cytokines act on wide range of cell types further studies in vitro on different cell 
types may indicate how the cytokines affect the progression of the disease.
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Chapter 5
Correlation of Interleukin-6 
and Hypogammaglobulinemia 
in Chronic Lymphocytic Leukemia
5.1. Correlation of IL-6 and hypogammaglobulinemia in CLL
The importance of cytokines in CLL has recently been highlighted at the "5“1 
International Workshop on Chronic Lymphocytic Leukemia", (Montserrat et al., 1992). 
There have been mixed reports as to whether on not IL-6 levels are increased in 
patients with CLL, (Freeman et al., 1988; Biondi et al., 1989; Schena et al., 1991; 
Aguilar-Santelises et al., 1992). B-CLL have been shown to produce a range of 
cytokines including BCGF which Kawamura et al., (1986) have suggested is a factor 
with a possible autocrine nature in B-CLL. Uggla et al., (1987) reported the 
spontaneous production of an IL-1 growth factor by CLL cells and Schena et al.,
(1991) reported that B-CLL cells produce IL-la, IL-6, TNF-a and TGF-(3 which are 
consistent with the cytokines produced by normal mantle B cells.
IL-6 is a multifunctional cytokine which is produced by a wide variety of cells 
including both lymphoid and non-lymphoid cells. IL-6 is involved in the regulation 
of immune responses, final differentiation of B cells into antibody-producing cells 
(Kishimoto, 1989), acute phase responses (Gauldie et al., 1987; Nijstein et al., 1987) 
and haematopoeisis (Hirano, 1991). The biology of IL-6 has been reviewed 
comprehensively in the introduction, (Section 1.3).
One of the clinical symptoms associated with CLL is hypogammaglobulinemia 
(Coperative Group on CLL, 1988). This may be a factor in some of the clinical 
symptoms of the disease such as the infections which are a major cause of morbidity 
and mortality in these patients. Correlations between the concentrations of IL-6 and 
IgG have been identified in several diseases. These include AIDS (Breen et al., 1990) 
and rheumatoid arthritis (Hermann et al., 1989) and are discussed in more detail in 
Section 5.4.
There were two main aims in the work described in this chapter. Firstly, the 
production of IL-6 by patients with B-CLL was examined. IL-6 levels in plasma and 
conditioned medium (CM), obtained from growing the cells in culture medium for 48 
hours, were assayed. The assays used were the MTT assay using IL-6-dependent B9 
cells and an ELISA specific for human IL-6. Of eleven patients examined IL-6 was 
detected in the plasma and CM of five.
Secondly, the plasma were examined by ELISA for the presence of IgG. The
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relationship between IL-6 and IgG levels in these patients may indicate if patients with 
elevated IL-6 levels have normal or raised IgG levels. This could represent a sub­
group of patients better able to fight infections. Alternatively raised IL-6 may be part 
of a cytokine network responsible for some of the clinical aspects of the disease.
5.2. IL-6 levels in CLL plasma
IL-6 levels in plasma from patients with CLL were determined by ELISA, [Figure
5.2.(a)], and an MTT-based bioassay using IL-6 dependent B9 cells [Figure 5.2.(b)]. 
Of 11 patients tested 5 were found to be positive for IL-6 in both systems [Table 5.2.]. 
The levels detected ranged from 2.0 - 3.3ng/ml in the ELISA system and 1.86 - 
3.1ng/ml in the MTT bioassay. A good correlation between both assays was obtained. 
IL-6 was not detected in any of 3 normal human plasma samples examined by both 
systems.
5.2.1. IL-6 levels in CLL-CM
Conditioned Medium (CM) was obtained by growing peripheral blood lymphocytes 
(PBL), obtained from patients with CLL cells (CLL-CM), and from normal healthy 
volunteers (PBL-CM), as described in Section 2.3.15. It was tested for IL-6 activity 
by ELISA and MTT bioassay, as described in Section 5.2. The levels of IL-6 
measured in CLL-CM correlated with those levels detected in CLL plasma [Section 
5.2]. The levels of IL-6 detected in CLL-CM ranged from 3.0 - 4.2ng/ml by ELISA 
and 3.1 - 3.9ng/ml by MTT assay [Table 5.2.1.]. IL-6 was not detected using either 
system in DMEM.S5 or PBL-CM.
5.3. IgG levels in plasma
Plasma samples from the 11 patients with B-CLL were also examined for the presence 
of circulating IgG using an ELISA specific for human IgG (Figure 5.3.). IgG was not 
detected in any of the CLL plasma samples examined. The 3 normal human plasma 
samples all had detectable IgG levels, (Table 5.3), ranging from 8-18mg/ml.
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Figure 5.2.1.(a).
Standard curve for the determination of interleukin-6 (IL-6) using an ELISA specific 
for human IL-6 (Regression coefficient = 0.997). This was used to determine IL-6 
levels in normal human plasma, plasma of patients with Chronic Lymphocytic 
Leukemia (CLL) and conditioned medium (CM) obtained from the growth of both 
normal human peripheral blood lymphocytes and peripheral blood lymphocytes from 
patients with CLL. Undiluted CLL plasma samples and CM were analyzed.
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Figure 5.2.1.0b).
Standard curve for the determination of interleukin-6 (IL-6) using an M I T-based 
bioassay with an IL-6-dependent cell line B9 (Regression coefficient = 0.999). This 
was used to determine IL-6 levels in normal human plasma, plasma of patients with 
Chronic Lymphocytic Leukemia (CLL) and conditioned medium (CM) obtained from 
the growth of both normal human peripheral blood lymphocytes and peripheral blood 
lymphocytes from patients with CLL.
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Sample Cone as determined by 
ELISA (ng/ml)
Cone as determined by 
MTT assay (ng/ml)
CLL-1 3.1 2.7
CLL-2 3.3 3.1
CLL-3 2.9 3.0
CLL-4 0.0 0.0
CLL-5 0.0 0.0
CLL-6 2.0 1.86
CLL-7 0.0 0.0
CLL-8 0.0 0.0
CLL-9 2.3 2.1
CLL-10 0.0 0.0
CLL-11 0.0 0.0
NHP 1 0.0 0.0
NHP 2 0.0 0.0
NHP 3 0.0 0.0
DMEM.S5 0.0 0.0
Table 5.2. The concentration of IL-6 in normal human plasma and in the plasma of 
patients with CLL were determined by an ELISA and an MTT-based bioassay both 
of which were specific for IL-6. Each sample was assayed on three occasions.
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Sample Cone as determined by 
ELISA (ng/ml)
Cone as determined by 
MTT assay (ng/ml)
CLL-1 4.1 3.63
CLL-2 4.2 3.9
CLL-3 4.2 3.8
CLL-4 0.0 0.0
CLL-5 0.0 0.0
CLL-6 3.0 2.9
CLL-7 0.0 0.0
CLL-8 0.0 0.0
CLL-9 3.5 3.1
CLL-10 0.0 0.0
CLL-11 0.0 0.0
NHP 1 0.0 0.0
NHP 2 0.0 0.0
NHP 3 0.0 0.0
DMEMS5 0.0 0.0
Table 5.2.1. The concentration of IL-6 in conditioned medium obtained from the 
growth of peripheral blood lymphocytes from normal healthy volunteers and from 
patients with B-CLL in complete medium for 48 hours were determined by an ELISA 
an an MTT-based bioassay, both of which were specific for IL-6. Each sample was 
assayed on three occasions.
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Figure 5.2.2.
Standard curve for the determination of human immunoglobulin-G (IgG) [Regression 
coefficient = 0.989]. IgG levels were detected in normal human plasma and in the 
plasma of patients with Chronic Lymphocytic Leukemia (CLL).
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Sample Cone IgG (mg/ml)
CLL 1 0.0
CLL 2 0.0
CLL 3 0.0
CLL 4 0.0
CLL 5 0.0
CLL 6 0.0
CLL 7 0.0
CLL 8 0.0
CLL 9 0.0
CLL 10 0.0
CLL 11 0.0
NHP 1 18.5
NHP 2 15
NHP 3 8
PBS (blank) 0.0
Table 5.3. The concentrations of IgG in normal human plasma (NHP) and plasma 
from patients with CLL were determined by an ELISA. Plasma samples were diluted 
1:1000 in the case of CLL samples and 1:5000 in the case of NHP. All dilutions were 
made in 0.15M PBS, pH 7.2. Each sample was assayed on three occasions.
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5.4. Discussion
In the work described here the concentrations of interleukin-6 (IL-6) and 
immunoglobulin-G (IgG) in the plasma of patients with Chronic Lymphocytic 
Leukemia (CLL) were examined. IL-6 is a crucial element in host-mediated responses 
to disease through its roles in the induction of both the acute phase response and final 
differentiation of B-cells into antibody-producing cells. IL-6 has been implicated in 
certain diseases to be responsible for the polyclonal B-cell activation responsible for 
such symptoms as the production of auto-antibodies and hypergammaglobulinemia. 
This may be the case in AIDS (Breen et al., 1990) and cardiac myxoma (Hirano et 
al., 1987). IL-6 has also been detected in the synovial fluid of patients with 
rheumatoid arthritis [RA] which is also an auto-immune disorder (Bhardwaj et al., 
1989; Hirano 1991). It has been demonstrated that the concentration of IL-6 and IgG 
in the synovial fluid of these patients is correlated. The association of IL-6 with 
various diseased states including CLL has been discussed fully in Section 1.3.
One of the clinical symptoms associated with CLL is hypogammaglobulinemia and 
one of the chosen methods of treatment is with the administration of intravenous (i.v.) 
IgG (Helenius et al., 1992). However, this, is a very costly form of therapy and, 
therefore, its use has been limited to a select number of patients. To review their 
policy on prophylatic treatment with i.v. IgG in patients with CLL Helenius et al.,
(1992) analyzed infection history, serum-IgG (s-IgG) levels and the disease stage of 
146 patients. S-IgG levels were available for 98 patients. 55% were 
hypogammaglobulinémie and 56% had presented with at least one serious infection. 
Severe infections tended to accumulate in patients with subnormal s-IgG and advanced 
disease stages, and these patients would benifit most from i.v. IgG prophylaxis. The 
Cooperative Group on CLL, (1988), performed a double-blind trial in which 84 
patients, who were judged to be at increased risk of infections, were chosen to receive 
i.v. IgG or placebo. Eligible patients had hypogammaglobulinemia, a history of 
infection or both. To determine which patients benefited most from i.v. IgG treatment 
several factors were determined prior to treatment. These were infection history, age, 
sex, disease stage and duration, previous therapy (including splenectomy), 
haemoglobulin level, neutrophil and platelet counts and s-IgG level. Patients receiving
i.v. IgG had significantly fewer bacterial infections and a longer time period before
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succumbing to their first serious bacterial infection. There was no significant 
difference between both groups in the incidence of non-bacterial infections, or, in the 
number of patients remaining infection-free. The group conclude that selected CLL 
patients with particular risk from infection may benefit from i.v. treatment. Viral and 
fungal infections which are thought to be less dependent on antibody responses were 
unaffected in both groups. The fact that bacterial infection was not completely 
eliminated using i.v. IgG highlights the fact that other factors also contribute to the 
risk of bacterial infection in these patients. These factors include T-cell dysfunction, 
NK dysfunction, defects in complement, neutropenia (often caused by cytotoxic 
therapy), monocytopenia and immunosuppressive therapy. Initial s-IgG levels did not 
correlate with the incidence of infection. The American Society of Hospital 
Pharmacists (1992), suggest that specific IgG could be more important than whole s- 
IgG levels. These workers go on to point out that the identification of specific 
subgroups of CLL which could benifit from from i.v. treatment is also desirable.
One such subgroup could be those patients with elevated IL-6 levels. Given the 
reported increased IL-6 levels in some patients with CLL it was investigated whether 
the levels of IL-6 and IgG in these patients correlated. The results presented in this 
chapter indicate that the concentration of IL-6 and IgG present in the plasma of 
patients with CLL are not correlated. IL-6 was detected in the plasma and CM in 5 
of 11 CLL patients examined by ELISA and an MTT based bioassay both of which 
were specific for IL-6. None of the plasma samples examined had detectable IgG 
levels as determined by ELISA. Given that IL-6 was detected in the CM it is probable 
that the neoplastic lymphocyte cells are responsible for some if not all of the observed 
IL-6 over-production.
The reasons for the elevated levels of IL-6 in CLL are still unclear. Under normal 
conditions IL-6 controls the immune response, the acute phase response and 
haematopoiesis. Patients with CLL have a high incidence of infections. During 
infection the acute phase response is induced (Helgfoot et al., 1989). This could be 
one explanation for the elevated IL-6 levels. It is unlikely that the elevated IL-6 are 
involved in the antibody responses because no correlation between IL-6 and IgG was 
detected. The IL-6 may be involved in the autocrine growth of the tumour cells or in
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the production of auto-antibodies.
The role of IL-6 in various diseased states have been reported. These include:
(1) the autocrine stimulation of tumour cells (Kawano et al., 1988; Yee et al., 1989 
and Seigall et al., 1990), AIDS Kaposi sarcoma-derived cells (Miles et al, 1990) and 
cells associated with mesangial proliferative glomerulonephritis (Blay et al., 1992),
(2) the induction of the acute phase response associated with glioblastoma (Van Meir 
et al., 1990), ovarian carcinoma (Erroi et al., 1989 and Watson et al., 1990), renal cell 
carcinoma (Blay et al., 1992) and acute bacterial infections (Helgfoot et al., 1989),
(3) the production of auto-antibodies in patients with cardiac myxoma (Hirano et al., 
1987),
(4) the polyclonal activation of B-cells associated with AIDS (Breen et al., 1990) and
(5) the induction of B-symptoms associated with lymphoma (Kurzrock et al., 1993).
In the course of this work IL-6 measurements were taken from single blood samples. 
It is conceivable that the levels of IL-6 and other cytokines change as the clinical 
course of the disease changes. Therefore, further studies could be conducted to 
investigate the cytokine profile of patients over a significant time period.
In the previous chapter it was reported that plasma from patients with CLL could 
stimulate the growth of hybridoma cells at the clonal stage. It was also shown that this 
was due to the cocktail of cytokines present in the plasma rather than the activities of 
IL-6 alone. Since hybribomas are of B-cell origin it is conceivable that the plasma 
causes a similar effect in vivo. It is possible that IL-6 is functioning as part of a 
cytokine network which could be responsible for some of the clinical symptoms 
experienced by these patients.
As a research area the field of cytokine study is still relatively new (Durum 1991). A 
majority of the studies performed thus far have been performed using individual 
cytokines. Now that a lot of the groundwork is established the role of cytokines in 
normal systems is under intense investigation. The action of the cytokines in vivo has
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been described as contextual (Spom and Roberts, 1988). In a living organism the 
cytokines are influenced by such factors as other cytokines, hormones and 
prostaglandins. During haematopoiesis cells are influenced by networks of these 
factors rather than by the action of the factors individually. Cytokines must, therefore, 
be studied as mixtures rather than individually. Understanding how these networks 
operate under normal conditions is central to assessing how they may operate in 
disease states. During a disease it is certain that production of various cytokines 
occurs. The consequence of this for the host depends on whether this production is 
normal or abnormal under the given conditions. For example, in the case of multiple 
myeloma (Kawano et al., 1988) an autocrine loop may operate whereby tumour cell 
growth requires IL-6 which in turn has been produced by the cells. Another example 
is the involvement of IL-6 in RA. IL-6 has been detected in the synovial fluid of 
patients with RA (Bhardwaj et al., 1989; Hirano, 1991c). Associated with this is an 
increase in the concentration of IgG in the synovial fluid which may be due to 
polyclonal B-cell activation (Hermann et al., 1989). IL-6 has been linked to various 
pathogenic aspects of the disease. These include the high frequency of EBV-positive 
B-cells associated with RA. IL-6 has been shown to be a growth factor for EBV- 
transformed cell lines (Tosato et al., 1988). In patients with Felty’s syndrome (RA 
associated with enlagement of the spleen) increases in serum levels of IL-6 are 
associated with aggravation of the arthritic condition. The involvement of IL-6 in both 
multiple myeloma and RA would seem to be indicative of worsening prognosis.
In times of disease IL-6 plays a vital role the regulation of defence mechanisms 
through its involvement in the acute phase response, the induction of the antibody 
response and haematopoiesis (Figure 5.4.). Some of the cytokine networks involving 
IL-6 have been well documented. It has been demonstrated that IL-3 and IL-6 act 
synergistically to induce the proliferation of murine pluri-potential haematopoietic 
progenitors (Ikebuchi et al., 1987). IL-1 has been shown to induce EL-6 production in 
stromal cells (Chiu et al., 1988), the resultant IL-6 can then exert its effect on 
haemotopoietic stem cells.
IL-6 acts on the hypothalamo-pituitary axis causing an increase in cortisol. Cortisol 
production has the dual functions of enhancing induction of the acute phase proteins 
in liver cells by IL-6 and of inhibiting IL-6 gene expression. Both IL-1 and TNF
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stimulate IL-6 synthesis and are, in turn, inhibited by EL-6. These complex networks 
control host response mechanisms. Progression of the various diseased states described 
above may involve the aberrant functioning of these networks.
Under normal circumstances differentiation and proliferation of activated B-cells into 
antibody-secreting cells is involves IL-4, IL-5 and IL-6 (Figure 1.3.2.). IL-4 and IL-5 
control early activation and proliferation of B-cells. Final differentiation of activated 
B-cells into antibody-secreting cells is controlled by EL-6.
IL-6 has been shown to induce Ig production in EBV transformed B-cell lines 
(Teranishi et al., 1982; Yoshizaki et al., 1982) and IgM, IgA and IgG production in 
B-cells which have been activated with either Staphylococcus aureus Cowan I or 
pokeweed mitogen but not in non-activated B-cells (Muraguchi et al., 1988). Antibody 
production in the latter case can be inhibited by anti-IL-6 antibodies indicating the 
essential role of IL-6. IL-6 has also been shown to induce the production of antibodies 
to polysaccharides in humans (Ambrosino et al., 1990) and to the influenza A virus 
in murine B-cells (Hilbert et al., 1989). A breakdown in the cytokine network 
controlling antibody production may be responsible for the hypogammaglobulinemia 
observed in patients with CLL.
CLL involves the clonal proliferation of a mature appearing but functionally immature 
B-cell (Gale and Foon 1987). The initial cell giving rise to CLL may not always have 
the same profile with regards to the cytokines being secreted. As the neoplasm 
develops (increase in cell numbers) the concentrations of cytokines would increase. 
The cytokine profile may also alter in response to the various cytokines which are 
now circulating. This scenario would mean that the cytokine profile would be due 
entirely to the cytokine profile of the B-cell giving rise to the neoplasm. Under normal 
conditions the levels of cytokines produced by this B-cell would be minuscule but on 
transformation to the neoplastic cell and subsequent proliferation the cytokine profile 
could alter dramatically. Neoplastic cell growth in individual cases of CLL may be 
dependent on the specific cytokines secreted at initial stages of the neoplasm. 
Treatment of these patients with functional agents which block cytokine production 
such as anti-cytokine antibodies could be of therapeutic value. This would explain why 
only some patients have elevated cytokine levels. It would also indicate that some, but 
not all, patients could have autocrine tumours.
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Figure 5.4.
The role of interleukin-6 (IL-6) as part of the host response mechanism to disease is 
represented diagrammatically above. The network begins with the induction of IL-6 
production by disease, IL-1 or tumour necrosis factor. IL-6 then induces cortisol 
production by the hypothalamo-pituitary axis. Cortisol has the dual role of firstly, 
enhancing acute phase protein production by liver cells in conjunction with IL-6 and 
secondly of inhibiting the expression of the gene encoding IL-6.
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Chapter 6
Conclusions
6. Conclusions
Bsabs were made using chemical methods. These recognised determinants on CLL 
cells and the enzyme HRP simultaneously. ELISA and immunocytochemical 
techniques were developed using these bsabs. The binding pattern of the bsab with 
various cell lines and CLL cells was similar to that of the parental anti-tumour 
antibody (G12) when examined by ELISA. When applied to immunocytochemical 
techniques the binding patterns of the bsab were altered. No reactivity was detected 
with the cell lines examined. However, reactivity of the bsab with the CLL cells 
remained similar to that observed during the ELISAs. Immunocytochemical staining 
using the parental G12 antibody was also performed using a commercial PAP 
amplification kit and a HRP-labelled goat anti-mouse antibody. Neither of these 
systems were successful in detecting antigenic determinants on the cell lines or the 
CLL cells. This would indicate that the bsab is more appropriate for use in such 
techniques. The observed alterations in the binding capabilities of antibodies between 
systems are not uncommon. The antibodies used in this work (H RP antiserum and the 
antibody secreted by the hybridoma G12) were initially assayed by ELISAs. Often the 
antibodies will not be suited to other forms of detection such as is the case here. The 
bsab maintained its ability to recognise the antigenic determinants present on the CLL 
cells indicating that the modifications to the G12 and anti-HRP antibodies may reduce 
cross-reactivity in the immunocytochemical system.
Somatic cell fusion techniques were used to fuse the G12 hybridoma cell line with 
rabbit and mouse splenocytes which secreted antibodies reactive with HRP. Two 
methods were used to induce HAT-sensitivity in the G12 hybridoma. Firstly the cells 
were grown in increasing concentrations of 8-aza and secondly the cells were 
mutagenised using EMS and new phenotypes were subsequently selected using 8-aza. 
These cells were then fused to either mouse or rabbit splenocytes both of which 
secreted antibodies reactive with HRP. Antibody production by newly formed triomas 
was examined by ELISA. Individual triomas secreted antibodies with parental binding 
patterns (anti-K562 or anti-HRP) only. No bsab was detected. Given the workload, 
cost and uncertainty involved in the production of antibodies using somatic cell fusion 
techniques it is important that biological methods of production be persued only if 
essential for the future of the work.
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The mouse-rabbit chimeric trioma may be of benefit in situations where rabbits give 
better antibody responses than mice to a particular antigen. For example, in the case 
of group A Streptococcus antibody responses are more superior in rabbits compared 
to mice (Raybould and Takahashi 1988). These authors have successfully produced 
mAb secreting chimeric cells by fusing hyperimmunized rabbit splenocytes and mouse 
myeloma cells. We have successfully fused mouse hybridoma cells and rabbit 
splenocytes. This type of system may be used in the future to produce bsabs which 
have proven difficult to make using the conventional mouse-mouse system. It was also 
possible to generate an immune response in the rabbit splenocytes using an in vitro 
immunization system. This could be of benefit in the case of weakly immunogenic 
antigens.
To date the main interest in bsabs has been as therapeutic agents either to redirect 
effector cells or toxins to tumour cells. Less work has been performed on their use in 
immunoassays. However, the therapeutic use of bsabs encounters such obstacles as 
host anti-foreign antibody responses. No such problems exist for bsabs used in 
immunoassays.
Studies on the production of the cytokine IL-6 by patients with CLL were also 
performed. These included measuring IL-6 levels in plasma and CM (prepared from 
the PBL) of patients with CLL by ELISA and by an MTT-based bioassay using IL-6 
dependent cells. Five of eleven patients had detectable levels of IL-6 as determined 
using both systems. The significance of IL-6 in CLL is still unclear. One of the 
clinical manifestations of the disease is hypogammaglobulinemia and this in turn may 
lead to the development of other clinical symptoms such as the increased numbers of 
infections experienced by these patients. Given that IL-6 is involved in the final 
differentiation of B-cells into antibody-secreting cells the possibility that patients with 
raised IL-6 levels had normal IgG levels (which could indicate better prognosis due 
to less infection) was examined. IgG presence in the plasma was determined by 
ELISA. All of the samples examined were hypogammaglobulinémie and, therefore, 
no correlation between elevated IL-6 levels and normal antibody production was 
recorded. Lack of patient data rendered it impossible to correlate the relevance, if any, 
between disease status and IL-6 levels. Discovering the significance of IL-6 in CLL
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may require that all the cytokines with reported elevated levels in CLL be examined 
together and not in isolation. This is highlighted in the final line of research of this 
thesis where the cytokines present in CLL operate in a network to stimulate 
hybridoma cell growth. This is outlined in more detail below.
The final area of research studied was the conditions required for optimal hybridoma 
cell growth at the clonal stage. IL-6, which is also known as HGF, was examined for 
its ability to enhance the cloning efficiency of the hybridomas examined. The T24 cell 
line was used as a source of IL-6 (T24-CM). T24-CM, conventional feeder layers and 
basal medium all had similar cloning efficencies. CM was also prepared using a range 
of concentrations rhIL-6 and no effect was observed on the cloning efficiency.
It was found that the cloning efficiency of hybridomas was enhanced using culture 
medium supplemented with CLL plasma. The levels of IL-6 in the plasma were 
measured by ELISA and IL-6 dependent MTT-bioassay. Of eight plasma samples 
examined only two had detectable levels of IL-6 indicating that IL-6 is not responsible 
for the observed enhanced cloning efficiency. This is in agreement with the initial 
results using T24-CM and rhIL-6. A likely scenario is that an increase in several 
cytokines causes enhanced clonal growth. Elevated levels of BCGF, IL-1, TNF-a and 
TGF-[3 have been reported in patients with CLL. Further studies on the exact nature 
of the cytokines which cause the increase in cloning efficiency should be possible 
given the availability of recombinant cytokines. These could then be used for the 
development of novel growth medium supplements. The implications of these results 
on patients with CLL are interesting. Hybridomas are of B-cell origin and given the 
enhanced growth of the hybridomas examined here it is quite feasable that alterations 
in the concentration of these cytokines in vivo have similar effects on B-cell growth. 
Treatment of hybridomas with IL-6 alone did not affect affect their growth. Therefore, 
it is likely that the cytokines are acting in a network. This network could affect normal 
(non)-haematopoietic development. The cytokines control the development of a wide 
range of cell types and further studies examining the effects of CLL plasma on cell 
lines of various origins could help to elucidate how these cytokines are influencing 
course of the disease.
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